PF-07960613 (Combination COVID- 19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 202 3)
TMF Doc ID: 164.01
Page 1A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND 
IMMUNOGENICITY OF COMBINED VACCINE CANDIDATE (S)AGAINST
INFECTIOUS RESPI[INVESTIGATOR_227897] ,INCLUDING COVID -19AND RSV ,IN 
HEALTHY INDIVIDUALS
Study Intervention Number: PF-07960613
Study Intervention Name: [CONTACT_228016] D-19and RSV Vaccine
US IND Number: [ADDRESS_274478] Number: NA
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number: NA
Protocol Number: C5481001
Phase: 1/2
Sponsor Legal Address: [COMPANY_007] I nc.
[ADDRESS_274479]
[LOCATION_001], NY [ZIP_CODE]
Brief Title:
A Study  to Learn About Combined Vaccine(s) Against Infectious Respi[INVESTIGATOR_227898],
Including CO VID-19 and RSV
This document and accom panying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information 
in confidence and not copy or disclose it to others (excep t where required by [CONTACT_1289]) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be 
promptly notified.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274480] of country  health authorities and IRBs/ECs and any  protocol administrative change 
letter(s).
Protocol Amendment Summary of Changes Table
Amendment 2 (18 January 2024)
Overall Rationale for the Amendment: 
Following a review of the needs of the overall development program
,Substudy  B was
removed from the protocol.
Description of Change Brief Rationale Section # and Name
[CONTACT_185628](s)
Removed Substudy  B Following a review of 
the needs of the overall 
development program,
Substudy  B was
removed from the 
protocolSection 10.12 Appendix 12: 
Substudy  B (Phase 1/2)
Nonsubstantial Modification(s)
Removed text in the 
body  of protocol that 
was specific to 
Substudy BFollowing a review of 
the needs of the overall 
development program ,
Substudy Bwas
removed from the 
protocolSection 1.1Synopsis
Section 2.1Study  Rationale
Section 2.2Background
Section 2.3Benefit/ Risk Assessment
Section 4.2.2 Rationale for 
Comparator
Section 4.3 Justification for Dose
Section 8.4.1 Time Period and 
Frequency  for Collecting AE and 
SAE I nformation
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 3Description of Change Brief Rationale Section # and Name
[CONTACT_8985] 8.4.[ADDRESS_274481]
Removed references that 
were specific to 
Substudy BFollowing a review of 
the needs of the overall 
development program,
Substudy  Bwas
removed from the 
protocolSection s 1through 9
Section [IP_ADDRESS] Data Monitoring 
Committee
Section 10.2 Appendix 2: Clinical 
Laboratory  Tests
Section 10.5 Appendix 5: Gen etics
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274482] OF TABLES ................................ ................................ ................................ ................... 11
1. PROTOCOL  SUMMARY ...................................................................................................12
1.1. Sy nopsis ..................................................................................................................12
1.2. Schema ....................................................................................................................16
1.3. Schedule of Activities .............................................................................................16
2. INTRODUCTION ...............................................................................................................17
2.1. Study  Rationale .......................................................................................................17
2.2. Background .............................................................................................................17
2.2.1. SARS -CoV -
2 ..............................................................................................17
2.2.2. RSV .............................................................................................................19
2.2.3. Clinical Overview .......................................................................................20
[IP_ADDRESS]. SARS -CoV - 2................................ ................................ ............. 20
[IP_ADDRESS]. RSVpreF Vaccination ...............................................................24
2.3. Benefit/Risk Assessment
.........................................................................................26
2.3.1. Risk Assessment
.........................................................................................27
2.3.2. Benefit Assessment .....................................................................................30
2.3.3. Overall Benefit/Risk Conclusion ................................................................30
3. OBJECTI VES, ENDPO INTS, AND ESTIMANDS ...........................................................30
4. STUDY DESIGN .................................................................................................................30
4.1. Overall Design .........................................................................................................30
4.2. Scientific Rationale for Study  Design .....................................................................30
4.2.1. Diversity  of Study  Population ....................................................................31
4.2.2. Rationale for Comparator ...........................................................................31
4.2.3. Choice of Contraception/Barrier Requirements ................................ ......... 31
4.3. Justification for Dose ..............................................................................................31
4.3.1. Bivalent BNT162b2 (Original/Omi BA.4/BA.5) ................................ .......31
4.3.2. RSVpreF .....................................................................................................31
4.3.3. Combined RSVpreF and Bivalent BNT162b2 (Original/Omi 
BA.4/BA.5) Vaccine [ RSVpreF+BNT162b2] .................................................32
4.4. End of Study  Definition ..........................................................................................32
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 55. STUDY POPUL ATION ......................................................................................................32
5.1. I nclusion Criteria .....................................................................................................32
5.2. Exclusion Criteria ....................................................................................................32
5.3. L ifesty le Considerations ..........................................................................................33
5.3.1. Contraception ..............................................................................................33
5.4. Screen Failures ........................................................................................................33
5.5. Criteria for Temporarily  Delay ing 
Enrollment/Randomization/Administration of Study  Intervention ...........................33
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................33
6.1. S tudy Intervention(s) Administered ........................................................................33
6.1.1. Administration ............................................................................................34
6.1.2. Medical Devices .........................................................................................34
6.2. P reparation, Handling, Storage, and Accountability ...............................................34
6.2.1. Preparation and Dispensing ........................................................................35
6.3. Assignment to Study I ntervention ...........................................................................35
6.4. Blinding
...................................................................................................................36
6.4.1. Blinding of Participants ..............................................................................36
6.4.2. Blinding of Site Personnel ..........................................................................36
6.4.3. Blinding of the Sponsor
..............................................................................36
6.4.4. Breaking the Blind ......................................................................................36
6.5. Study  Intervention Compliance ...............................................................................36
6.6. Dose Modification ...................................................................................................36
6.7. Continued Access to Study  Intervention After the End of the Study ......................37
6.8. Treatment of Overdose
............................................................................................37
6.9. Prior and Concomitant Therap y
..............................................................................37
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRA WAL ...........................................................................37
7.1. Discontinuation of Study  Intervention ....................................................................37
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_274483] to Follow -Up...................................................................................................38
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 68. STUDY ASSESSMENTS AND PROCEDURES ...............................................................39
8.1.Administrative Procedures ......................................................................................39
8.1.1. Telehealth Visits .........................................................................................39
8.2. Efficacy  and/or Immunogenicity
 Assessments .......................................................40
8.2.1. Biological Samples .....................................................................................40
8.3. Safet y Assessments .................................................................................................41
8.3.1. Phy sical Examinations ................................................................................41
8.3.2. Vital Signs ..................................................................................................41
8.3.3. Cli nical Safety  Laboratory  Assessments ....................................................42
8.3.4. Electronic Diary ..........................................................................................42
[IP_ADDRESS]. Grading Scales ...........................................................................42
[IP_ADDRESS]. L ocal Reactions .........................................................................42
[IP_ADDRESS]. Sy stemic Events ................................ ................................ ........ 43
[IP_ADDRESS]. Fever ..........................................................................................44
[IP_ADDRESS]. Antipy retic Medication .............................................................45
8.3.5. Stoppi[INVESTIGATOR_1869]
............................................................................................45
8.4. A
dverse Events, Serious Adverse Events, and Other Safet y Reporting .................45
8.4.1. Time Period and Frequency  for Collecting AE and SAE I nformation .......46
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................46
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................47
8.4.2. Method of Detecting AEs and SAEs ..........................................................47
8.4.3. Follow -Up of AEs and SAEs ......................................................................47
8.4.4. Regulatory
 Reporting Requirements for SAEs ...........................................47
8.4.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................48
[IP_ADDRESS]. Exposure During Pregnancy ......................................................48
[IP_ADDRESS]. Exposure During Breastfeeding ................................................50
[IP_ADDRESS]. Occupational Exposure .............................................................50
8.4.6. Cardiovascular and Death Events ................................ ............................... 50
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................51
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274484].............................................................51
[IP_ADDRESS]. Lack of Efficacy ........................................................................52
8.4.9. Medical Device Deficiencies ......................................................................52
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies .........52
[IP_ADDRESS]. Follow -
Up of Medical Device Deficiencies..............................52
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to the Sponsor ........52
[IP_ADDRESS]. Regulatory  Reporting Requiremen
ts for Device 
Deficiencies .......................................................................................53
8.4.10. Vaccination Errors
....................................................................................53
8.5. Pharmacokinetics ....................................................................................................54
8.6. G enetics ...................................................................................................................54
8.7. Biomarkers ..............................................................................................................54
8.8. I mmunogenicit y Assessments .................................................................................54
8.9. Health Economics ...................................................................................................55
9. STATI STICAL CONSI DERATIONS
................................................................................55
9.1. Statistical Hy potheses .............................................................................................55
9.2. Analy sis Sets ...........................................................................................................55
9.3. Statistical Analy ses.................................................................................................55
9.3.1. General Considerations ...............................................................................55
[IP_ADDRESS]. Analy ses for Binary  Data ..........................................................56
[IP_ADDRESS]. Analy ses for Continuous Data ...................................................56
9.4. I nterim Anal yses.....................................................................................................57
9.5. Sample Size Determination .....................................................................................57
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................58
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Consi derations ...............58
10.1.1. Regulatory and Ethical Considerations ....................................................58
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................58
10.1.2. Financial Disclosure .................................................................................59
10.1.3. I nformed Consent Process ........................................................................59
10.1.4. Data Protection .........................................................................................60
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 810.1.5. Committees Structure ...............................................................................60
[IP_ADDRESS]. Data Monitoring Committee ...................................................60
10.1.6. Dissemination of Clinical Study  Data ......................................................61
10.1.7. Data Qualit y Assurance ............................................................................62
10.1.8. Source Documents ....................................................................................63
10.1.9. Use of Medical Records ................................ ................................ ............ 64
10.1.10. Study  and Site Start and Closure ............................................................64
10.1.11. Publication Policy ...................................................................................65
10.1.12. Sponsor’s Medically  Qualified Individual ..............................................65
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................66
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................67
10.3.1. Definition of AE .......................................................................................67
10.3.2. Definition of an SAE ................................................................................68
10.3.3. Recording/Reporting and Follow
-Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................70
10.3.4. Reporting of SAEs
....................................................................................73
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................75
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................75
10.4.2. Female Participant Reproductive Inclusion Criteria .................................75
10.4.3. Woman of Childbearing Potential ............................................................76
10.4.4. Contraception Methods .............................................................................77
10.5. Appendix 5: Genetics
............................................................................................78
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -Up Assessments .......79
10.7. Appendix 7: Kidney  Safety  Monitoring Guideline s
.............................................81
10.7.1. Laboratory  Assessment of Change in Kidney  Function and 
Detection of Kidney  Injury ..............................................................................81
10.7.2. Age -Specific Kidney  Function Calculation Recommendations ...............81
[IP_ADDRESS]. Adults (18 Years and Above) —2021 CKD - EPI 
[INVESTIGATOR_185560] ................................ ................................ ........................... 81
10.7.3. Kidney  Function Calcul ation Tools ..........................................................82
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 910.7.4. Adverse Event Grading for Kidney  Safet y Laboratory  
Abnormalities ................................ ................................ ................................ ...82
10.8. Appendix 8: ECG Findings of Potential Clinical Concern ...................................83
10.9. Appendix 9: Criteria for Allowing Inclusion of Participants With Chronic 
Stable HIV, HCV, or HBV Infection
........................................................................85
10.10. Appendix 10: AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs, and Device 
Deficiencies: Definitions and Procedures for Recording, Evaluating, 
Follow -
Up, and Reporting in Medical Device Studies .............................................86
10.10.1. Definition of AE and ADE .....................................................................86
10.10.2. Definition of SAE, SADE, and [LOCATION_003]DE ................................................86
10.10.3. Definition of Device Deficiency .............................................................87
10.10.4. Recording/Reporting and Follow -Up of Medical Device 
Deficienc ies......................................................................................................87
10.10.5. Reporting of SAEs
..................................................................................89
10.10.6. Reporting of SADEs ...............................................................................89
10.11. Appendix 11: Substudy  A (Phase 1/2) ................................................................90
10.11.1. Sy nopsis 
–Substudy  A ...........................................................................90
10.11.2. Schema –Substudy  A (Phase 1/2) ..........................................................90
10.11.3. SoA –Substudy  A (Phase 1/2) ...............................................................91
10.11.4. I ntroduction –Substudy  A
......................................................................93
[IP_ADDRESS]. Substudy  A Rationale ............................................................93
[IP_ADDRESS]. Background ...........................................................................93
[IP_ADDRESS]. Benefit/Risk Assessment
.......................................................93
10.11.5. Objectives, Endpoints, and Estimands –Substudy  A.............................94
10.11.6. Substudy  A Design .................................................................................97
[IP_ADDRESS]. Overall Design
.......................................................................97
[IP_ADDRESS]. Scientific Rationale for Stud y Design ...................................98
[IP_ADDRESS]. Justification for Dose ............................................................98
[IP_ADDRESS]. End of Study  Definition ........................................................98
10.11.7. Substudy  A Population ................................ ................................ ........... 98
[IP_ADDRESS]. Substudy  A Inclusion Criteria ...............................................98
[IP_ADDRESS]. Substudy  A Exclusion Criteria ..............................................99
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 1010.11.7.3. Criteria for Temporarily  Delay ing 
Enrollment/Randomization/Administration of Study  
Intervention ................................ ................................ ...................... 101
10.11.8. Substudy  A Intervention and Concomitant Therapy ............................101
[IP_ADDRESS]. Study  Intervention(s) Administered ....................................103
[IP_ADDRESS]. Blinding
...............................................................................106
[IP_ADDRESS]. Study  Intervention Compliance ...........................................108
[IP_ADDRESS]. Dose Modification ...............................................................108
[IP_ADDRESS]. Continued Access to Study  Intervention After the End 
of the Study ......................................................................................108
[IP_ADDRESS]. Treatment of Overdose ........................................................108
[IP_ADDRESS]. Prior and Concomitant Therap y
..........................................108
10.11.9. Discontinuation of Substudy  A Intervention and Participant 
Discontinuation/Withdrawal ..........................................................................109
10.11.10. Substudy  A Assessments and Procedures ...........................................109
[IP_ADDRESS]. I mmunogenicity  Assessments ...........................................110
[IP_ADDRESS]. N
-Binding Antibody  Test ..................................................110
[IP_ADDRESS]. Biological Samples ............................................................110
[IP_ADDRESS]. Safet y Assessments ...........................................................110
[IP_ADDRESS]. Stoppi[INVESTIGATOR_1869]
..................................................................110
[IP_ADDRESS]. Adverse Events, Serious Adverse Events, and Other 
Safety  Reporting ..............................................................................111
[IP_ADDRESS]. Study  Procedures ...............................................................111
10.11.11. Statistical Considerations –Substudy  A
.............................................116
[IP_ADDRESS]. Statistical Hypotheses
.......................................................116
[IP_ADDRESS]. Analy sis Sets .....................................................................119
[IP_ADDRESS]. Statistical Analy ses...........................................................119
[IP_ADDRESS]. I nterim Analy ses...............................................................122
[IP_ADDRESS]. Sample Size Determination ...............................................122
10.12. Appendix 12: Protocol Amendment History .....................................................124
10.13. Appendix 13: Abbreviations .............................................................................127
11. REFERENCES ................................ ................................ ................................ ................ 131
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274485] OF TABLES
Table 1. Local Reaction Grading Scale ..................................................................43
Table 2. Systemic Event Grading Scale ..................................................................44
Table 3. Scale for Fever ..........................................................................................45
Table 4. Substudy  A Enrollment Strata ..................................................................97
Table 5. Power to Demonstrate Noninferiority  (N=135 per Group) ....................123
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 121.PROTOCOL SUMMARY 
1.1.Synopsis 
Protocol Title: 
A Study  to Evaluate the Safety , Tolerabilit y, and Immunogenicit y of Combined Vaccine 
Candidate (s)Against Infectious Respi[INVESTIGATOR_227898] , Including COVID -19and RSV ,in 
Health y Individuals
Brief Title:
A Study  to Learn About Combined Vaccine (s)Against Infectious Respi[INVESTIGATOR_227898], 
Including COVID -19 and RSV
Regulatory Agency Identification Number(s):
US IND Number: [ADDRESS_274486] Num ber: NA
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number: NA
Protocol Num ber: C5481001
Phase: 1/2
Rationale :
Respi[INVESTIGATOR_227899] ( RSV ), influenza, and severe acute respi[INVESTIGATOR_103949] 2 ( SARS -CoV -
2) viruses are cocirculating infections , with a tendency  to peak in 
winter .
Vaccines against influenza and coronavirus disease 2019 ( COVID -19) can be 
administered at a single
healthcare visit as individual vaccinations, requiring multiple 
injections. The [COMPANY_007] RSV vaccine , RSV stabilized prefusion F s ubunit vaccine (RSVpreF ) ,
was recentl yfound to be efficacious against RSV -associated lower respi[INVESTIGATOR_227900] 
(LRTI) in older adults (≥60 years of age).Concurrent administration of vaccines against 
these respi[INVESTIGATOR_227901]. A combination vaccine with RSVpreF and [COMPANY_007]’s 
COVID -19 vaccine ( BNT162 b2)would require 1 injection at a healthcare provider visit. A 
study  of combined vaccination is required to investigate potential immunological interference 
in addition to safety  and tolerability . 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 13The nucleoside -modified messenger ribonucleic acid ( modRNA )within BNT162b2 encodes 
the SARS -CoV -2 spi[INVESTIGATOR_227902] 
(RNA -LNPs ).  BNT162b2 has demonstrated potent immunogenicity , high vaccine efficacy  
(VE), and a favorable s afety  profile in Phase 1, 2, and [ADDRESS_274487] , the relevant authorized /approved variant -adapted 
version of the BNT162b2 vaccine will be used in thesubstudy .
RSVpreF is a bivalent RSV prefusion F subunit vaccine developed b y [COMPANY_007]. The RSV 
Fglycoprotein facilitates fusion of the virion and host cell membrane through a dramatic 
transition from an unstable but highl y immunogenic prefusion conformation to the more 
stable postfusion state. RSV preF is composed of engineered, stabilized, trimeric, prefusion F 
glycoproteins matching the 2 subgroups (A andB) to help ensure the broadest coverage 
against RSV illness. RSVpreF efficacy  against RSV -associated LRTI with ≥ 2 and 
≥
3symptoms in older adul ts (≥60 years of age) was 66.7% and 85.7% ,respectivel y. On 
31May 2023, the Food and Drug Administration ( FDA )approved RSVpreF under the name 
[CONTACT_228017]™ for the prevention of lower respi[INVESTIGATOR_53121] d isease caused by  [CONTACT_227969] 
[ADDRESS_274488] RSV and SARS -CoV -2may be conducted in the 
future at a similar time of y ear, when influenza vaccine is also administered, developi[INVESTIGATOR_227903] b y allowing for more convenient scheduling than if these vaccinations were to be 
administered separatel yand/or at different visits .Hence, this stud y will include the 
following substudy :
Substudy  A: A Phase 1 /2substudy  in up to approximately  1050 healthy  participants 
≥65years of age to describe the safet y, tolerability, and immunogenicity of a 
combined RSVpreF andbivalent BNT162b2 (original/Omi BA.4/BA.5) vaccine
[RSVpreF+ BNT162b2], administered concomitantly  with a seasonal influenza
vaccine or administered alone .
Objectives, Endpoints, and Estimands
Please refer to the substudy  appendi xfor the objectives and endpoints for thesubstudy .
Overall Design:
This is a master s tudy to evaluate c
ombined vaccine candidate (s)against infectious
respi[INVESTIGATOR_10711] , including COVID - 19and RSV .Thesubstudy  design is detailed 
separately in the substudy  appendix .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 14Substudy A (Phase 1 /2)
This is a Phase 1 /2randomized, parallel -group, observer-bl inded substudy  to assess the 
safet y
, tolerability, and immunogenicit y ofa combined RSVpreF and bivalent BNT162b2 
(original/Omi BA.4/BA.5) vaccine [RSVpreF+BNT162b2 ], administered concomitantly  with 
a seasonal influenza vaccine or administered alone . Approximately  1050 healthy  participants 
≥65 y ears of age will be enrolled in Substudy  A
.
Randomization will be conducted across 2enrollment strata (see the table below ).
Substudy A: Enrol lment Strata 
Enrol lment 
StratumTotal Number 
of ParticipantsNumber of 
Participants per 
Vaccine GroupVaccine 
Group 
NumberVaccine Group Description
1 750 150 1 [ RSVpreF+BNT162b2 ]administered 
concurrently in the opposite arm to 
licensed QIV 
150 2 [ RSVpreF+BNT162b2 ]administered 
concurrently in the opposite arm to 
placebo
150 3 Bivalent BNT162b2 administered 
concurrently in the opposite arm to 
placebo
150 4 RSVpreF administered concurrently in 
the opposite arm to placebo
150 5 Licensed QIV administered 
concurrently in the opposite arm to 
placebo
2 300 150 6 RSVpreF and bivalent BNT162b2 
(2injections in the same arm) 
coadministered concurrently in the 
opposite arm to placebo
150 7 RSVpreF and bivalent BNT162b2 
(2injections in the same arm) 
coadministered concurrently in the 
opposite arm to licensed QIV
All participants will be asked to complete a reactogenicity  electronic diary  (e-diary )for 
7days following vaccination.  Blood samples of approximately  50mL will be collected for 
immunogenicit y assessments prior to vaccination atVisit A 101and 1month after 
vaccination (Visit A102) . 
E
-diary  data from Day  [ADDRESS_274489] 20 participants in Groups 6 and 7, will be evaluated prior to enrollment of the remaining 
participants in each group.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 15Adverse events ( AEs) will be collected from the signing of informed consent through 
Visit A102 (1 -month follow -up visit). Serious adverse events (SAEs) will be collected from 
the signing of informed consent through Visit A103 (6- month telephone contact).
Substudy  A will have stoppi[INVESTIGATOR_227904]162b2 (original/Omi BA.4/BA.5) vaccine 
[RSV preF+BNT162 b2]as detailed in the protocol .
The total duration of Substudy  Afor each participant will be up to approximately  6month s.
Number of Participants:
Substudy A (Phase 1 /2)
Up to approximate ly 1050 participants will be enrolled in Substudy  A (750 participants in 
enrol lment 
stratum 1 and300 participants in enrol lment stratum 2).
Note : “Enrolled” means a participant ’s, or their legall y authorized representative ’s, 
agree ment to participate in a clinical study  following completion of the informed consent 
process.
Study Population: 
Please refer to the substudy  appendi xfor the inclusion and exclusion criteria of thesubstudy .
Study Arms and Duration :
Please refer to the appendi xfor the study  arms and duration of thesubstudy .
Statistical Methods :
Statistical methods applicable to thesubstud yare specified in the body  of the protocol. 
Statistical methods specific to thesubstudy  are specified in the substudy  appendix.
Ethical Considerations :
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines;
Applicable ICH GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 16The protocol, protocol amendments, I CD, SRSD(s), and other relevant documents 
(eg,advertisements) must be reviewed and approved by  [CONTACT_456] , submitted t o an I RB/EC 
by [CONTACT_093] , and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation, except for changes necessary  to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC;
Notify ing the IR B/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/[ADDRESS_274490] 2017/745 for clinical device research, 
and all other applicable local regulations.
1.2.Schema
Please refer to the stud y-specific appendi xfor the schema of thesubstudy . 
1.3. S chedule of Activ ities
The schedule of activities ( SoA)table (s)provides an overview of the protocol visits and 
procedures.  Refer to the STUDY  ASSESSMENTS AND PROCEDURES section ( Section 8)
of the protocol for detailed information on each procedure and assessment required for 
compliance with the protocol.
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA  
table(s), in order to conduct evaluations or assessments required to protect the well -being of 
the participant.
See Section 10.11.3 for the Substudy  A SoA.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 172.INTRODUCTION
2.1.Study Rationale
BNT162b2 (Comirnat y®) is an RNA -based vaccine that has been granted full marketing 
authorization, conditional marketing authorization, EUA, or temporary  authorization in more 
than 100countries for the prevention of COVID -[ADDRESS_274491] developed a
bivalent BNT162b2 (original/Omi BA.4/B A.5) vaccine , to further protect against COVID-19 
caused b y em ergent and potentially  more antigenically  diverse variant s. Bivalent BNT162b2 
(original/Omi BA.4/BA.5) ,consisting of the original SARS -CoV -2 spi[INVESTIGATOR_227905], 
targeting the ancestral strain of the virus, in combination with mRNA encoding the spi[INVESTIGATOR_227906] (BA.4/BA.5 sublineage) ,was therefore used in Substudy  A.
RSVpreF is a bivalent RSV prefusion F subunit vaccine developed b y [COMPANY_007]. The RSV 
Fglycoprotein facilitate s fusion of the virion and host cell membrane through a dramatic 
transition from an unstable but highl y immunogenic prefusion conformation to the more 
stable postfusion state. RSVpreF is composed of engineered, stabilized, trimeric, prefusion F 
glycoprote ins matching the 2 subgroups (A andB) to help ensure the broadest coverage 
against RSV illness. RSVpreF was recently  found to be efficacious against RSV -associated 
LRTI in older adults ,5and on 31 May  2023, the FDA approved RSVpreF under the name 
[CONTACT_228017]™ for the prevention of lower respi[INVESTIGATOR_227907] 
60 years of age or older.6
RSV and SARS -CoV -2 viruses 
often cocirculat e, with a tendency  to peak in winter.7,8,9
In older adults, coadministration of vaccines in a single injection could reduce the need for 
multiple healthcare or pharmacy  visits and improve vaccine uptake by  [CONTACT_227970] a subsequent injection.10Studies of combination
vaccination are required 
toinvestigate potential immunological interference in addition to safet y and tolerability. 
Substudy  A will investigate a combined RSVpreF and bivalent BNT162b2 
(original/Omi BA.4/BA.5) vaccine [RSVpreF+BNT162b2] administered concomitantly  with 
a seasonal influenza vaccine or administered alone.
2.2.Background
2.2.1. SARS -CoV -[ADDRESS_274492] been 
used as a critical mitigation strategy  of the COVID -19 pandemic. However, waning 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274493] emergency  room and urgent care encounters as well as hospi[INVESTIGATOR_602], 
when comparing 2 months versus ≥[ADDRESS_274494] emergency  room or urgent care visits was 87% during the first 
2months after a third dose and decreased to 66% among those vaccinated 4 to 5 months 
earlier; VE against hospi[INVESTIGATOR_219057] 91% during the first [ADDRESS_274495] dose 
and decreased to 78% ≥[ADDRESS_274496] dose.13  In another large study  conducted in 
approximately  2.5 million [LOCATION_006] adults vaccinated with either ChAdOx1 -S, BNT162b2, or 
mRNA -1273, approximately  80% of the participants with SARS -CoV -2 had Omicron variant 
infections and approximately  20% had Delta variant infections.  In those who received 
3doses of BNT162b2, VE increased to 67.2% at 2 to 4 weeks before declining to 45.7% at 
[ADDRESS_274497] vaccine dose was evidenced by  
a higher neutralization efficiency  (by a factor of 100) against the Omicron variant after the 
third dose compared to the second dose.  However, even with [ADDRESS_274498] the Omicron variant was lower (b y a factor of 4) than that against the Delta variant.15
The bivalent (original/Omi BA.4/BA.5) vaccine has shown improved neutralization of recent 
Omicron sublineages, which has translated to improved real -world protection against the 
Omicron variant.16Real-world studies show that bivalent mRNA vaccines increase 
protection relative to original monovalent -only mRNA vaccination against a range of 
COVID -[ADDRESS_274499] more severe outcomes such as hospi[INVESTIGATOR_059].17,18,19,20,21,22,23
Further, earl y evidence suggests that the bivalent vaccine may  bemore effective than the 
original 
monovalent mRNA booster inthose 12 years of age or older during periods in which 
recent Omicron sublineages, including BA.5, BQ.1/BQ.1.1, and XBB .1were prevalent.16,21
At that time, [COMPANY_007] -BioNTech had developed a bivalent BNT162b2 
(original/Omi BA.4/BA.5) vaccine to further protect against COVID -19 caused by [CONTACT_227971] y diverse variants ;thisformulation wasused in Substudy  A.
But at present, Omicron and its sublineages continue to cause the majority of SARS -CoV -2 
infections. The Omicron sublineage XBB.1.5 has been globall y dominant since 
February 2023, while the prevalence of other XBB sublineages (ie, XBB.1.16, XBB.1.9.1, 
XBB.1.9.2, and XBB.2.3) is growing.4Sublineages XBB and XBB.1 are more antigenicall y 
distant from prior Omicron strain sublineages (eg, BA. 2, BA.4/BA.5); more so than the 
distance of these early  Omicron sublineages from the ancestral WT strain. They  also show 
the greatest magnitude of immune escape that has be en observed to date.24
,25,26While the 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 19bivalent BNT162b2 (original/Omi BA.4/BA.5 )–adapted booster increased neutralizing titers 
against currently  dominant strains, XBB.1.[ADDRESS_274500] the matched Omi BA.4/ BA.5.Preclinical data showed 
an Omicron 
XBB –adapted vaccine (eg, Omicron XBB.1.5) , when administered as a booster 
or 2-dose primary  series ,elicited higher neutralizing responses against Omicron XBB.1.5 and 
XBB.1.16 strains compared to the bivalent BNT162b2 (original /Omi BA.4/BA.5) –adapted 
vaccine. Based on th
eseavailable data, FDA guidance, VRBPAC recommendation 
(held 15 June 2023),27and [COMPANY_007]/BioNTech strategies for manufacturing and testing using 
the same plat forms, a variant -modified formulation targeting Omicron XBB.1.5 
(approved 11 September 2023) for 2023/ 2024 became commercially available .28
2.2.2. RSV
RSV is a major cause of respi[INVESTIGATOR_227908], which can result in severe illness in 
both infants an d older adults. There are 2 antigenic variants of RSV: subgroups A (RSV A) 
and B (RSV B) ,
which cocirculate.29Like influenza, RSV infection follows a seasonal 
pattern, causing yearly wintertime epi[INVESTIGATOR_227909], usually between late 
autumn and earl y spring. In tropi[INVESTIGATOR_227910], the outbreaks are generall y associated with 
rainy  seasons but are more unp redictable and frequently  continuous.30Because of the 
COVID -19 pandemic, which spread worldwide in 2020 -2021, the seasonality  of several 
pathogens, including RSV, has been disrupted and the shift of peak incidence has been 
observed in a majorit y of geogra phic areas. RSV now cocirculates with influenza and 
SARS -CoV -2 and increases the incidence of respi[INVESTIGATOR_23739] –related disease.7
Adults ≥60 years of age ar e at increased risk of RSV infection, which can trigger 
exacerbations of underl ying comorbid conditions such as COPD and CHF. RSV infection 
has been associated with up to 22% of acute COPD exacerbations in prospective cohort
studies and 11% of wintertime hospi[INVESTIGATOR_227911].31Current 
epi[INVESTIGATOR_227912]
 177,000 hospi[INVESTIGATOR_4355] 
14,000 deaths annuall y in US adults 65 y ears of age and older.32Morbidity  is significant 
among adults hospi[INVESTIGATOR_227913], with 18% requiring intensive care, 31%
needing home health services at discharge, and 26% dy ing within 1 y ear of hospi[INVESTIGATOR_059].33
In the US, RSV disease incidence rates in older adults are approximately  half those of 
influenza, with va riation year to year.34Incidence rates and risk for severe complications 
from RSV infection are higher among immunocompromised adults and those with chronic 
conditions (eg, cardiopulmonary  or renal disease, hematological malignancies, receipt of 
chemother apy, or HIV infection).35,36However, the burden of adult RSV disease could be 
underestimated since testing for RSV is less common in older adults than in children.37RSV 
disease in adults is also difficult to diagnose based on clinical signs and s ymptoms alone, 
and, prior to the broader use of more sensitive detection methods, laboratory confirmation of 
RSV in adults was challenging because of low levels of virus shedd ing.31
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274501] disease caused by  [CONTACT_227972] 32 through 36 weeks gestational age b y the FDA.39
2.2.3.
Clinical Overview
[IP_ADDRESS]. SARS -CoV -2
Study  C4591001 ([STUDY_ID_REMOVED]) is an ongoing Phase 1/2/3 trial in ~46,000 participants 
designed to generate safety , tolerabilit y, immunogenicity, and efficacy data from a novel 
RNA -
based vaccine candidate.40  The trial is being conducted in a heterogeneous study  
population: eligible participants ≥12 y ears of age ;healthy  participants, including those 
participants with stable chronic medical conditions, including HIV -, HCV -, and 
HBV -positive participants.  The study  consists of 2 parts: Phase 1: to identify  the preferred 
vaccine candidate (BNT162b1 or BNT162b2) and dose level (10 µg, 20 µg, 30 µg, or 100 µg 
[for BNT162b1]); Phase 2/3: an expanded
-cohort and efficacy  part to evaluate the selected 
vaccine candidate (BNT162b2).
The immunogenicit y data from Phase [ADDRESS_274502] 
IgG-binding response to S1 and a SARS -CoV -2–neutralizing response.  Immunogenicit y 
substantially  increased following the second dose of vaccine.  BNT162b2 induces a strong 
antigen -
specific Th1-skewed CD4+ response and a strong antigen-specific CD8+ response.  
BNT162b2 was selected from the Phase 1 part of the study  based on the overall safety , 
tolerability, and immunogenicity .  In a mid–November 2020 anal ysis of 36,621 participants 
randomized 1:[ADDRESS_274503] 7 day s after the second dose of vaccine was 95.0%, with 
8COVID -[ADDRESS_274504] dose, and in preventing COVID -19 in indi viduals with prior SARS -CoV -2 
infection, although available data for these outcomes did not allow for firm conclusions.41
In a subsequent anal ysis of 927 confirmed s ymptomatic cases of COVID -19, an efficacy  rate 
of 91.3% was observed for BNT162b2 in prevent ing such cases occurring between [ADDRESS_274505] an efficacy of: 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 21100% in preventing severe disease as defined b y the CDC.
95.3% in preventing severe disease as de fined by  [CONTACT_1622].
100% in preventing COVID-[ADDRESS_274506] 16 y ears of age randomized 1:1 
to vaccine or placebo with a me dian of 2 months of follow -up after the second dose 
demonstrated a favorable safet y profile.  Available safet y data from all participants enrolled 
through the 14 November 2020 data cutoff (N = 43,252), which include d late enrollment of 
additional adolescen t and adult participants, were consistent with the safet y profile for the 
approximately  38,000 participants with a median follow -up of 2 months and also did not 
raise specific safet y concerns.41
A booster dose (Dose 3) of BNT162b2 was administered to 306 Phase 3 participants without 
prior evidence of SARS -CoV -2 infection ~6 months after completing the 2 -dose schedule.  
The immune response 1 month after administration of Dose 3 was noninferior to that 
observed 1 month after Dose 2 in the same participants.  Furthermore, from the same 
analysis, among participants without prior evidence of SARS -CoV -2 infection up to 1 month 
after Dose 3, a high proportion of participants (99.5%) had a seroresponse at 1 month after 
Dose 3 compared with 98.0% at 1 month after Dose 2.2
On 22 September 2021, based on safet y and immunogenicity data from approximately  
300immunocompetent adult booster dose recipi[INVESTIGATOR_227914]  C4591001, the FDA issued 
the EUA for a single booster dose of BNT162b2 30 µg for 1) individuals 65 years of age and 
older; 2) individuals 18 thro ugh 64 years of age at high risk of severe COVID- 19; and 
3)individuals [ADDRESS_274507] 6 months after 
completion of primary  vaccination with BNT162b2.  I n addition, a booster dose of the 
vaccine is authorized in the EU and other countries, with recommendations for populations 
varying based on local health authority  guidance.  
The per -protocol interim safet y and efficacy anal ysis was conducted in October 2021 for 
Study  C4591031 Substudy  A.  In this study , approximately  10,000 participants who had 
previously  received 2 doses of BNT162b2 as a primary  series in Study  C4591001 were 
randomized 1:1 in Study  C4591031 to receive either a 30
-µg booster dose (the same dosage 
strength as in the 2 -dose primary  series) or placebo.  The time between the second dose and 
administration of the booster dose or placebo for most participants was ≥10 to <12 months.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 22Symptomatic COVID -19 occurrence was measured from ≥7 day s after booster or placebo, 
with a median follow -up of 2.5 months.  During t he blinded placebo -controlled study  period 
up to a data cutoff date of 05 October 2021, there were a total of 6 cases of COVID-19 in the 
booster group and 123 cases in the nonboosted placebo group, in the evaluable efficacy  
population without evidence of p rior SARS -CoV -2 infection.  The observed relative VE was 
95.3% (2 -sided 95% CI: 89.5%, 98.3%), which reflects the reduction in disease occurrence in 
the boosted group versus the nonboosted group.  The AE profile was generally  consistent 
with other previous ly submitted clinical safet y data for the vaccine, with no new safety 
concerns identified.  No cases of m yocarditis or pericarditis were reported.[ADDRESS_274508] previously  received 3 doses of BNT162b2 (30 -μg dose). 
Participants in this substudy  received a fourth dose of either BNT162b2 or BNT162b2 
Omicron (BA.1 sublineage) or a combination of both at a total dose level of either 30 μg or 
60μg.From the available safet y data from this study, the tolerability  and safet y profile of 
bivalent BNT162b2 30 μg, up to 1 month after study  vaccination (to the data cutoff date),
was acceptable and consistent with the known safety profile of BNT162b2 and pr eviously  
reported AE profile for Omicron BA.1 –modified BNT162b2 vaccines. In participants 
>18through 55 years of age ,the 
bivalent Omicron -modified vaccine at the 30 -μg dose level 
showed a similar local reaction and s ystemic event reactogenicity  profile as the prototy pe 
BNT162b2 vaccine. From the immunogenicity  data, in participants >55 years of age 
without evidence of COVID -19 infection, Omicron BA.1–neutralization activity  
substantially increased with Omicron -modified bivalent vaccines as a fourth dose . 
Additionally ,analysis of immunogenicit y data from this study
 demonstrated a robust 
vaccine -elicited immune response to thebivalent Omicron BA.1 –modified vaccines when 
administered as a booster (Dose 4) to BNT162b2 -experienced participants 18 through 
55years of age. Bivalent Omicron -modified vaccines (BNT162b2 + BNT162b2 O mi30µg 
and 60 µg) met the defined 
superiority criteria against Omicron BA.1 and noninferiority 
response to the reference strain, in participants within the group >55 yearsof age .Based on 
the1-month postdose safety  and immunogenicity findings from the C4591031 S ubstudy  E 
>
55-year age group , the FDA granted EUA on [ADDRESS_274509] SARS -CoV -2 infection 
andCOVID -19 wanes over a period of months, particularl y in the context of 
variant s.13,14,50  
Inlight of the waning effectiveness of the 2 -dose primary  series of BNT162b2 as well as the 
existence of variant s with cumulative mutations in the spi[INVESTIGATOR_227915] 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 23existing immune response, particularly  Omicron, an enhanced bivalent vaccine was 
developed. Study  C4591044 is currentl y evaluating bivalent BNT162b2 
(original/Omi BA.4/BA.5) consisting of the LNP -formulated original SARS -CoV -2 spi[INVESTIGATOR_227916], targetin g the ancestral strain of the virus, in combination with 
LNP -formulated mRNA encoding the spi[INVESTIGATOR_227917] 
(BA.4/BA.5 sublineage) in approximately  900 participants ≥[ADDRESS_274510] neutralizing immune response 1 month after a 
30-µg booster dose of Omicron BA.4/BA.5 –adapted bivalent COVID -19 vaccine 
([COMPANY_007] -BioNTech COVID-19 vaccine, bivalent [original and Omicron BA.4/BA.5]).  
Immune responses against the BA.4/BA.5 sublineages were substantiall y higher for those 
who received the bivalent vaccine compared to the companies’ original COVID -19 vaccine, 
with a similar safet y and tolerability profile between both vaccines.51  
Omicron BA.4/BA.5 remained dominant in the US until October 2022 ,when they  were 
replaced b y XBB and BQ.1 sublineages. BQ.1 is a subvariant of BA.5, but XBB is a 
recombinant subvariant, combining BA.2.10.1 and BA.2.75.52  Preliminary  data comparing 
immune responses to the monovalent BNT162b2 (original) vaccine and the b ivalent 
BNT162b2 (original/Omi BA.4/BA.5) in adults 
>55years o f age who had received 3 prior 
doses of monovalent BNT162b2 showed that bivalent BNT162b2 (original/Omi BA.4/BA.5) 
induced higher GMFRs against BA.4/ BA.5, BA.4.6, B A.2.75.2, BQ.1.1, and XBB .1, 
suggesting that the biva lent BNT162b2 (original/Omi BA.4/ BA.5) vaccine is more 
immunogenic against circulating Omicron sublineages compared with the original 
BNT162b2 monovalent vaccine .53
Data on SARS -CoV -2 evolution indicated that Omicron XBB sublineages accounted for 
more than 95% of the circulating virus variants in the US as of earl y June 2023. While 
XBB.1.5 has declined to less than 40% of presumed circulating virus in the US, XBB.1.16 is 
on the rise and XBB.2.3 is slowly  increasing in proportion.  Th e current trajectory  of virus 
evolution suggests that XBB.1.16 could be dominant by  [CONTACT_227973] 2023. XBB.2.3 and other XBB 
sublineages could also continue to increase in proportion as the virus evolves. Although 
SARS -CoV -2 continues to evolve, the protein sequ ences of the XBB.1.5, XBB.1.16, and 
XBB.2.3 spi[INVESTIGATOR_227918], with few amino acid differences. Available evidence 
suggests little to no further immune evasion from these new substitutions in the XBB.1.16 
spi[INVESTIGATOR_227919].1.5. By[CONTACT_227974], including escape from antibody  
neutralization and waning protection, the bivalent COVID-19 (original/Omi BA.4/BA.5) 
vaccines appear less effective against currentl y circulating variants (eg, XBB -lineage viruses) 
than against previous str ains of virus. The totality  of available evidence suggested that a 
monovalent XBB-lineage vaccine was warranted for the 2023- 2024 update ,and the FDA has 
advised that manufacturers seeking to update their COVID -19 vaccines should develop 
vaccines with a monovalent XBB.1.5 composition ,which was approved on 
11September 2023 in US.28,54
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page [IP_ADDRESS]. RSVpreF Vaccination
RSVpreF is a bivalent RSV prefusion F subunit vaccine developed b y [COMPANY_007]. The RSV 
Fglycoprotein facilitates fusion of the virion and host cell membrane through a dramatic 
transition from an unstable but highl y immunogenic prefusion conformation to the more 
stable postfusion state. Preclinical studies show that prefusion F elicits much higher 
neutralizing antibody titers than postfusion F and that the most potent neutralizing antibodies 
from postinfection human sera target the prefusion form. RSVpreF is composed of 
engineered, stabilized, trimeric, prefusion F gl ycoproteins matching the 2 subgroups 
(AandB) to help ensure the broadest coverage against RSV illness.
RSVpreF is being developed for 2 indications:
Older Adult: Prevention of ARI -RSV and LRTI -RSV in adults 60 y ears of age and older 
via active immunization.
Maternal: Prevention of L RTI-RSV and severe LRTI -RSV in infants by  [CONTACT_227975].
As of September 2023, RSVpreF has been studied in healthy  adults and pregnant women.  
RSVpreF was shown to be well tolerated, with an acceptable safet y profile, and highl y 
efficacious in older adults and infants of women vaccinated during pregnancy .
In the Phase 1/2 study  C3671001, 123 3healthy  adults 18 through 49 and 50 through
85years of age received 3 dose levels of RSVpreF (60 µg, 120 µg, and 240 µg), with or 
without Al(OH) 3, or placebo, administered with or without concomitant in flu enza
vaccine. The results have shown that the va ccine was well tolerated and immunogenic in 
both age groups. RSVpreF elicited robust neutralizing responses against RSV A and 
RSV B 1 month after vaccination for both age groups across all vaccine dose levels and 
formulations; these responses remained hig h through the 12 months after vaccination. 
In616vaccinated participants in the 50- through 85 -year age group, RSV 50% NT 
GMFRs were high across all study  groups, ranging from [ADDRESS_274511] reported local reactions or systemic events were mild or 
moderate in severity .
The p roportions of participants reporting AEs were generally  similar across RSVpreF 
groups, andno SAEs were considered related to the investigational vaccine.
Phase 1/2 study  C3671002, in 313 older adults 65 through 85 years of age, studied the 
3dose levels of RSVpreF with Al(OH) 3, or CpG/Al(OH) 3(60 µg, 120 µg, and 240 µg), 
given as a single dose or on a schedule of 2 doses administered 2 months apart. 
AllRSVpreF doses and formulations elicited high RS V A–and RSV B –neutralizing 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 25antibody  GMTs 1 month after vaccination (GMFRs ranging from 4.8 to 11.6 and 4.5 to 
14.1, respectivel y). CpG -containing formulations did not further increase neutralizing 
GMTs compared to RSVpreF with or without Al(OH) 3. GMTs in all groups declined but 
remained higher than baseline (before vaccination) and placebo (SIIV onl y) at 12 months 
after vaccination (GMFRs ranging from 2.1 to 3.5 and 2.2 to 4.3, respectively ). 
Noincrease in GMTs was observed 1 month after Vaccination 2 (GMFR of 0.9). 
Alldoses and formulations were safe and well tolerated. 
Study  C3671014 is a completed Phase 3, multicenter, parallel- group, placebo -controlled, 
randomized, double -blind lot -consistency  study  in a population of up to 1000 healthy  
adults 18 to ≤49 y ears of age. The stud y examined the immune response and the safet y 
and tolerability  profiles across 3 manufactured lots of RSVpreF when administered as a 
single 120-µ g dose to healthy  adults. The primary  analy ses showed that the ratios of 
neutral izing GMTs for each of the 3 manufactured RSVpreF lots 1 month after 
vaccination are equivalent, and that the 120- μg dose of RSVpreF is well tolerated and has 
an acceptable safet y profile.
A Phase 2a, Randomi zed, Double -Blind, Placebo- Controlled Study  to E valuate the 
Safety , Immunogenicit y and Efficacy  of aRespi[INVESTIGATOR_227920] 
(RSVpreF) in aVirus Challenge Model in Healthy Adults ( [STUDY_ID_REMOVED]) was 
conducted b y hV IVO in 70 healthy  participants 18 to 50 y ears of age .Participants
received a s ingle dose of either 120 μg RSVpreF or placebo and 4 weeks later underwent 
intranasal challenge with RSV A Memphis 37b virus. The immunogenicity and efficacy  
of RSVpreF vaccination on virus replication, clinical symptoms, and incidence of 
symptomatic RSV infection following the intranasal challenge were evaluated. The 
primary  anal ysis of the human challenge stud y showed that a 120-μg dose of RSVpreF 
was well tolerated and has an acceptable safet y profile. The study  demonstrated 
100% efficacy  of RSVpreF 
against RT -PCR–confirmed sy mptomatic infection.
C3671013 is an ongoing Phase 3, multicenter, randomized, double -blind, 
placebo- controlled 
study to assess the safet y, immunogenicity , and efficacy of [COMPANY_007]’s 
RSVpreF in prevention of RSV-associated LRTI in a dults 60 y ears of age and older. 
Both health y adults and adults with stable chronic cardiopulmonary conditions are 
included. Approximately  10% of participants with stable chronic cardiopulmonary  
conditions such as COPD, asthma, or CHF are being enrolled. The stud y enrolled over 
37,000 participants, randomized to receive RSVpreF or placebo in a 1:[ADDRESS_274512] LRTI -RSV 
defined b y 2 or more s ymptoms demonstrated VE: 66.7%. VE of 85.7% was observed in 
participants with a more severe disease primary  endpoint of L RTI-RSV defined by  
[CONTACT_227976] 3 or more RSV -associated s ymptoms. The vaccine was well tolerated, with 
no safet y concerns.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 26C3671006 is a completed Phase 3, multicenter, parallel -group, placebo -controlled, 
randomized, double -blind study designed to assess the safet y and immunogenicity  of 
RSVpreF when coadministered with SIIV compared to sequential administration of the 
vaccines when given 1 month apart (SIIV followed by  [CONTACT_227977]) .Approximately  
1400 healthy  adults ≥65 y ears of age were randomized 1:1 to either a coadministration 
group or a sequential -administration group.  The intention was to demonstrate that the 
immune responses generated with a 120 -µg RSVpreF dose coadministered with SIIV 
were noninferior to the immune responses when these products were administered 
4weeks apart. The safety  and tolerability  of RSVpreF were also exami ned. Results 
demonstrated noninferiority  of the RSVpreF and SIIV immune responses when RSVpreF 
was coadministered with SIIV. The results of this study  support the acceptability  of 
coadministration of RSVpreF and SIIV in an older adult population.
C3671016 is Phase 1/2/3 study  in participants 2 to <18 y ears of age at high risk of RSV 
disease initiated in June 2023.55  The study  consists of 2 phases: Phase 1 and Phase 2/3. 
Phase 1 is an open
-label, age descending, dose- finding stud y and Phase 2/3 is a
placebo- controlled, randomized, double -blinded study  to evaluate the safety , tolerability , 
and immunogenicity of RSVpreF. Both the 120 -µg dose level and a 60 -µg dose level will 
be evaluated. Approximately  120 participants w ill be enrolled in the Phase 1 c ohort and 
up to 1860 participants will be enrolled in the Phase 2/3 cohort.
C3671023 is a Phase 3 study  to evaluate the safet y, tolerability , and immunogenicity  of 
RSVpreF in adults at high risk of severe RSV disease. The stud y is divided into 
2substudie s: Substudy  A and Substudy  B. Substudy  Ais a double -blinded, randomized, 
placebo-controlled trial, enrolling participants ≥18 to <60 y ears of age who are at high 
risk for severe RSV disease due to underl ying medical conditions, such as COPD, 
asthma, and C HF, or due to living in a skilled -nursing facility . Participants (N=675) will 
be randomized 2:1 to 1 dose of RSVpreF or placebo and followed for 6 months.
Substudy  Bis an open- label trial which has completed enrollment of participants age 
18years and o lder with immunocompromising conditions . Participants (approximately  
N=200) received 2 doses (1 month apart) of RSVpreF and were followed for [ADDRESS_274513] dose.
RSVpreF is also being studied in the maternal program, which includes Phase 2b and
Phase 3 studies in pregnant women and a Phase 2b study in nonpregnant women. Details of 
each of these studies are provided in the RSVpreF IB.
2.3.Benefit/Risk Assessment
The available safet y, immunogenicit y, and effectiveness data from ongoing clinical trials for 
RSVpreF and BNT162b2 support a favorable benefit/risk profile and support clinical 
development of a vaccine combining these components. The s tability  of RSV preF and LNP 
mRNA formulation has been assessed, and there is no observed difference in stability profile 
of RSV preF as a result of mixing with L NP.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 27Taking into account the measures to minimize risk to study  participants, the potential risks 
identified in association with the study  intervention are justified by  [CONTACT_227978].
Clinical investigation is justified, given:
The threat posed b y continuous new outbreaks of SARS -CoV -2 infections worldwide.
The threat posed b y the SARS -CoV -2 variants emerging worldwide.
The potential need for enhancing immune responses to overcome waning immunity .
The potential advantages and convenience to individuals in developi[INVESTIGATOR_007] a combined 
vaccine against RSV andSARS -CoV -2 that would align with the recent FDA 
recommendations for an a nnual COVID -19 vaccination approach .
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of bivalent BNT162b2 (original/Omi BA.4/BA.5) and RSVpreF may  be found 
in the irIBs, which are the SRSDs for this study .The SRSD for QIV is the Fluzone HD
USPI .Refer to the Study I ntervention(s) table in Section 6 for a complete d escription of 
SRSDs.
2.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale 
for RiskMitigation Strategy
Study Intervention(s): [RSVpreF +BNT162b2 ]
The potential risks for the combination 
vaccine areexpected to be similar to 
the potential risks for the individual 
components as detailed below .It is anticipated that common 
adverse reactions seen with 
the individual components 
will also be seen with the 
combination vaccine, as 
detailed below .The mitig ations for the combination 
vaccine will be similar to the 
mitigations for the individual 
components as detailed below .
Study Intervention(s): BNT162b2 , BNT162b2 Omicron ( BA.4/BA.5 S ublineage)
For BNT162b2 Omicron ( BA.4/BA.5 
sublineage):
Thesevaccine shave the same 
modRNA platform (with sequence 
changes limited to those that are 
Omicron specific) and LNP 
formulation as BNT162b2; therefore, 
the safety profile is expected to be 
similar to that of BNT162b2, ie, local 
reactions, such as injection site 
redness , injection site swelling, and These are common adverse 
reactions seen with other 
vaccines as well as the 
COVID -19 vaccine.
Data available from the 
C4591001 study (with 
BNT162b2) show ed low  
incidence of severe or serious 
events and no clinically 
concerning safety 
observations across the safety The study employs the use of a 
reactogenicity e -diary, which allows 
the investigator to monitor local 
reactions and systemic events in real 
time through an electronic portal. 
Severe reactions will require an 
unscheduled telephone call, and visit 
if required, to be conducted per 
protocol.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 28Potential Risk of Clinical 
SignificanceSummary of Data/Rationale 
for RiskMitigation Strategy
injection site pain, and systemic 
events , such as fever, fatigue, 
headache, chills, muscle pain, and 
joint pain.
Other key risks identified for 
BNT162b2 are lymphadenopathy; 
hypersensitivity reactions, such as 
rash, pruritus, urticaria, angioedema, 
and anaphylaxis; and myocarditis and 
pericarditis.population and within 
demographic subgroups based 
on age, sex, race/ethnicity, 
country, and baseline 
SARS -CoV- 2 status.41
Anaphylaxis: Frequency not 
known.
Myocarditis and pericarditis: 
Very  rare cases of myocarditis 
and pericarditis have been 
reported follow ing 
vaccination with mRNA 
COVID -19vaccines .
Typi[INVESTIGATOR_897], the cases have 
occurred more often in 
younger men and after the 
second dose of the vaccine 
and within [ADDRESS_274514]. 
Healthcare profes sionals 
should be alert to the signs 
and symptoms of myocarditis 
and pericarditis in vaccine 
recipi[INVESTIGATOR_840].
Postauthorization safety data 
surveillance has confirmed 
the safety profile observed in 
Study C4591001 and has 
resulted in identification of 
some addit ional adverse 
reactions (risks) as noted in 
the SRSD.AEs will be collected from the 
signing of informed consent through 
Visit 2 (1-month follow -up visit) .
SAEs will be collected from the 
signing of informed consent th rough 
Visit 3 ([ADDRESS_274515]). 
Specific references to risks and events 
of interest are made within the ICD, 
with reporting instructions if a case is 
suspected.
Study Intervention(s): RSVpreF
For RSV preF :[COMPANY_007] has identified 
the most common risks for RSVpreF 
as local reactions, such as injection 
site redness, injection site swelling, 
and injection site pain, and systemic 
events, such as fatigue, headache, 
diarrhea, joint pain, nausea, vomiting, 
muscle pai n, and fever.39These are common adverse 
reactions seen with other 
vaccines as well as 
RSVpreF.57
Data available from 
completed and ongoing 
studies showed a low  
incidence of severe or serious 
events, and no clinically The study employs the use of a 
reactogenicity e -diary, which allows 
the investigator to monitor local 
reactions and systemic events in real 
time through an electronic portal. 
Severe reactions will require an 
unscheduled telephone call, and visit 
if required, to be conducted per 
protocol.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 29Potential Risk of Clinical 
SignificanceSummary of Data/Rationale 
for RiskMitigation Strategy
Guillain -Barré syndrome has been 
identified as a potential risk for 
RSVpreF.
Other events of interest include atrial 
fibrillation, polyneuropathy, preterm 
birth ( delivery at <37 0/7 w eeks’ 
gestation) , and hypertensive disorders 
of pregnancy.[ADDRESS_274516] labels may vary 
depending on the requirements of the 
respective regulatory authorities 
(eg,EUSmPC and USPI).concerning events. The 
vaccine appears to be safe and 
well tolerated across the 
safety population and within 
demographic subgroups based 
on age, sex, and 
race/ethnicity .58
In Study C3671013, 
conducted in adults 60 years 
of age and older, there w as 
1case of Guillain -Barré
syndrome and 1 case of Miller 
Fisher syndrome (both with a 
plausible temporal 
relationship with vaccination).
Both cases had confounding 
factors or an alternative 
etiology. 
In Study C3671013, 
conducted in adults [ADDRESS_274517] of the 
participants who had atrial 
fibrillation and received 
RSVpreF had a p reexisting 
medical history of atrial 
fibrillation and/or cardiac 
disease.59All study participants will be 
observed for at least 30 minutes after 
vaccination .
AEs will be collected from the 
signing of informed consent through 
Visit 2 (1 -month follow -up visit) .
SAEs will be collected from the 
signing of informed consent through 
Visit 3 ([ADDRESS_274518]). 
Specific references to risks and events 
of interest are made within the ICD, 
with reporting instructions if a case is 
suspected.
Study Intervention(s): QIV
Local and systemic reactions to the 
vaccine may occur.The follow ing summary 
represents an example QIV 
safety profile.
In adults [ADDRESS_274519] commonly 
reported injection -site adverse 
reaction waspain ( 41.3%).
The most commonly reported 
systemic adverse reactions 
were myalgia (22.7%) , The study employs the use of a 
reactogenicity e -diary, which allows 
the investigator to monitor local 
reactions and systemic events in real 
time through an electronic portal.  
Severe reactions will require an 
unscheduled telephone call, and visit 
if required, to be conducted per 
protocol.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 30Potential Risk of Clinical 
SignificanceSummary of Data/Rationale 
for RiskMitigation Strategy
headache (14.4%) ,and 
malaise (13.2 %).60All study participants will be 
observed for at least 30 minutes after 
vaccination .
AEs will be collected from signing of 
the ICD through 1monthand SAEs 
through 6 months after study 
vaccination.
Study Procedures
Venipuncture will be performed 
during the study.There is the risk of bleeding, 
bruising, hematoma 
formation, and infection at the 
venipuncture site.Only appropriately qualified 
personnel will obtain the blood draw .
2.3.2. Benefit Assessment
Benefits to individual participants enrolled in Substudy A are detailed in Section [IP_ADDRESS].
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the measures to minimize risk to study  participants, the potential risks 
identified in association with RSVpreF and BNT162b2 RNA -based COVID -19 vaccines are 
justified by  [CONTACT_227979] y participants.
3.OBJECTIVES, ENDPOINT S, AND ESTIMANDS
See Section 10.11.5 for the Substudy  A objectives, endpoints, and estimands.
4.STUDY DESIGN
4.1.Overall Design
See Section 10.11.6 for the Substudy  A design.
4.2.Scientific Rationale for Study Design
See Section 2.1.
See the substudy  appendi xfor the rationale supporting the 
substudy .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274520] historically  been shown to recruit diverse 
participants and/or are geographicall y located in diverse communities. Early  and ongoing 
site interactions will include diversity  discussions, and diver sity materials will be provided to 
support the sites’ participant engagements.
4.2.2. Rationale for Comparator
Active comparators to the combination vaccine [ RSVpreF+BNT162b2] have been chosen for 
Substudy  A, including individual injections of RSVpreF and bivalent BNT162b2. The doses 
for these comparators were chosen based on the doses that demonstrated efficacy  in the 
pi[INVESTIGATOR_9205] 3 study  (RSVpreF) and the dose granted with an EUA by  [CONTACT_1622] (bivalent 
BNT162b2 [original/Omi BA.4/BA.5 ]).
4.2.3. Choice of Contr aception/Barrier Requirements
Abry svo ( for the prevention of lower respi[INVESTIGATOR_227921] b y RSV in individuals 
60 years and older) has not been studied in pregnant individuals less than 24 weeks 
gestational age and in those at increased risk for preterm birth, and available data on 
Comirnaty (for the prevention of COVID -19 caused by  [CONTACT_7544] -CoV -2) administered to 
pregnant women are insufficient to inform vaccine -associated risks in pregnancy . The use of 
a highl y effective method of contraception is required for sexual intercourse involving a 
WOCBP (see Section 10.4.3 ).
4.3.Justification for Dose
4.3.1. Bivalent BNT162b2 (Original/Omi BA.4/BA.5)
The FDA has granted EUA for the use of bivalent BNT162b2 ( original/Omi BA.4/BA.5) at a 
dose level of 30 
µg (15 µg original BNT162b2 and 15 µg BNT162b2 Omicron [B.1.1.529 
sublineage BA.4/BA.5]) in individuals ≥12 years of age ,61and this dose level is being used 
when bivalent BNT162b2 ( original/Omi BA.4/BA.5) is administered alone and as part of the 
RSVpreF and bivalent BNT162b2 (original/Omi BA.4/BA.5) vaccine 
[RSVpreF+BNT162b2
]administered in Substudy  A.
4.3.2. RSVpreF
The120-μgdose, without any  adjuvants ,was the dose that demonstrated efficacy in the 
pi[INVESTIGATOR_9205] 3 study  in adults 60years of age and older . This dose has been shown to be 
well tolerated . This dose also demonstra ted no interference when administered concurrently  
with a seasonal influenza vaccine (Study C3671006).5
The dose and formulation for Substudy  A is 120 μg RSVpreF without any adjuvants.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 324.3.3. Combined RSV preF and Bivalent BNT162b2 (Original/Omi BA.4/BA.5) Vaccine 
[RSVpreF+BNT162b2]
The dose and formulation for Substudy Ais based on the combination of the individual 
components of the vaccine as detailed inSection 
10.11.8.
4.4.End of Study Definition
The end of 
thesubstudy  is defined as the date of the last visit of the last participant in the 
substudy .
A participant is considered to have completed the substudy  if they  have completed all periods 
of the substudy , including the last visit.
The end of the overall study is the last visit of the last participant in the substudy  to be 
completed.
5.STUDY POPULATI ON
Thesubstud ycan fulfill theobjectives onl y if appropriate participants are enrolled, including 
participants across diverse and representative racial and ethnic backgrounds.  If a 
prescreening tool is utilized for study recruitment purposes, it will in clude collection of 
information that reflects the enrollment of a diverse participant population including, where 
permitted under local regulations, age, sex, race, and ethnicity .  The following eligibility  
criteria are designed to select participants for whom participation in the substudy  is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
Note : “Enrolled” means a participant’s, or their legall y authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process.
5.1. Inclusion Criteria
See Section [IP_ADDRESS] for the Substudy  A inclusion criteria.
5.2.Exclusion Criteria
See Section [IP_ADDRESS] for the Substudy  A exclusion criteria.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 335.3.Lifestyle Considerations
5.3.1. Contraception
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contraception methods (see Section 10.4) and 
will confirm t hat 
the participant has been instructed in it s consistent an d cor rect use. The 
investigator or designee will advise the participant to seek advice about the donation and 
cryopreservation of germ cells prior to the start of study intervention, if applicable.
At time points indicated in the SoA(
s), the investigator or designee will inform th e 
participant of the need to use acceptable effective contraception consistently and correctl y 
and document the conversation and the participant ’s affirmation in the participant’ s chart.  
Participants need to affirm their consistent and correct use of at l east [ADDRESS_274521] the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol- specified method, including if the participant will no longer use abstinence 
as the selected contraception method, or if pregnancy is known or suspected in the participant 
or part ner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study .  A minimal set of screen failure information is 
required to ensure transparent reporting of sc reen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities.  Minimal 
information includes demograph y, screen failure details, and an y SAEs.
Individuals who do not meet the criteria for partic ipation in thesubstudy  (screen failures) 
may be rescreened.
5.5.Criteria for Temporarily Delaying Enrollment/Randomization/Administration of 
Study Intervention
See Section [IP_ADDRESS] for temporary  delay  criteria for Substudy  A.
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
SeeSection 10.11.8 for study  intervention(s) and concomitant therap y for Substudy  A.
6.1.Study Intervention(s) Administered
See Section [IP_ADDRESS] for study  interventions to be administered during Substudy  A.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274522] 
immunization practices.
Administration of study  interventions willbe performed by  [CONTACT_227980] y 
qualified, trained, and vaccine -experienced member of the stud y staff (eg, physician, nurse, 
physician ’
s assistant, nurse practitioner , pharmacist, or medical assistant) as allowed by  [CONTACT_5737], 
state, and institutional guidance.
Study  intervention administration details will be recorded on the CRF .
See Section [IP_ADDRESS].1 (Substudy  A) for study  intervention administration details.
6.1.2. Medical Devices
In this stud y, medical devices being deplo yed are for the reconstitution diluent for some of 
the 
study  interventions. 
All medical device deficiencies (including malfunction, use error, and inadequate labeling) 
shall be documented and reported b y the investigator throughout the clinical investigation 
(see Section 8.4.9) and appropriatel y managed b y the sponsor.
6.2.Preparation, Handling, Storage, and Accountability
1.The investigator or designee must confirm that appropriate conditions (eg, temperature) 
have been maintained during transit for all study  interventions r eceived and any  
discrepancies are reported and resolved before use of the study  intervention.
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply , prepare, and/or administer study  intervention.
3.
All study  interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximum temperatures for all site storage locations must 
be documented and available upon request.  Data for nonworking day s must indicate the 
minimum and maximum temperatures since previously  documented upon return to 
business.
4.Any excursions from the study  intervention label storage conditions should be reported to 
[COMPANY_007] upon discovery  along with actions taken.  The site should activel y pursue options 
for returning the stud y intervention to labeled storage conditions, as soon as p ossible.  
Once an excursion is identified, the study intervention must be quarantined and not used 
until [COMPANY_007] provides permission to use the study  intervention.  Specific details regarding 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 35the excursion definition and information to report for each excur sion will be provided to 
the site in the I PM.
5.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_214341].  See the I PM for storage conditions of the prepared study  intervention.
6.Study  interventions should be stored in their original containers.
7.The investigator, institution, head of the medical institution (where applicable), or 
authorized site staff is responsible for study  intervention accountability , reconciliation, 
and record maintenance (ie, receipt, reco nciliation, and final disposition records), such as 
the IPAL or sponsor -approved equivalent.  All study  interventions will be accounted for 
using a study intervention accountabilit y form/record.
8.Further guidance and information for the final disposition of unused study  interventions 
are provided in the I PM.  All destruction must be adequatel y documented.  If destruction 
is authorized to take place at the investigator site, the investigator must ensure that the 
materials are destro yed in compliance with applicable environmental regulations, 
institutional policy , and any  special instructions provided by  [CONTACT_4618].
Upon identification of a product complaint, notify the sponsor within 1 business day  of 
discovery as described in the I PM.
6.2.1. Preparation and Dispensing
See the IPM for instructions on how to prepare the study  intervention for administration.  
Study  intervention should be prepared and dispensed by  [CONTACT_227981] (eg, phy sician, nurse, phy sician
’s assistant, nurse 
practitioner, pharmacy  assistant/technician, or pharmacist) as allowed by  [CONTACT_5737], state, and 
institutional guidance.  A second unblinded staff member will verify  the dispensing.
See Section [IP_ADDRESS].3.1 for further details regarding preparation and dispensing for 
Substudy A.
6.3.Assignment to Study Intervention
Allocation (randomization) of participants to vaccine groups will proceed through the use of 
an IRT s ystem (I WR) .  The site personnel (stud y coordinator or specified designee) will be 
required to enter or select information including, but not limited to, the user’s ID and 
password, the protocol number, and the participant number.  The site personnel will then be 
provided with a randomization number *.  The I RT sy stem will provide a confirmation report 
containing the participant number, randomization number, and stud y inter
vention allocation 
assigned.  This report will be provided to blinded or unblinded site staff as appropriate on the 
role/permission the user is granted and must be stored in the site’s blinded or unblinded files 
as appropriate.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 36*Do not randomize until eligibility  is confirmed and the participant is present.
Study  intervention will be dispensed at the study  visits summarized in the SoA(s). 
6.4.Blinding
See Section [IP_ADDRESS] for Substudy  A blinding arrangements.
6.4.1. Blinding of Participants
Substudy  A blinding arrangements for participants are detailed in Section [IP_ADDRESS].1.
6.4.2. Blinding of Site Personnel
Substudy  A blinding arrangements for site personnel are detailed in Section [IP_ADDRESS].2.
6.4.3. Blinding of the Sponsor
Substudy  A blinding arrangements for the sponsor are detailed in Section [IP_ADDRESS].3.
6.4.4. Breaking the Blind 
The I RT will be programmed with blind -breaking instructions. In case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s study  
intervention assignment is warranted. Participant safet y must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make every  effort to contact [CONTACT_227982] a participant’s study  intervention assignment unless this could delay  
further management of the participant. If a participant’s study  intervention assignment is 
unblinded, the sponsor must be notified within [ADDRESS_274523] information and 
further details on the use of the I RT sy stem.
6.5. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recor ded in the source documents and recorded in the CRF.  
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention .
6.6. Dose Modification
Dose modification is NAto this protocol .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274524] -of-care treatments, as 
advised b y their usual care physician .
6.8.Treatment of Overdose
For this study , any  dose of study  intervention greater than 1 dose of study  intervention within 
a 24-hour time period will be considered an overdose.
[COMPANY_007] does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_219876] 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities as 
medically  appropriate and at least until the next scheduled follow
-up.
3.Document the quantit y of the excess dose as well as the duration of the overdose in the 
CRF.
4.Overdose is reportable to [COMPANY_007] Safety  only when a ssociated with an SAE.
6.9.
Prior and Concomitant Therapy
See Section [IP_ADDRESS] for Substudy  A prior and concomitant therapy .
7.DISCONTI NUATION OF STUDY INT ERVENTION AND PARTIC
IPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Since this is a single -dose study , this section is NA.
7.2.Participant Discontinuation/Withdrawal From the Study
A participant may  withdraw from the study  at an y time at their own request.  Reasons for 
discontinuation from the study  include the following:
Refused further stud y procedures
Lost to follow -up
Death
Study  terminated by  [CONTACT_3211]
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 38AEs
Participant request 
Investigator request
If a participant w ithdraws from the study , they  may  request destruction of any  remaining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the st udy and also withdraws consent (see Section 7.2.1)
for disclosure of future information, no further evaluations will be performed ,and no 
additional data will be coll ected.  The sponsor may retain and continue to use an y data 
collected before such withdrawal of consent.
When a participant is withdrawn from the study , the investigator will complete the6-month 
telephone contact [CONTACT_227983] .
7.2.1. Withdrawal of Consent
Participants who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -up procedures.  The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_185609].  
Participants should notify  the investigator in writing of the decision to withdraw consent 
from future follow -up, whenever possible.  The withdrawal of consent should be explained in 
detail in the medical records by  [CONTACT_093], as to whether the withdrawal is only  from 
further receipt of study  intervention or also from study  procedures and/or postvaccination 
study  follow -up, and entered on the appropriate CRF page. In the event that vital status 
(whether the participant is alive or dead) is being measured, publicl y available information 
should be used to determine vital status only  as appropriatel y directed in accordance with 
local law .
7.3.Lost to Follow -Up
A participant will be considered lost to follow -up if the participant repeatedly  fails to return 
for scheduled visits and is unable to be contact[CONTACT_17066].
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_46342].  Counsel the participant on the importance of maintaining the assigned visit 
schedu le, and ascertain whether the participant wishes to and/or should continue in the 
study .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 39Before a participant is deemed lost to follow- up, the investigator or designee must make 
every  effort to regain contact [CONTACT_6635] (where possible, 3 telepho ne calls and, 
if necessary , a certified letter to the participant’s last known mailing address or local 
equivalent methods).  These contact [CONTACT_13140]’s 
medical record .
Should the participant continue to be unreachable, the participant will be considered to 
have withdrawn from the study .
8.STUDY ASSESSMENTS AND PROCEDURES
8.1.Administrative Procedures
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.
Study  procedures and their timing are summarized in the SoA(s).  Protocol waivers or 
exemptions are not allowed.
Adherence to the study design requirements, including those specified in the SoA(s), is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria.  The investigator will maintain a screening log to 
record details o f all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every ef fort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However , it is anticipated that fr om time to time there may  be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that they  have taken to ensure that required processes are adhered to as soon as 
possible.  The study  team m ust be informed of these incidents in a timely  manner .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
8.1.1. Telehealth Visits
If in-clinic study  visits cannot be conducted, every effort should be made to follow up on the 
safet y of stud y participants.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274525] data points. Telehealth includes the exchange of healthcare 
information and services via telecommunication technologies (eg, audio, video, 
videoconferencing software) remotel y, allowing the participant and the investigator to 
communicate on aspects of clinical care, including medical advice, reminders, education, and 
safet y monitoring. 
The following assessments must be performed during a telehealth visit: 
Review and record study interve ntion(s), including compliance and missed doses .
Review and record any AEs and SAEs since the last contact. Refer to Section 10.3.3.
Review and record an y new concomitant medications or changes in concomitant 
medications since the last contact.
Review and record contraceptive method and results of pregnancy testing. Confirm that 
the participant is adhering to the contraception method(s) required in the protocol. Refer 
toSection 10.4.
Study  participants must be reminded to promptl ynotify site staff about an y change in 
their health status.
Additionally ,for Substudy  A:
Obtain stop dates forpreviously  reported AEs and SAEs. 
Obtain stop dates for an y reactogenicity events reported as present on the last day  of 
e
-diary  completion.
Record the use of prohibited medications in the CRF as noted in Section [IP_ADDRESS].1 .
Record the use of 
any new nonstudy vaccines in the CRF .
8.2.Efficacy and/or Immunogenicity Assessments
See Section [IP_ADDRESS] for Substudy  A immunogenicity  assessments.
8.2.1.
Biological Samples
Blood samples will be used only  for scientific research.  Each sample will be labeled with a 
code so that the laboratory  analy st testing the samples will not know the participant’s 
identity, study  visit, or study  cohort associated with the sample.  Samples that remain after 
performing assays outlined in the protocol may be stored by  [CONTACT_4618].  Unless a time limitation 
is required b y local regulations or ethical requirements, the samples will be stored for up to 
15 years after the end of the study  and then des troyed.  If allowed b y the ICD, stored samples 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 41may be used for additional testing to better understand the immune responses to the 
vaccine(s) under study  in this protocol, to inform the development of other vaccines or 
vaccine -related products, and/or for vaccine -related assay  work supporting vaccine programs.  
No testing of the participant’s DNA will be performed.
The participant may  request that their samples, if still identifiable, be destroy ed at any  time; 
however, an y data already collected from those samples will still be used for this research.  
The biological samples may be shared with other researchers as long as confidentiality  is 
maintained and no testing of the participant’s DNA is performed.
8.3.Safety Assessments
Planned time points for all safety assessments are provided in the SoA(s).  Unscheduled 
safet y measurements may be obtained at an y time during the stud y to assess any perceived 
safet y issues.
A clinical assessment, including medical history, will be performed on all participants at their 
first visit to establish a baseline.  Significant medical history  and observations from any  
physical examination, if performed, will be documented in the CRF.
AEs and SAEs are collected, recorded, and reported as defined in Section 8.4.
Acute reactions within the first 30 minutes after administration of the study  intervention will 
be assessed and documented in the AE CRF.
Safety  parameters also include reactogenicit y e-diary  reports of local reactions, sy stemic 
events (including fever), and use of antip yretic medication that occur in the [ADDRESS_274526] physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE 
(Section 10.3) must be reported according to the processes in 
Sections 8.4.[ADDRESS_274527] vital sign 
findings that are identified during the active collection period and 
meet the definition of an AE or SAE ( Section 10.3 ) must be repor ted according to the 
processes in Sections 8.4.1 to 8.4.3.
For details, refer to the substudy  appendix.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 428.3.3. Clinical Safety Laboratory Assessments
Clinical safety  laboratory assessments will not be collected in this study .Measurement of 
troponin will be performed locall y for potential myocarditis/pericarditis evaluation. 
For details, refer to the substudy  appendix .
8.3.4. Electronic Diary
All participants will be required to complete a reactogenicit y e-diary  after each vaccinati on 
through an application installed on a provisioned device or on the participant’s own personal 
device.  All participants will be asked to monitor and record local reactions, sy stemic events, 
and use of antip yretic medication for 7 days from the day  of ad ministration of the study  
intervention.  The reactogenicity  e-diary  allows recording of these assessments only  within a 
fixed time window, thus providing the accurate representation of the participant’s experience 
at that time.  Data on local reactions and systemic events reported in the reactogenicit y 
e
-diary  will be transferred electronically  to a third- party vendor, where they will be available 
for review b y investigators and the [COMPANY_007] clinicians at all times via an internet -based portal.
At intervals a greed to b y the vendor and [COMPANY_007], these data will be transferred electronicall y 
into [COMPANY_007]’s database for anal ysis and reporting.  These data do not need to be reported by  
[CONTACT_227984].
Investigators (or designee) will be required to review the reactogenicity  e-diary  data online at 
frequent intervals as part of the ongoing safet y review.
The investigator or designee must obtain stop dates from the participant for any  ongoing 
local reactions, sy stemic events, or use of antipy retic med ication on the last day  that the 
reactogenicity  e-diary  was completed.  The stop dates should be documented in the source 
documents and the information entered in the CRF.
[IP_ADDRESS]. Grading Scales
The grading scales used in this study  to assess local reactions and systemic events as 
described below are derived from the FDA CBER guidelines on toxicity  grading scales for 
healthy  adult volunteers enrolled in preventive vaccine clinical trials .57
[IP_ADDRESS]. Local Reactions
During the reactogenicit y e-diary  reporting period, participants will be asked to assess 
redness, swelling, and pain at the injection sit e and to record the s ymptoms in the 
reactogenicity  e-diary .  In Substud y A, local reactions will be assessed at the injection site on 
the right arm.
If a local reaction persists bey ond the end of the reactogenicity  e-diary  period following 
vaccination, th e participant will be requested to report that information.  The investigator will 
enter this additional information in the CRF.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 43Participants will be provided with a measuring device.  Redness and swelling will be 
measured and recorded in measuring device units (range: 1to21) and then categorized 
during anal ysis as absent, mild, moderate, or severe based on the grading scale in Table 1.  
Measuring device units can be
converted to centimeters according to the following formula: 
1measuring device unit = 0.[ADDRESS_274528] 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated.  Onl y an investigator or medicall y qualified person is able to classify  a 
participant’s local reaction as Grade
4.  If a participant experiences a confirmed Grade [ADDRESS_274529] immediately  notify  the sponsor.
Table 1. Local Reaction Grading Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially 
Life-Threatening 
(Grade 4)
Pain at the 
injection siteDoes not interfere 
with activityInterferes with activity Prevents daily 
activity Emergency room visit 
or hospi[INVESTIGATOR_214308] >2.0 cm to 5.0 cm 
(5 to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11to 20 measuring 
device units)>10cm 
(≥21measuring 
device units)Necrosis or exfoliative 
dermatitis
Swelling >2.0 cm to 5.0 cm 
(5 to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11to 20 measuring 
device units)>10cm 
(≥21measuring 
device units)Necrosis
[IP_ADDRESS]. Systemic Events
During the reactogenicit y e-diary  reporting period, participants will be asked to assess 
vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain, and new or 
worsened joint pain and to record the s ymptoms in the reactogenicit y e-diary .  The symptoms 
will be assessed b y the participant as absent, mild, moderate, or severe according to the 
grading scale in Table 2.
If a systemic event persists bey ond th e end of the reactogenicity  e
-diary  period following 
vaccination, the participant will be requested to report that information.  The investigator will 
enter this additional information in the CRF.
If a Grade [ADDRESS_274530] 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated.  Onl y an investigator or medicall y qualified person is able to classify  a 
participant’s s ystemic event as Grade 4.  If a participant experiences a confirmed Grade [ADDRESS_274531] immediately notify  the sponsor and, if it is determined 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 44to be related to the administration of the study  intervention, further vaccinations will be 
discontinued in that partic ipant.
Table 2. Systemic Event Grading Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially 
Life-Threatening 
(Grade 4)
Vom iting 1-2 times in 
24hours>2 times in 
24hoursRequires IV 
hydrationEmergency room visit 
or hospi[INVESTIGATOR_106318] 2 to 3 loose stools 
in 24 hours4 to 5 loose stools 
in 24 hours6 or more loose stools 
in 24 hoursEmergency room visit 
or hospi[INVESTIGATOR_214309]/tiredness Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospi[INVESTIGATOR_227922] w orsened 
muscle painDoes not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospi[INVESTIGATOR_214311] w or worsened 
muscle pain
New  or w orsened 
joint painDoes not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospi[INVESTIGATOR_214311] w or worsened 
joint pain
[IP_ADDRESS]. Fever
In order to record information on fever, a thermometer will be given to participants with 
instructions on how to measure oral tem perature at home.  Temperature will be collected in 
the reactogenicit y e-diary in the evening dail y during the reactogenicit y e-diary  reporting 
period.  It will also be collected at an y time during the reactogenicit y e-diary  data collection 
periods when fe ver is suspected.  Fever is defined as an oral temperature ≥38.0°C 
(≥100.4°F).  The highest temperature for each day  will be recorded in the reactogenicit y 
e-diary .  Temperature will be measured and recorded to [ADDRESS_274532].  Temperatures 
recorded in de grees Fahrenheit will be programmatically  converted to degrees Celsius and 
then categorized according to the scale shown in Table 3during analy sis.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 45If a fever of ≥39.0°C ( ≥102.1°F) is reported in the reactogenicity  e-diary , a telephone contact 
[CONTACT_214345] a site visit is clinically  
indicated.  Onl y an investigator or medicall y qualified person is able to confirm a 
participant’s fever as >40.0°C (>104.0°F).  If a participant experiences a confirmed fever 
>40.0°C (>104.0°F), the investigator must immediately  notify  the sponsor and, if it is 
determined to be related to the administration of the study  intervention, further vaccinations
(if applicable) will be discontinued in that participant.
Table 3. Scale for Fever
≥38.0 -38.4°C (100.4 -101.1°F)
>38.4 -38.9°C (101.2 -102.0°F)
>38.9 -40.0°C (102.1 -104.0°F)
>40.0°C (>104.0°F)
[IP_ADDRESS]. Antipyretic Medication
The use of antip yretic medication to treat s ymptoms associated with study  intervention 
administration will be recorded in the reactogenicity  e-diary  daily during the reporting period 
(Day  1 through Day 7).
8.3.5. Stoppi[INVESTIGATOR_227923]  A; see Section [IP_ADDRESS].
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Section 10.3.
The definitions of device
-related safet y events (ADEs and SADEs) can be found in 
Sections 10.10.1 and10.10.2. Device defici encies are c overed in Section 10.10.3 .
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or , when appropriate, by  a caregiver , surrogate, or the participant ’s legally  
authorized representative), or they  may  arise from clinical findings of the investigator or 
other healthcare providers (clinical signs, test results, etc).
The invest igator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whethe r the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  (see Section 7.1 ).
During the active collection period as described in Section 8.4.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 46In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -up 
informati on in an expedited fashion.
8.4.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“ active collection 
period”) for each participant begins from the time the participant provides i nformed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention), through and including 
VisitA102 (1- month follow -up visit) , per the SoA in the substudy  appendix . 
Record an y AEs that occur within the 48 hours after the blood draw . 
SAEs will be collected from the time the participant provides informed consent t hrough and 
including Visit A103
(6-month follow -up visit) , per the SoA in the substudy appendix .
Follow -up by  [CONTACT_185615] a level acceptable to the investigator .
When a clinically  important AE remains ongoing at the end of the active collection period, 
follow -up by  [CONTACT_227985] a level acceptable to the investigator and [COMPANY_007] concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a parti cipant permanently  discontinues or temporaril y discontinues study because of an AE 
or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using the 
Vaccine SAE Reporting Form.
Investigators are not obligated to activel y seek information on AEs or SAEs after the 
participant has concluded study  participation.  However , if the investigator learns of any  
SAE, including a death, at any  time after a participant has completed the study , and they  
consider the event to be reasonabl y related to the st udy intervention, the investigator must 
promptly  report the SAE to [COMPANY_007] using the Vaccine SAE Reporting Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in
Section 8.4.1 are reported to [COMPANY_007] Safety  on the Vacci ne SAE Reporting Form immediatel y 
upon awareness and under no circumstance should this exceed 24 hours, as indicated in
Section 10.3.4.  The investigator will submit any updated SAE data to the sponsor within 
24
hours of its being available.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page [IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which be gins after obtaining informed consent as described inSection 8.4.1, will be recorded 
on the AE section of the CRF .
The investigator is to record on the CRF all directly  observed, and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
As part of ongoing safet y reviews conducted b y the sponsor, an y nonserious AE that is 
determined b y the sponsor to be serious will be reported by [CONTACT_74094].  To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.4.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing an d transmitting SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.4.3. Follow -Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at s
ubsequent visits/contacts.  For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in suf ficient detail to 
allow for a complete medical assessment of the ca se and independent determination of 
possible causality .  Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety .
Further information on follow -up procedures is provided in Section 10.3.
8.4.4. Regulatory 
Reporting Requirements for SAEs
Prompt notification by  [CONTACT_227986] y of participants and the safet y of a 
study  intervention under clinical investigation are met.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 48The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.  The 
sponsor will comply  with country -specific reg ulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study  and will notify  the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact [CONTACT_78261].  Such exposure 
may or may  not lead to the occurrence of an AE or SAE.  Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed.  An 
environmental exposure may  include EDP, EDB, and occupational exposure.
Any such exposures to the study  intervention under study  are reportable to [COMPANY_007] Safety  
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP  occurs if:
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention.
A male participant who is receiving or has discontinued study  intervention 
inseminates a female partner.
A female nonparticipant is found to be pregnant while being exposed or having been 
exposed to study  intervention because of environmental exposure.  Below are 
examples of environmental EDP:
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_19991].
A male famil y member or healthcare provider who has been exposed to the study 
intervention by  [CONTACT_227987].
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274533] report EDP  to [COMPANY_007] Safe ty within 24 hours of the investigator ’s 
awareness, irrespective of whether an SAE has occurred.  The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy).
If EDP occu rs in a participant/participant’s partner, the investigator must report this 
information to [COMPANY_007] Safety  on the Vaccine SAE Reporting Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred.  Details of the 
pregnancy will be collected after the start of stud y intervention and until 28 day s after 
the study  intervention.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the Vaccine SAE Reporting Form and EDP 
Supplemental Form.  Since the exposure information does not pertain to the 
participant enrolled in the study , the information is not recorded on a CRF; however, 
a cop y of the completed Vaccine SAE Reporting Form is maintained in the 
investigator site file.
Follow -upis conducted to obtain general information on the pregnancy  and its outcome for 
all EDP  reports with an unknown outcome.  The investigator will follow the pregnancy until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP  Supplemental Form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clini cally  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs.  If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y), the investigator should follow the procedures 
for reporting SAEs.  Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion ,including miscarriage and missed abortion ,should be reported 
as an SAE;
Neonatal deaths that occur within [ADDRESS_274534] 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 50Additional information regarding the EDP  may  be requested by  [CONTACT_456] .  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will p rovide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner .  The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner .
[IP_ADDRESS]. Exposure During Breastfeeding
An EDB occurs if:
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention.
A female nonparticipant is found to be breastfeeding while being exposed or having 
been exposed to study  intervention (ie, environmental exposure).  An example of 
environmental EDB is a female famil y member or healthcare provider who reports 
that she is breastfeeding after having been exposed to the study  intervention by  
[CONTACT_227988].
The investigator must report EDB to [COMPANY_007] Safety within 24 hours of the investigator ’s 
awareness, irrespective of whether an SAE has occurred.  The information must be reported 
using the V accine SAE Reporting Form.  When EDB occurs in the setting o f environmental 
exposure, the exposure information does not pertain to the participant enrolled in the study , 
so the information is not recorded on a CRF .  However , a copy  of the completed V accine 
SAE Reporting Form is maintained in the investigator site f ile.
An EDB report is not created when a [COMPANY_007] drug specificall y approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use.  
However , if the infant experiences an SAE associated with such a drug, the SAE is r eported 
together with the EDB.
[IP_ADDRESS]. Occupational Exposure
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 
24hours of the investigator ’s awareness using the V accine SAE Reporting Form, regardless 
of whether there is an associated SAE.  Since the information about the occ upational 
exposure does not pertain to a participant enrolled in the study , the information is not 
recorded on a CRF; however , a copy  of the completed V accine SAE Reporting Form must be 
maintained in the investigator site file.
8.4.6. Cardiovascular and Death Eve nts
Deaths will be recorded throughout the stud y as detailed in Section 8.4.1.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 518.4.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.4.8. Adverse Events of Special Interest
The following events are considered AESI s:
Confirme d diagnosis of influenza.
Confirmed diagnosis of RSV infection.
Confirmed diagnosis of my ocarditis or pericarditis occurring within 4 weeks after 
vaccination.  See Section [IP_ADDRESS].5.
Confirmed COVID -
19 diagnosis (clinical signs/s ymptoms per the CDC62and positive 
SARS -CoV -[ADDRESS_274535] result).
Diagnosis of Guillain- Barrésyndrome .
Diagnosis of acute pol yneuropathy  without an underly ing etiology .
Diagnosis of atrial fibrillation .
Preterm delivery  (delivery  at <37 0/7 weeks’ gestation) .
Diagnosis of a h ypertensive disorder of pregnancy .
Details of the AESIs listed above are further defined in the investigat or site file.
AESI sare examined as part of routine safet y data review procedures throughout the clinical 
trial and as part of signal detection processes.  Should an aggregate analy sis indicate that 
these prespecified events occur more frequentl y than expe cted, eg, based on epi[INVESTIGATOR_227924], literature, or other data, then this will be submitted and reported in accordance with 
[COMPANY_007]’s safet y reporting requirements.  Aggregate anal yses of safet y data will be performed 
on a regular basis per internal SOP s.
All AESI s must be reported as an AE or SAE following the procedures described in
Sections 
8.4.[ADDRESS_274536] be reported using the Vaccine SAE Reporting 
Form.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page [IP_ADDRESS]. Lack of Efficacy
The investigator must report signs, s ymptoms, and/or clinical sequelae resulting from lack of 
efficac y.Lack of efficacy or failure of expected pharmacological action is reportable to 
[COMPANY_007] Safety only if associated with an SAE .
8.4.9. Medical Device Deficiencies
Medical devices being provided for use in this study are those listed in Section 6.1.2.  I n 
order to fulfill regulatory reporting obligations worldwide, the unblinded site staff is 
responsible for the detection and documentation of events meeting the definitions of device 
deficiency  that occur during the study  with such devices.
The definition of a medical device deficiency  can be found in Section 10.10.
Note: AEs and/or SAEs that are associated with a medical device deficiency  will follow the 
same processes as other AEs or SAEs, as outlined in Secti ons 8.4.1 through 8.4.3 and 
Section 10.3.
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies that result in an incident will be detected, documented, and 
reported during all periods of the study
 in which the medical device is used.
Importantly , reportable device deficiencies are not limited to problems with the device itself 
but also include incorrect or improper use of the device and even intentional misuse, etc.
If the unblinded site staff learns of an y device deficiency  at any  time after a participant has 
been discharged from the study , and such deficienc y is considered reasonably  related to a 
medical device provided for the study , the unblinded site staff will promptly  notify  the 
sponsor .
The method of documenting medical device deficiencies is provided in Section 10.10.
[IP_ADDRESS]. Follow -
Up of Medical Device Deficiencies
Follow -up applies to all participants, including those who discontinue study  intervention.
The unblinded site staff is responsible for ensuring that follow- up includes any  supplemental 
investigations as indicated to elucidate the nature and/or causality  of the deficiency .
New or updated information will be recorded on a follow- up form with all changes signed 
and dated b y the unblinded site staff.
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to the Sponsor
When a device deficiency  occurs: 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274537] be recorded on the Medical Device Complaint form.
3.If an AE (eit her serious or nonserious) associated with the device deficiency  occurs, then 
the AE must be entered into the AE section of the CRF.
4.If an SAE associated with the device deficiency  is brought to the attention of the 
unblinded site staff, the unblinded site staff must immediately  notify  [COMPANY_007] Safety  of 
theSAE (see Section [IP_ADDRESS]).  All relevant details related to the role of the devic e 
intheevent must be included in the Vaccine SAE Reporting For mas outlined in 
Sections [IP_ADDRESS] and8.4.1.2.
The sponsor will be the contact [CONTACT_227989].
[IP_ADDRESS]. Regulatory Reporting Requirements for Device Deficiencies
The unblinded site staff will promptly  report all device deficiencies occurring with any  
medical device provided for use in the stud y in order for the sponsor to fulfill the legal 
responsibility  to notify  appropriate regulatory  authorities and other entities about certa in 
safet y information relating to medical devices being used in clinical studies.
Theunblinded site staff , or responsible person according to local requirements (eg, the head 
of the medical institution), will comply  with the applicable local regulatory re quirements 
relating to the reporting of device deficiencies to the I RB/EC.
8.4.10. Vaccination Errors
Vaccination errors may  result from the administration or consumption of the study  
intervention by  [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.
Vaccination errors are recorded and reported as follows:
Recorded on the 
Vaccination Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the Vaccine 
SAE Reporting Form to 
[COMPANY_007] Safety Within 
24Hours of Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the vaccination errorOnly  if associated with an 
SAE
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 54Vaccination errors include:
Vaccination errors involving participant exposure to the study  intervention;
Potential vaccination errors or uses outside of what is foreseen in the protocol that do or 
do not involve the study  participant;
The administration of expi[INVESTIGATOR_214312];
The administration of an incorrect study  intervention;
The administration of an incorrect dosage;
The administration of study  intervention that has undergone temperature excursion from 
the specified storage range, unless it is determined by  [CONTACT_214348].
Such vaccinat ion errors occurring to a study  participant are to be captured on the vaccination 
error page of the CRF , which is a specific version of the AE page.
Whether or not the vaccination error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275] , the vaccin ation error is recorded on the vaccination error page of the CRF and, 
if applicable, an y associated AE(s), serious and nonserious, are recorded on the AE page of 
the CRF .
In the event of a vaccination dosing error , the sponsor should be notified within 24 hours.
Vaccination errors should be reported to [COMPANY_007] Safety  within 24 hours on a V accine SAE 
Reporting Form only when associated with an SAE.
8.5.Pharmacokinetics 
Pharmacokinetic parameters are not evaluated in this study . 
8.6.Genetics
NAfor Substudy  A.
8.7.Biomarkers
Biomarkers are not evaluated in this study .
8.8.Immunogenicity Assessments
See Section [IP_ADDRESS] for Substudy  A .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 558.9.Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in Substudy  A.
9.STATISTICAL CONSIDERATIONS
Methodology for summary  and statistical anal yses of the data collected in this study  is 
described here and f urther detailed in theSAP, which will be maintained by [CONTACT_456]. The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
Refer to Section [IP_ADDRESS] for statistical hy potheses for Substudy  A.
9.2.Analysis Sets
Refer to Section [IP_ADDRESS] for anal ysis sets in Substudy  A.
9.3.
Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
Statistical analy ses for Substudy  A are detailed in Section [IP_ADDRESS].
9.3.1.
General Considerations
Unless stated otherwise, “vaccine group” in this section refers to the stud y intervention
group. CI s for all endpoints in the statistical analysis will be presented as 2 -sided at the 
95%
level unless specified otherwise.
The safet y analyses are based on the safet y population.  Participants will be summarized by  
[CONTACT_227990] y received. In general,
completely  missing reactogenicity  e-diary  data (ie, all 7 day s of e -diary  collection were 
missing) will not be imputed . For partially  complete e -diary  data (ie, 1- 6 day s of 
reactogenicity  data are available), it is assumed that no reactions or events were experienced 
on missing day s based on the e -diary  data source. Missing AE dates will be handled 
according to the [COMPANY_007] safety  rules.
The estimands to evaluate the immunogenicity  objective are based on the evaluable 
immunogenicit y population. These estimands estimate the immune response after stud y 
intervention in the hy pothetical setting where participants follow the study  schedules and 
protocol requirements as directed. For all the immunogenicity  endpoints, the anal ysis will be 
based on the evaluable immunogenicit y population.  An additional anal ysis may  be 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 56performed based on the mI TT immunogenicit y population if there is a large enough 
difference in sample size between the mITT immunogenicity  population and the evaluable 
immunogenicit y popul ation.  Participants will be summarized according to the vaccine group 
to which they  were randomized.  Missing immunogenicity  results will not be imputed. 
Immunogenicit y results that are below the LLOQ will be set to 0.5 × LLOQ in the anal ysis; 
this may  be adjusted once additional data on the assay  characteristics become available.
[IP_ADDRESS]. Analyses for Binary Data
Descriptive statistics for binary  variables (eg, proportions) are the percentage (%), the 
numerator (n) and the denominator (N) used in the percentage 
calculation, and the 95% CIs 
where applicable.
The exact 95% CI for binary  endpoints for each group will be computed using the 
Fdistribution (Clopper -Pearson).
The95% CI for the difference in the proportions will be computed using the Miettinen and
Nurmi nen method .The 95% CI  will be presented in terms of percentage.
[IP_ADDRESS]. Analyses for Continuous Data
Unless otherwise stated, descriptive statistics for continuous variables are n, mean, median, 
SD, minimum, and maximum.
CIsfor the mean of the continuous variable swill be constructed by [CONTACT_227991] t distribution.
[IP_ADDRESS].1. Geometric Mean 
Continuous immunogenicity  endpoints will be logarithmically  transformed for anal ysis. 
Geometric means and associated 2 -sided 95% CIs will be derived b y calc ulating group 
means and CIs on the natural log scale based on the t distribution, and then exponentiating 
the results.
[IP_ADDRESS].2. Geometric Mean Fold Rises
Fold rises are defined as ratios of the results after vaccination to the results before 
vaccination.  The calcu lations of fold rises are limited to participants with nonmissing values 
at both time points.
GMFRs will be calculated as the mean of the difference of logarithmicall y transformed 
assay results (later time point minus earlier time point) and exponentiating the mean.  
The associated 2 -sided 95% CI s will be obtained by  [CONTACT_227992] t 
distribution for the mean difference on the logarithm scale and exponentiating the confidence 
limits.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page [IP_ADDRESS].3. Geometric Mean Ratios
The GMRs will be calculated as the mean of the difference of logarithmically  transformed 
assay  results between 2 vaccine groups and exponentiating the mean. Two-sided CI s will be 
obtained by  [CONTACT_214359] s using theStudent t distribution for the mean difference of the 
logarithmicall ytransformed assay  results and exponentiating the confidence limits.
[IP_ADDRESS].4. Reverse Cumulative Distribution Curve s
Empi[INVESTIGATOR_214315] a 
specified assay  value versus the indicated assay  value, for all observed assay  values.  Data 
points will be joined by  a step function with the line first going down and then to the right to 
the next assay  value.
9.4.Interim Analyses
Details for interim analy ses will be provided in Sectio n [IP_ADDRESS] for Substudy A .
9.5.Sample Size Determination
Refer to Section [IP_ADDRESS] for sample size determination related to Substudy  A.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 5810. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_78269],submitted to an I RB/EC 
by [CONTACT_093], and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation, except for changes necessary  to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or more 
frequentl y in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by [CONTACT_1744]/EC 
procedures ;
Providing oversight of the conduct of the stud y at the site and adherence to requirements 
of 21 CFR, I CH GCP guidelines, the I RB/EC, European regulation 536/[ADDRESS_274538] 2017/745 for clinical device research, and all other applicable 
local regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the eve nt of any  prohibition or restriction imposed (ie, clinical hold) by  [CONTACT_78270] y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study 
intervention , [COMPANY_007] should be informed immediately . 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274539], and 
of an y serious breaches of this protocol or of the ICH GCP  guidelines that the investigator 
becomes aware of.
10.1.2.
Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the spons or to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities.  I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year aft er completion of the study .
10.1.3. Informed Consent Process
The investigator or the investigator ’s representative will explain the nature of the study , 
including the risks and benefits, to the participant and answer all questions regarding the 
study .  The partic ipant should be given suf ficient time and opportunity  to ask questions and 
to decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary .  Participants will be 
required to sign a statement of info rmed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center .
The investigator must ensure that each participant is fully  informed about the nature and 
objectives of the study , the sharing of data related to the study , and possible risks associated 
with participation, including the risks associated with the processing of the participant ’s 
personal data.
The participant must be informed that their personal study -related data will be used by  [CONTACT_20004] .  The level of disclosure must also be 
explained to the participant.
The participant must be informed that their medical records may  be examined by [CONTACT_160439] , by 
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study participant is fully  informed about their 
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in th e study  and the date on which the written consent was 
obtained.  The authorized person obtaining the informed consent must also sign the ICD.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274540] current version of the IRB/EC -approved ICD(s) 
during their participation in the study  as required per local regulations.
A copy of the ICD(s) must be provided to the participant.
Participants who are rescreened are required to sign a new ICD.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws r egarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access.  The stud y site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disast er.  In the event of a potential personal data breach, the study  site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code.  Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; particip ant names will not be transferred.  All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant -specific code.  The study site will 
maintain a confidential list of participants who participated in the study , linkin g each 
participant ’s numerical code to their actual identity  and medical record ID.  I n case of data 
transfer , the sponsor will protect the confidentiality  of participants’ personal data consistent 
with the clinical study agreement and applicable privacy  laws.
Information technology  systems used to collect, process, and store study -related data are 
secured b y technical and organizational securit y measures designed to protect such data 
against accidental or unlawful loss, alteration, or unauthorized disclosure or access.
The sponsor maintains SOPs on how to respond in the event of unauthorized access, use, or 
disclosure of sponsor information or sy stems.
10.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
Substud yA will use an IRC .  The IRCis independent of the study  team and includes 
only 
internal members.  The IRC charter describes the role of the IRC in more detail.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 61The IRCwill be responsible for ongoing monitoring of the safet y of participants in the study  
according to the charter .  The recommendations mad e by [CONTACT_227993].  [COMPANY_007] will 
communicate such decisions, which may  include summaries of aggregate analy ses of safet y 
data, to regulatory  authorities and investigators, as appropriate.
The responsibilities of the I RC will include at a minimum:
Review of safet y data in the case of a stoppi[INVESTIGATOR_227925]  A.
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly disclose clinical study  results through posting the 
results of studies on www .clinicaltrials.gov (ClinicalT rials.gov), the EudraCT /CTI S, and/or 
www .pfizer .com, and other public registries and websites in accordance with applicable local 
laws/regulations. In addition, Pfize r reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of th e stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www .clinicaltrials.gov for [COMPANY_007] -sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or ef ficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT /CTI S
[COMPANY_007] posts clinical trial r esults on EudraCT /CTI Sfor[COMPANY_007] -sponsored interventional studies 
in accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts CSR synopses and plain- language study  results summaries on www .pfizer .com 
for [COMPANY_007] -sponsored interventional stu dies at the same time the corresponding study  results 
areposted to www.clinicaltrials.gov. CSR sy nopses will have personally  identif iable 
information anon ymized.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 62Documents within marketing applications
[COMPANY_007] complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary  documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally  identifiable information anony mized.
Data sharing
[COMPANY_007] provides researchers secure access to participant -level data or full CSRs for the 
purposes of “ bona -fide scientific research ” that contribute sto the scientific understanding of 
the disease, target, or compound class. [COMPANY_007] will make data from these trials available 
18months after study  completion. Participant -level data will be anon ymized in accordance 
with applicable privacy  laws and regul ations. CSRs will have personall y identifiable 
information anon ymized.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a biostatistician. Data will no t 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and c orrect by  [CONTACT_20010] .
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic an d/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
QTL s are predefined parameters that are monitored during the study .  Important deviations 
from the QTLs and any remedial actions taken w ill be summarized in the CSR.
The investigator must permit study -related monitoring, audits, IRB/EC review , and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study completion. It is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that suf ficient time is devoted to the process.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 63Monitoring details describing strategy , including definitio n of study -critical data items and 
processes (eg, risk- based initiatives in operations and quality  such as risk management and 
mitigation strategies and anal ytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of n oncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and 
monitoring plan maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data ma nagement of this study , including 
quality  checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for [ADDRESS_274541] ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted fr om all sy stems.
The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigat or site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the study data and the p articipant ’s medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity  to review and comment on responses to any  such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.  Source documents are filed at the investigat or site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator may  need to request previous medical records or transfer records, depending on 
the study .  Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the Source 
Document Locator , which is maintained by  [CONTACT_456] .
Description of the use of the computerized system is documented in the data management 
plan, which is maintained by  [CONTACT_456] .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.[ADDRESS_274542] maintain accurate documentation (source data) that supports the 
information entered in the CRF .
The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by [CONTACT_1191], complete, and verifiable from source documents; 
that the safet y and rights of participants are being protected; and that the study is being 
conducted in accordance with the c urrentl y approved protocol and an y other study  
agreements, I CH GCP  guidelines, and all applicable regulatory  requirements.
10.1.9. Use of Medical Records
Not applicable.
10.1.10. Study and Site Start and Closure
The study  start date is the date of the first participant’ s first visit.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor , including (but not limited to) 
regulatory  authorit y decision, change in opi[INVESTIGATOR_2511] I RB/EC, or change in benefit -risk 
assessment.  Study  sites will be closed upon study completion.  A study  site is considered 
closed when all required documents and study  supplies have been collected and a study -site 
closure visit has been performed.
The inves tigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants.
Reasons for the earl y closu re of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the I RB/EC 
or local health authorities, the sponsor’s procedures, or the I CH GCP guidelines;
Inadequate recru itment of participants by  [CONTACT_093]; 
Discontinuation of further study  intervention development.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any CRO(s) used in the study of 
the reason for termination or suspension, as specified by  [CONTACT_20013].  The investigator shall promptly inform the participant and should assure 
appropriate participant therap y and/or follow -up.
Study termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 6510.1.11. Publication Policy
For multicenter trials, the primary  publication w ill be a joint publication developed b y the 
investigator and [COMPANY_007] reporting the primary  endpoint(s) of the study  covering all study  sites.  
The investigator agrees to refer to the primary  publication in any  subsequent publications.  
[COMPANY_007] will not provi de any financial compensation for the investigator’s participation in the 
preparation of the primary congress abstract, poster, presentation, or primary manuscript for 
the study .
Investigators are free to publish individual center results that they  deem to be clinically  
meaningful after publication of the overall results of the study  or [ADDRESS_274543] to the other 
requirements described in this section.
The investigat or will provide [COMPANY_007] an opportunity  to review any  proposed publication or 
any other t ype of disclosure of the stud y results (collectively , “publication”) before it is 
submitted or otherwise disclosed and will submit all publications to [COMPANY_007] [ADDRESS_274544], remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y intervention or [COMPANY_007] -related 
information necessary  for the appropriate scienti fic presentation or understanding of the 
study  results.  For joint publications, should there be disagreement regarding interpretation 
and/or presentation of specific anal ysis results, resolution of, and responsibility  for, such 
disagreements will be the c ollective responsibility  of all authors of the publication.
For all publications relating to the stud y, the investigator and [COMPANY_007] will comply with 
recognized ethical standards concerning publications and authorship, including those 
established by  [CONTACT_227994].  The investigator will 
disclose an y relationship with [COMPANY_007] and any relevant potential conflicts of interest, including 
any financial or personal relationship with [COMPANY_007], in any publications.  All authors will have 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication.
10.1.12. Sponsor’s Medically Qualified Individual 
The contact [CONTACT_1133] ’s MQI for the study  is documented in the study  
contact [CONTACT_185623] y documentation/study  portal or other electronic 
system.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 66To facilitate access to their investigator and the sponsor’ s MQI for study -related medical 
questions or problems f rom nonstudy  healthcare professionals, participants are provided with 
an ECC at the time of informed consent.  The ECC contains, at a minimum, (a) protocol and 
study  intervention identifiers, (b) participant’ s study  identification number , (c) site 
emergenc y phone number active 24 hours/day , 7 day s per week, and (d) [COMPANY_007] Call Center 
number .
The ECC is intended to augment, not replace, the established communication pathway s 
between the participant and their investigator and site staf f, and between the investigator and 
sponsor study  team.  The ECC is only  to be used by  [CONTACT_227995] , as a means of reaching the investigator or site staf f related to the care of a 
participant.  The [COMPANY_007] Call Center number is to be used when the investigator and site staff 
are unavailable.   The [COMPANY_007] Call Center number is not for use by  [CONTACT_185625] y; if a 
participant calls that number directly , they  will be directed back to the investigator site.
10.2. Appendix 2: Clinical Lab oratory Tests
Routine clinical laboratory  tests are NA to Substudy  A.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 6710.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study  
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator .Any abnormal test results that 
meet an y of the con ditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms.
Requires additional diagnostic testing or medical/surgical intervention .
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinu ation from the study, significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including an 
increase in either frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 68suicidal/self- harming intent. Such overdoses should be reported regardless of 
sequelae.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being stu died, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (soci al and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event 
thathypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or
outpatient setting. Complications that occur during hospi[INVESTIGATOR_227926] A Es.If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 69serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.
d.Results in persistent or significant disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance , such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidenta l trauma (eg, sprained ankle) ,thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, pathog enic 
or nonpathogenic  
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “ suspected 
transmission” and “transmission ” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_78278], such as significant
medical events that may jeopardize the participant or may  require medical or 
surgical intervent ion to prevent one of the other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bro nchospasm, blood dy scrasias or
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 7010.3.3. Recording/Reporting and Follow -Up of A Esand/or SAE sDuring the Active 
Colle ction Period 
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the Vaccine SAE Reporting Form to [COMPANY_007] Safety  throughout the active 
collection period. These requirements are delineated for 3 t ypes of events: (1) SAEs; 
(2)nonserious AEs; and (3) exposure to the study  intervention under study  during 
pregnancy  or breastfeeding, and occupational exposure.
It should be noted that the Vaccine SAE Reporting Form for reporting of SAE information 
is not the same as the AE page of the CRF. When the same data are collected, the forms 
must be completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the Vaccine SAE 
Reporting Form for reportin g of SAE information.
Safety Event Recorded on the CRF Reported on the Vaccine 
SAE Reporting Form to 
[COMPANY_007] Safety Within 
24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding All AEs or SAEs associated 
with EDP or EDB
Note: I nstances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRFAll instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE)**
Environmental or 
occupational exposure to 
the product under stud y to 
a nonparticipant (not 
involving EDP or EDB)None.  Exposure to a study  
nonparticipant is not 
collected on the CRFThe exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to [COMPANY_007] 
Safety using the Vaccine SAE Reporting Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the Vac cine SAE Reporting 
Form .
**EDB is reported to [COMPANY_007] Safety using the Vaccine SAE Reporting Form, which would also include 
details of any SAE that might be associated w ith the EDB.
***Environmental or occupational exposure: AEs or SAEs associated with oc cupational exposure 
are reported to [COMPANY_007] Safety using the Vaccine SAE Reporting Form.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 71When an AE or SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the Va ccine SAE 
Reporting Form/AE or SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety.  In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis 
(notthe individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories:
GRADE If required on the AE page of the CRF, the investigator will use the 
adjectives MILD, MODERATE, SEVERE, or LIFE- THREATENING to 
describe the maximum intensity  of the AE.  For purposes of consistency , 
these intensity  grades are defined as follows:
1 MILD Does not interfere with participant’s usual 
function.
2 MODERATE Interferes to some extent with participant’s usual 
function.
3 SEVERE Interferes significantl y with participant’s usual 
function.
4 LIFE -THREATENING Life-threatening consequences; urgent 
intervention indicated.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 72Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE.  The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  interve ntion 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in their assessment.
For each AE or SAE, the investigator must document in the medical notes that they  
have reviewed the AE or SAE and have provided an assessment of causality.
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor.  However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor.
The investigator may  change their opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up repor t with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention” for reporting 
purposes, as defined b y the sponsor.  In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the sour ce documents and CRF, and report such an 
assessment in the dedicated section of the Vaccine SAE Reporting Form and in 
accordance with the SAE reporting requirements.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 73Follow -Up of A Esand SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  [CONTACT_103], to elucidate the nature and/or causalit y of the AE or SAE as full y as 
possible.  This may  include additional laboratory  tests or investigations,
histopathological examinations, or consultation with other healthcare providers.
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings, including histopathology .
New or updated information will be recorded in the originally  submitted 
documents.
The investigator will submit any  updated SAE data to the sponsor within [ADDRESS_274545]
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic DCT (eg, eSAE or PSSA) .
If the electronic s ystem is unavailable, then the site will use the paper SAE report 
form (see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic DCT (eg, eSAE or PSSA) or 
paper form (as applicable) as soon as the data become available.
After the stud y is completed at a given site, the electronic DCT will be taken 
off-line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic DCT has been taken off- line, 
then the site can report this information on a paper SAE form (see next section) or 
to [COMPANY_007] Safety  by [CONTACT_756].
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 74SAE Reporting to [COMPANY_007] Safety via the Vaccine SAE Reporting Form
Facsimile transmission of the Vaccine SAE Reporting Form is the preferred 
method to transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, an alternative method should 
be used, eg, secured (Transport L ayer Security ) or password- protected email.  I f 
none of these methods can be u sed, notification b y telephone is acceptable with a 
copy  of the Vaccine SAE Reporting Form sent by  [CONTACT_22855].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Vaccine SAE Rep orting Form pages within the designated 
reporting time frames.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 7510.4. Appendix 4: Contraceptive and Barrier Guidance 
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least [ADDRESS_274546] dose of stud y intervention, which 
corresponds to the time needed to eliminate reproductive safe ty risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse as their preferred and usual lifesty le 
(abstinent on a long -term and persistent basis) and agree to remain abstinent.
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception as a condom may 
break or leak when having sexual intercourse with a WOCBP who is not currentl y 
pregnant.
OR
Be vasectomized, with the absence of sperm having been confirmed.
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of inclusion criterion 1 (Age and Sex; Section 5.1) and specify  the 
reproductive requirements for including female participants. Refe rto Section 10.4.[ADDRESS_274547] 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 
10.4.3).
OR
Is a WOCBP and agrees to use an acceptable contraceptive method during the 
intervention period (for a minimum of [ADDRESS_274548] dose of stud y 
intervention).  The investigator sho uld evaluate the effectiveness of the contraceptive 
method in relationship to the first dose of stud y intervention.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 76The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy .
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1. Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to a medical cause other than the above
(eg,mullerian agenesis, androgen insensitivity ), investigator discretion should be applied to 
determining stud y entr y.
Note: Documentation for any of the above categories can come from the site personnel ’s 
review of the participant ’s medical records, medical examination, or medical history  
interview .  The method of documentation should be recorded in the participant’ s medical 
record for the study
.
2.Postmenopausal female:
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  In addition:
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal 
contraception or HRT.
A female on HRT and whose menopausal status is in doubt will be required to use 
one of the highly  effective nonestrogen horm onal contraception methods if she 
wishes to continue her HRT during the stud
y.  Otherwise, she must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 7710.4.4. Contracepti onMethods
Contraceptive use b y men or women should be co nsistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
The following contraceptive methods are appropriate for this study :
Highl y Effective Methods That Have Low User Dependency
1. Implantable progestogen- only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion.
5.Vasectomized partner:
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has been 
confirmed.  If not, an additional highly  effective method of contraception should be 
used.  The spermatogenesis cy cle is approximately  90 day s.
High ly Effective Methods That Are User Dependent
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
Oral;
Intravaginal;
Transdermal.
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable.
8. S exual abstinence is considered a highl y effective method only  if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study  
intervention.  The reliability  of sexual abstinence needs to be evaluated in relation to the 
duration of the study  and the preferred and usual lifesty le of the participant.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 202 3)
TMF Doc ID: 164.01
Page 78Other Effective Methods
9.Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary  mode of action.
10. Male or female condom, with or without spermicide.
11. Cervical cap, diaphragm, or sponge with spermicide.
12. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).
10.5. Appendix 5: Genetics
NAfor Substudy  A.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 7910.6. Appendix 6: Liver Safety: Suggested Actions and Follow -Up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators, ” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participants fail to adapt and therefore are 
“susceptible ” to progressive and serious liver injury , commonly  referred to as DILI.  
Participants who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently  to determine if they  are “adaptors ” or are “ susceptible. ”
LFTs are not required as a routine safety  monitoring procedure in this study .  However , 
should an investigator deem it necessary  to assess LFT s because a participant presents with 
clinical signs/s ymptoms, such LFT  results should be managed and followed as described 
below .
In the majority  of DILI cases, elevations in AST
 and/or ALT precede T bili elevations 
(>2 × ULN) b y several days or weeks.  The increase in T bili typi[INVESTIGATOR_1306] y occurs while 
AST/AL T is/are still elevated above 3 × ULN (ie, AST/AL T and T bili values wil l be elevated 
within the same laboratory sample).  In rare instances, b y the time T bili elevations are 
detected, AST/AL T values might have decreased.  This occurrence is still regarded as a 
potential DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to Tbili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important medical events, even before all 
other possible causes of liver injury  have been e xcluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions.  Participants who present 
with the following laboratory  abnormalities should be evaluated furthe r as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and T bili baseline values within the normal range who 
subsequently  present with AST OR AL T values ≥3 × ULN AND a T bil i value ≥2×ULN 
with no evidence of hemoly sis and an alkaline phosphatase value <2 ×ULN or not 
available.
For participants with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
oPreexisting AST or ALT baseline values above the normal range: AST or ALT 
values 
≥2times the baseline values AND ≥3 ×ULN; or ≥8 ×ULN (whichever is 
smaller).
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 80oPreexisting values of T bili above the normal range: T bili level increased from 
baseline value b y an amount of ≥1 × ULN orif the value reaches ≥3×ULN 
(whichever is smaller).
Rises in AST/AL T and T bili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; an y case where uncertainty  remains as to whether it 
represents a potential Hy ’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y withi n [ADDRESS_274549] and ALT and T bili for suspected Hy ’s law 
cases, additional laborat ory tests should include albumin, CK, direct and indirect bilirubin, 
GGT , PT/I NR, total bile acids, and alkaline phosphatase.  Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology .  A detailed history , including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either b y itself or as a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history , history  of contact 
[CONTACT_4490] a jaundiced person, sur gery, blood transfusi on, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary  tract), and collection of serum 
samples for acetam inophen/paracetamol drug and/or protein adduct levels may  be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
Tbili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT  abnormalities has y et been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 8110.7. Appendix 7: Kidney Safety Monitoring Guidelines
10.7.1. Laboratory Assessment of Change in Kidney Function and Detection of Kidney 
Injury
Standard kidney  safety  monitoring requires assessment of baseline and postbaseline Scr eat
measurement to estimate eGFR (Screat-based eGFR ) orcreatinine clearance (eCrCl).  
Baseline and postbaseline Scy s makes it feasible to distinguish AKI from other causes of 
Screatincrease.  If Scr eatincrease is confirmed after baseline, then reflex measurement of 
Scys is indicated (for adult and for pediatric participants). Screat and reflex Scy s values are 
needed to est imate the combined Screat -Scys eGFR calculation to ascertain whether eGFR 
change from baseline is comparable for 2021 CKD-EPI [INVESTIGATOR_227927]- only and for 
2021 CKD -EPI [INVESTIGATOR_227928] s (for adult participants only ).
Regardless of whether kidney  function monitoring tests are required as a routine safet y 
monitoring procedure in the study , if the investigator or sponsor deems it necessary  to further 
assess kidney  safety  and quantify  kidney  function, then these test results should be managed 
and follo wed per standard of care.
10.7.2. Age-Specific Kidney Function Calculation Recommendations
[IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD- EPI [INVESTIGATOR_227929] (mL/min/1.73m²)
2021 CKD -EPI [INVESTIGATOR_227930]
2021 CKD -EPI
[INVESTIGATOR_227931]
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤0.7 NA eGFR = 143 × (Scr eat/0.7)-0.241 × (0.9938)Age
Female if >0.7 NA eGFR = 143 × ( Screat /0.7)-1.200 × (0.9938)Age
Male if ≤0.9 NA eGFR = 142 × (Scr eat/0.9)-0.302 × (0.9938)Age
Male if >0.9 NA eGFR = 142 × (Scr eat/0.9)-1.200 × (0.9938)Age
2021 CKD -EPI
[INVESTIGATOR_227932]-Scys 
CombinedScreat
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if≤0.7 if ≤0.8 eGFR = 130 × (Scr eat/0.7)-0.219 × (Scys/0.8)-0.323 × (0.9961)Age
Female if ≤0.7 if >0.8 eGFR = 130 × (Scr eat/0.7)-0.219 × (Scys/0.8)-0.778 × (0.9961)Age
Female if >0.7 if ≤0.8 eGFR = 130 × (Scr eat/0.7)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age
Female if >0.7 if >0.8 eGFR = 130 × (Scr eat/0.7)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age
Male if ≤0.9 if ≤0.8 eGFR = 135 × (Scr eat/0.9)-0.144 × (Scys/0.8)-0.323 × (0.9961)Age
Male if ≤0.9 if >0.8 eGFR = 135 × (Scr eat/0.9)-0.144 × (Scys/0.8)-0.778 × (0.9961)Age
Male if >0.9 if ≤0.8 eGFR = 135 × (Scr eat/0.9)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age
Male if >0.9 if >0.8 eGFR = 135 × (Scr eat/0.9)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age
a. Inker LA et al. N Engl J Med. 2021;385:1737 -49.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.[ADDRESS_274550] baseline v isits. Site 
calculations of kidney  function can be performed manually , using the age -appropriate 
formulae (see Section 10.7.2 ) andcan use recommended online kidney  function calculators 
to reduce the likelihood of a calculation error. 
TheUS National Kidney  Foundation Online Calculators :
Adults (18 y ears and above) 
-2021 CKD -EPI [INVESTIGATOR_227933] (eGFR): 
https://www.kidney .org/professionals/KDOQI /gfr_calculator
Adolescents (12 years to <18 y ears) -Cockcroft -Gault Formula (eCrCl): 
https://www.kidney .org/professionals/kdoqi/gfr_calculatorCoc
Investigational sites are responsible forensur ingthat the accurate age -specific equation is 
selected and that the correct units are used for Screat(mg/dL only ), Scys(mg/L only ), total 
body  weight (kg only ), and age (y ears). Investigators are expected to (i) review and confirm 
correctness of the kidne y function calculation results and (ii) evaluate the calculated value 
within the context of historical information available to them in the participant’s medical 
record. Investigators are responsible for the clinical oversight of the participant eligibili ty 
process, kidney  function calculation, and dose selection and adjustments per study  protocol.
Investigators are encouraged to direct questions or uncertainties regarding kidney  function 
and dosing to the [COMPANY_007] clinical team and medical monitor, if need ed.
10.7.4. Adverse Event Grading for Kidney Safety Laboratory Abnormalities
AE grading for decline in kidney  function (ie, eGFR or eCrCl) will be according to KDIGO
criteria.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 8310.8. Appendix 8: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as A Es
Marked sinus brad ycardia (rate <40 bpm) lasting minutes .
New PR interval prolongation >280 ms.
New prolongation of QTcF to >480 ms (absolute).
New prolongation of QTcF b y >60 ms from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: 
ie,rate<120 bpm .
New -
onset t ype I second -degree (Wenckebach) AV block of > 30-second duration .
Frequent PVCs, 
triplets, or short intervals (<30 seconds) of consecutive ventricular 
complexes
.
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms .
Absolute value of QTcF >450 ms AND QTcF change from baseline >60 ms.
New ST- T changes suggestive of my ocardial ischemia .
New -onset LBBB (QRS complex >120 ms) .
New -
onset right bundle b ranch block (QRS complex >120 ms) .
Symptomatic bradycardia .
Asystole
In awake, s ymptom -free participants in sinus rhy thm, with documented 
asystolic pauses ≥3 seconds or an y escape rate <40 bpm, or with an escape 
rhythm that is below the AV node ;
In awake, s ymptom -free participants with atrial fibrillation and brad ycardia 
with [ADDRESS_274551] 5 seconds or longer . 
Atrial f lutter or fibrillation, with rapid ventricular response rate: 
rapid =rate>120 bpm.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 84Sustained s upraventricular tachycardia (rate >120 bpm) 
(“sustained ”= short duration with relevant sy mptoms or lasting >1 minute) .
Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm 
(HR<40 bpm), accelerated idioventricular rh ythm (HR 40 bpm to <100 bpm), and 
monomorphic/poly morphic vent ricular tach ycardia (HR >100 bpm [such as torsades 
de pointes]).
Type II second -degree (Mobitz II) AV block.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30-second duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventr icular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The major events of potential clinical concern listed above are recommended as “alerts ”or notifications from 
the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be considered as all -inclusive of 
what is to be reported as A Es/SAEs.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 8510.9. Appendix 9: Criteria for Allowing Inclusion of Participants With Chronic Stable 
HIV, HCV, or HBV Infection
Potential participants with chronic stable HIV, HCV, or HBV infection may  be considered 
for inclusion if they  fulfill the following respective criteria.
Known HIV infection
Confirmed stable HIV disease defined as documented viral load <50 copi[INVESTIGATOR_014]/mL  and 
CD4 count >200 cells/mm3within [ADDRESS_274552] 6 months.
Known HCV infection
History  of chronic HCV with evidence of sustained virological response (defined as 
undetectable HCV RNA) for ≥12 weeks following HCV treatmen t or without evidence of 
HCV RNA viremia (undetectable HCV viral load).
Known HBV infection
Confirmed inactive chronic HBV infection, defined as HB sAg present for ≥6 months and the 
following:
HBeAg negative, anti -HBe positive
Serum HBV DNA <2000 IU/mL
Persistently  normal ALT and/or AST levels
In those who have had a liver biopsy  performed, findings that confirm the absence of 
significant necroinflammation
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 8610.10. Appendix 10: A Es , ADEs, SAEs, SADEs, [LOCATION_003]DEs, and Device Deficiencies:
Definition sand Procedures for Recording, Evaluating, Follow -Up, and Reporting in 
Medical Device Studies
Definitions of a Medical Device Deficiency
The definitions and procedures detailed in this appendix are in accordance with I SO [ADDRESS_274553] 2017/74 5 for clinical device research (if applicable).
Both the investigator and the sponsor will comply  with all local reporting requirements for 
medical devices.
The detection and documentation procedures described in this protocol apply  to all sponsor 
medical devices provided for use in the study  (see Section 6.1.[ADDRESS_274554] of sponsor 
medical devices).
10.10.1. Definition of AE and ADE
AE and ADE Definition
An AE is defined in Appendix 3 ( Section 10.3.1).
An ADE is defined as an AE related to the use of an investigational medical 
device.  This definition includes an y AEs resulting from insufficient or 
inadequate instructions for use, depl oyment, implantation, installation, or 
operation, or an y malfunction of the investigational medical device as well as 
any event resulting from use error or from intentional misuse of the 
investigational medical device.
10.10.2. Definition of SAE, SADE, and [LOCATION_003]DE
SAE Definition
An SAE is defined in Appendix 3 (Section 10.3.2).
SADE Definition
An SADE is defined as an ADE that has resulted in any  of the consequences 
characteristic of an SAE.
Any device deficiency  that might have led to an SAE if appropriate action had 
not been taken, intervention had not occurred, or circumstances had been less 
fortunate.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 87[LOCATION_003]DE Definition
A [LOCATION_003]DE (also identified as UADE in US Regulation 21 CFR 813.3) is an 
SADE that by  [CONTACT_5942], incidence, severit y, or outcome has not been identified 
in the current version of the risk anal ysis management file.
10.10.3. Definition of Device Deficiency
Device Deficiency Definition
A device deficiency  is an inadequacy  of a medical device with respect to its 
identity , quality , durability , reliability , safet y, or performance.  Device 
deficiencies include malfunctions, use errors, and inadequate information 
supplied by  [CONTACT_3455].
10.10.4. Recording/Reporting and Follow -Upof Medical Device Deficiencies
Device Deficiency Recording
When a device deficiency  occurs, it is the responsibility  of the unblinded site staff to 
review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and 
diagnostic reports) related to the event.
The unblinded site staff will then record all relevant device deficiency  information 
in the participant’s medical records, in accordance with the investigator’s normal 
clinical practice, and will also capture the required information on the Medical 
Device Complaint form.
It is notacceptable for the unblinded site staff to send photocopi[INVESTIGATOR_227211]’s medical records to [COMPANY_007] Safety  in lieu of following the reporting 
process describ ed in the Medical Device Complaint form.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety.  In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
If the unblinded site staff determines that the medical device deficiency  may  have 
injured the participant (ie, the medical device deficiency  is associated with an AE or 
SAE), then the un
blinded site staff will attempt to establish a diagnosis of the event 
based on signs, s ymptoms, and/or other clinical information.  Whenever possible, 
the diagnosis will be documented in the participant’s medical record and recorded as 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 88the AE or SAE rather than the individual signs/symptoms.  Requirements for 
recording and reporting an AE or SAE are provided in Appendix 3 (Section 10.3.3).
For device deficiencies, it is very  important that the unblinded site staff describe any  
corrective or remedial actions taken to prevent recurrence of the incident.
A remedial action is an y action other than routine maintenance or servicing of a 
medic al device where such action is necessary  to prevent recurrence of a device 
deficiency .  This includes any  amendment to the device design to prevent 
recurrence.
Assessment of Causality Occurring in Conjunction With a Medical Device Deficiency
If an AE or SAE has occurred in conjunction with a medical device deficiency , the 
investigator must assess the relationship between each occurrence of the AE or SAE 
and the medical device deficiency .  The investigator will use clinical judgment to 
determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products in thei r assessment.
For each device deficiency , the investigator must document in the medical notes 
that they  have reviewed the device deficiency  and have provided an assessment of 
causality .
There may  be situations in which an SAE has occurred and the investiga tor has 
minimal information to include in the initial report to the sponsor.  However, it is 
very important that the investigator alway s make an assessment of causality for 
every  event before the initial transmission of the SAE data to the sponsor.
The investigator may  change their opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 89The causality  assessment is one of the criteria used when determining regulatory  
reporting requirement s.
Follow -Up of Medical Device Deficiency
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  [CONTACT_55900]/or causalit yof the device deficiency  as fully  as 
possible.  This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers.
New or updated information regarding the nature of the device deficiency  will be 
recorded in the originall y completed Medical Device Complaint form.
New or updated information regarding an y SAE that was potentially associated with 
the medical device deficiency  will be submitted to [COMPANY_007] Safety  on the Vaccine SAE 
Reporting Form within [ADDRESS_274555] be performed according to the processes 
described in Section 10.3.4 .
10.10.6. Reporting of SADE s
SADE Reporting to [COMPANY_007] Safety
Note: There are additional reporting obligations for medical device deficiencies that are 
potentially  related to SAEs (ie, anSADE) that must fulfill the legal responsibility  to notify  
appropriate regulatory  authorities and other entities about certain safet y information relating 
to medical devices being used in clinical studies.
Any device deficiency  that is associated with an SAE must be reported to the 
sponsor within 24 hours after the investigator determines that the event meets the 
definition of a device deficiency .
The sponsor shall review all device deficiencies and determine and document in 
writing whether they  could have led to an SAE.  These shall be reported to the 
regulatory  authorities and I RBs/ECs as required by  [CONTACT_2091].
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID- 19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 9010.11. Appendix 11 : Substudy A (Phase 1 /2)
10.11.1. Synopsis – Substudy A
SeeSection 1.1.
10.11.2. Schema –Substudy A (Phase 1 /2) 
Vaccination 1-Month 
Follow -Up 
Visit6-Month 
Telephone 
Contact
[CONTACT_227996]
(Visit Window)0 
(Day 1)1 
(28 to 35 Days 
After 
Vaccination)6 
(175 to 189 Days 
After 
Vaccination)
Visit Identifier Visit A101 Visit A102 Visit A103
Vaccination 1 
(Right Arm)Vaccination 2
(Left Arm)Vaccination 3
(Right Arm)
Group 1 
(n=150)Combination 
[RSVpreF+BNT162b2] QIV
Group 2 
(n=150)Combination 
[RSVpreF+BNT162b2]Placebo
Group 3 
(n=150)Bivalent BNT162b2Placebo
Group 4 
(n=150)RSVpreFPlacebo
Group 5 
(n=150)QIVPlacebo
Group 6a
(n=150) Bivalent BNT162b2Placebo RSVpreF
Group 7a
(n=150) Bivalent BNT162b2QIV RSVpreF
a.Separate administration sites on right arm by 1 inch (2.5 cm).
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 9110.11.3. SoA – Substudy A (Phase 1 /2)
Visit Identifier A101 A102 A103 Notes
Visit Description Vaccination 1-Month
Follow -Up 
Visit6-Month 
Telephone 
Contact
[CONTACT_227997] (Days) Day 1 28to 35
Days After
Visit A1 [ZIP_CODE] to 189
Days After
Visit A1 01Day 1 = Day of Vaccination
Obtain informed consent X See Section 10.1.3 . 
Assign participant number X See Section 6.3.
Obtain demography and medical history data *(including 
confirmed COVID -[ADDRESS_274556] result [NAAT or antigen test])X * Include date of onset and resolution 
(ifapplicable).
Perform clinical assessment X Including, if indicated, a physical 
examination. Examinations and assessments 
must occur prior to vaccination. 
See Section 8.3.1 .
Measure height and w eight X
Measure vital signs (including oral temperature) X Blood pressure and pulse rate; see 
Section 8.3.2 .
Confirm use of contraceptives (if appropriate) X X See Section 10.4.[ADDRESS_274557] nonstudy vaccine information X X X See Section [IP_ADDRESS] .
Collect prohibited medication use X X See Section [IP_ADDRESS].1.
Confirm eligibility X See Section 10.11.[ADDRESS_274558] blood sample for immunogenicity assessment ~50 mL † ~50 mL † Prior to vaccination. 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.[ADDRESS_274559]
Visit Window (Days) Day 1 28to 35
Days After
Visit A1 [ZIP_CODE] to 189
Days After
Visit A1 01Day 1 = Day of Vaccination
Administer study intervention X See Section [IP_ADDRESS].[ADDRESS_274560] the participant with downloading the app lication or issue 
provisioned device if requiredX See Section 8.3.4 .
Provide thermometer and measuring device X
Revie w reactogenicity e -diary data (daily review is optimal 
during the active diary period)X Days [ADDRESS_274561] been transferred 
prior to e- diary deactivation or removal of 
the app.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 9310.11.4. Introduction – Substudy A
[IP_ADDRESS]. Substudy A Rationale
This is a Phase 1/2substudy in up to approximately  1050healthy participants ≥65 y ears of 
ageto describe the safety , tolerability ,and immunogenicity  of a combined RSV preF and 
bivalent BNT162b2 (original/Omi BA.4/BA.5) vaccine [RSVpreF+BNT162b2], 
administered concomitantly  with a seasonal influenza vaccine or administered alone.
[IP_ADDRESS]. Background
SeeSection 2.2.
[IP_ADDRESS]. Benefit/Risk Asse ssment
See Section 2.3.1 for overall study  risks.  No unique risks are identified for Substudy  A.
Benefits to individual participan ts enrolled in Substudy  A may  be:
Receipt of a dose of an efficacious or potentiall y efficacious COVID -19 vaccine .
Receipt of a 
licensed influenza vaccine at no cost to the participant.
Receipt of a potentiall y efficacious RSV vaccine at no cost to the participant.
Contributing to research to help others.
Please see Section 2.3for details of the SRSDs relating to thestudy  intervention sused in 
Substudy  A.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 9410.11.5. Objectives, Endpoints, and Estimands –Substudy A
Substudy A (Phase 1 /2)
Objectives Estimands Endpoints
Primary Primary Primary
To describe the safety and tolerability of 
[RSVpreF+BNT162b2 ]In participants receiving study intervention, the percentage of participants 
reporting:
Local reactions within 7 days following vaccination
Systemic events within 7 days following vaccination
AEs from vaccination through 1month after vaccination
SAEs from vaccination through 6 months after vaccinationLocal reactions (pain at the injection 
site, redness, and swelling)
Systemic events (fever, fatigue, 
headache, chills, vomiting, diarrhea, 
new or worsened muscle pain, and 
new or worsened joint pain)
AEs
SAEs
To demonstrate that the immune responses elicited by 
[RSVpreF+BNT162b2] when coadministered with QIV 
are noninferior to those elicited by [CONTACT_227998]:
1. RSVpreF alone (Group 1 vs Group 4)1. In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 1 and 4):
 GMR of NTs at 1 month after vaccination in Group 1 to 
Group 4for RSV sub group A 
 GMR of NTs at 1 month after vaccination inGroup 1 to 
Group 4 for RSV subgroup B1. RSV A and RSV B NTs
2. Bivalent BNT162b2 alone (Group 1 vs Group 3) 2. In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 1 and 3 ):
 GMR of NTs at 1 month after vaccination in Group 1 to 
Group 3 for SARS -CoV -2 Omicron BA.4/BA.5
 GMR of NTs at 1 month after vaccination in Group 1 to 
Group 3 for SARS -CoV -2 reference strain2. SARS -CoV -2 Omicron BA.4/BA.5
and reference -strain NTs
3. QIV alone (Group 1 vs Group 5) 3. In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 1 and 5):
 GMR of HAI titers at 1 month after vaccination in Group 1 to 
Group 5 for each influenza strain included in the QIV3. HAI titers for each strain contained in 
the QIV
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 95Substudy A (Phase 1 /2)
Objectives Estimands Endpoints
To demonstrate that the immune responses elicited by 
[RSVpreF+BNT162b2 ]are noninferior to those elicited 
by [CONTACT_227999]:
1. RSVpreF alone (Group 2 vs Group 4)1.In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 2and 4):
 GMR of NTs at 1 month after vaccination in Group 2 to 
Group 4 for RSV subgroup A 
 GMR of NTs at 1 month after vaccination in Group 2 to 
Group 4 for RSV s ubgroup B1.RSV A andRSV B NTs
2.Bivalent BNT162b2 alone (Group 2 vs Group 3)2.In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 2and 3 ):
 GMR of NTs at 1 month after vaccination in Group 2 to 
Group 3 for SARS -CoV -2 Omicron BA.4/BA.5
 GMR of NTs at 1 month after vaccination in Group 2 to 
Group 3 for SARS -CoV -2 reference strain2.SARS -CoV -2 Omicron BA.4/BA.5 and 
reference -strain NTs
Secondary Secondary Secondary
To demonstrate that the immune responses elicited by
[CONTACT_227977] ,bivalent BNT162b2 , and QIV, when 
administered concomitantly, are noninferior to those 
elicited by [CONTACT_227999]:
1.RSVpreF (Group 7 vs Group 4)1.In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 7and 4):
 GMR of NTs at 1 month after vaccination in Group 7 to 
Group 4for RSV sub group A
 GMR of NTs at 1 month after vaccination inGroup 7to 
Group 4 for RSV s ubgroup B1. RSV A and RSV B NTs
2.Bivalent BNT162b2 (Group 7 vs Group 3)2.In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 7and 3 ):
 GMR of NTs at 1 month after vaccination in Group 7 to 
Group 3 for SARS -CoV -2 Omicron BA.4/BA.5
 GMR of NTs at 1 month after vaccination in Group 7 to 
Group 3 for SARS -CoV -2 reference strain2. SARS -CoV -2 Omicron BA.4/BA.5
and reference -strain NTs
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 96Substudy A (Phase 1 /2)
Objectives Estimands Endpoints
3.QIV (Group 7 vs Group 5)3.In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 7and 5):
 GMR of NTs at 1 month after vaccination in Group 7 to 
Group 5for each influenza strain included in the QIV3. HAI titers for each strain contained in 
the Q IV
To demonstrate that the immune responses elicited by 
[CONTACT_228000]162b2 when administered 
concomitantly are noninferior to those elicited by [CONTACT_228001]:
1. RSVpreF (Group 6 vs Group 4) 1.In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 6and 4):
 GMR of NTs at 1 month after vaccination in Group 6 to 
Group 4 for RSV subgroup A 
 GMR of NTs at 1 month after vaccination in Group 6 to 
Group 4 for RSV subgroup B1.RSV A and RSV B NTs
2. Bivalent BNT162b2 (Group 6 vs Group 3) 2.In participants in compliance with the key protocol criteria 
(evaluable participants for Groups 6and 3 ):
 GMR of NTs at 1 month after vaccination in Group 6 to 
Group 3 for SARS -CoV -2 Omicron BA.4/BA.5
 GMR of NTs at 1 month after vaccination in Group 6 to 
Group 3 for SARS -CoV -2 reference strain2.SARS -CoV -2 Omicron BA.4/BA.5 and 
reference -strain NTs
Exploratory Exploratory Exploratory
To further describe the immune responses elicited by 
[RSVpreF+BNT162b2 ]NA NA
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 9710.11.6. Substudy A Design
[IP_ADDRESS]. Overall Design
This is a Phase 1 /2randomized, parallel -group , observer-bl inded substudy  to describe the 
safet y
, tolerability, and immunogenicit y ofa combined RSVpreF and bivalent BNT162b2 
(original/Omi BA.4/BA.5) vaccine [RSVpreF+BNT 162b2], administered concomitantly  with 
a seasonal influ
enza vaccine or administered alone . Approximately 1050 healthy  participants
≥65 y ears of age will be enrolled in Substudy  A
.
Note: "Enrolled" means a participant's , or their legally  authorized representative ’s, agreement 
to participate in a clinical study  following completion of the informed consent process.
Randomization will be conducted across 2 enrollment strata (see Table 4).
Table 4. Substudy A Enrollment Strata
Enrol lment 
StratumTotal Number 
of ParticipantsNumber of 
Participants per 
Vaccine GroupVaccine 
Group 
NumberVaccine Group Description
1 750 150 1 [RSVpreF+BNT162b2] administered 
concurrently in the opposite arm to 
licensed QIV 
150 2 [RSVpreF+BNT162b2] administered 
concurrently in the opposite arm to 
placebo
150 3 Bivalent BNT162b2 administered 
concurrently in the opposite arm to 
placebo
150 4 RSVpreF administered concurrently 
in the opposite arm to placebo
150 5 Licensed QIV administered 
concurrently in the opposite arm to 
placebo
2 300 150 6 RSVpreF and bivalent BNT162b2 
(2injections in the same arm) 
coadministered concurrently in the 
opposite arm to placebo
150 7 RSVpreF and bivalent BNT162b2 
(2injections in the same arm) 
coadministered concurrently in the 
opposite arm to QIV
All participants will be asked to complete a reactogenicity  e-diary  for 7 days following 
vaccination.  Blood samples of approximately  50mL will be collected for immunogenicit y 
assessments prior to vaccination atVisit A 101and 1month after vaccination (Visit A102). 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.[ADDRESS_274562] 20 participants in Groups 6 and 7, will be evaluated prior to enrollment of the remaining 
participants in each group.
AEs and SAEs will be c ollected from the signing of informed consent through Visit A102
(1-month follow -up visit) . SAEs will be collected from the signing of informed consent 
through Visit A103 ( 6-month telephone contact).
Substudy  A will have s
toppi[INVESTIGATOR_227934] [IP_ADDRESS], with monitoring by  [CONTACT_228002] . If a stoppi[INVESTIGATOR_227935], further randomization and study  intervention 
administration will be paused while additional information is gathered, and cumulative 
unblinded safet y data will be reviewed b y the IRC .Participants who have received stud y 
intervention will continue further stud y visits and procedures as scheduled. A charter for the 
IRC will be prepared and finalized before the first participant provides informed consent.
The total duration of the study  for each participant will be up to appr oximately  6month s .
[IP_ADDRESS]. Scientific Rationale for Study Design
See Section 2.1.
[IP_ADDRESS]. Justification for Dose
See Section 4.3.
[IP_ADDRESS]. End of Study Definition
SeeSection 4.4.
10.11.7. Substudy A Population
[IP_ADDRESS]. Substudy A Inclusion Criteria
Participants are eligible to be included in Substudy  A only if all of the following criteria 
apply :
Age and Sex:
1.Male or female partici
pants ≥65years of age at Visit 1 (Day 1).
Refer to Section 10.4 for reproductive criteria for male Section 10.4.1 and female 
(Section 10.4.2) participants.
Disease Characteristics:
N
A.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 99Other Inclusion Criteria:
2.Participants who are willing and able to compl y with all scheduled visits, investigational 
plan, laboratory  tests, lifesty le considerations, and other stu dy procedures.
3.Health y participants who are determined b y medical history, ph ysical examination 
(ifrequired), and clinical judgment of the investigator to be eligible for inclusion in the 
study .
Note: Health y participants with preexisting stable disease, defined as disease not 
requiring significant change in therap y or hospi[INVESTIGATOR_227936] [ADDRESS_274563] dose being an updated (bivalent ) vaccine given at least ≥150 day s 
before Visit
A101 (Day  1).Any dose of modRNA SARS -CoV -2 vaccine received after 
01
September 2022 in the US may  be considered to be a bivalent vaccine.
Note: Documented confirmation of prior doses of COVID -19vaccines received must be 
obtained prior to randomization.
[IP_ADDRESS]. Substudy A Exclusion Criteria
Participants are excluded from Substudy  A if any of the following criteria apply :
Medical Conditions:
1.A confirmed diagnosis of COVID -19, RSV infection ,or influenza ≤120 day s before 
study  intervention administration.
2.History  of severe adverse reaction associated with any  vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of the study  intervention(s).
3.
Immunocompromised individuals with known or suspected immunodeficiency , as 
determined b y history  and/or laboratory /physical examination.
4.
Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opi[INVESTIGATOR_871], contraindicate intramuscular injection.
5.Allergy  to egg proteins (egg or egg products) or chicken proteins.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 1006.Any medical or ps ychiatric condition including recent (within the past year) or active 
suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk of study  
participation or, in the investigator’s judgment, make the participant inappropriate for the 
study .
Prior/Concomitant Therapy:
7.Receipt of chronic s ystemic treatment with known immunosuppressant medications 
(including cy totoxic agents or sy stemic corticosteroids), or radiothera py, within 60 days 
before enrollment through conclusion of the study.
Note : Systemic corticosteroids are defined as those administered for ≥14 day s at a dose 
of ≥20 mg/day  of prednisone or equivalent (eg, for cancer or an autoimmune disease).  
Inhaled/nebulized, intra -articular, intrabursal, or topi[INVESTIGATOR_2855] (skin or ey es) corticosteroids are 
permitted.
8. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 
60days before study  intervention administration, or planned receipt throughout t he study .
9.Receipt of an y RSV vaccine at an y time prior to enrollment, or planned receipt 
throughout the stud y.
10.Receipt of an y influenza vaccine ≤120 day s before study  enrollment .
Prior/Concurrent Clinical Study Experience:
11. Participation in other studies involving a study  intervention within 28 day s before 
randomization
.
12.Anticipated participation in other studies within 28 day s after receipt of study  
intervention in this study .
Diagnostic Assessments:
NA.
Other Exclusion Criteria:
13.Investigator site staff directly  involved in the conduct of the study  and their family  
members, site staff otherwise supervised b y the investigator, and sponsor and sponsor 
delegate employ ees directly  involved in the conduct of the study  and their family  
members.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].11.7.3. Criteria for Tem porarily Delaying 
Enrollment/Randomization/Administration of Study Intervention
The following conditions may  allow a participant to be randomized once the conditions have 
resolved and the participant is otherwise considered eligible.  Participants meeting these 
criteria at Visit 1 will be considered screen failures if enrollment has closed once the 
condition(s) has/have resolved.
1.A positive SARS -CoV -[ADDRESS_274564] result (NAAT or rapid antigen test) within the previous 
28days.
2.Current febrile illness (oral tempera ture ≥38.0°C [≥100.4°F]) or other acute illness within 
48 hours before study  intervention administration.  This includes sy mptoms that could 
represent a potential COVID- 19 illness (refer to Section 8.4.8).
Note: The participant should be directed to seek additional testing through their primary  
healthcare provider at a licensed clinical laboratory when exhibiting potential COVID -
19 
symptoms or otherwise receiving a positive result and counseled on whether to take any  
precautionary  measures pending confirmatory  testing, as per local guidance.
3.Receipt of an y nonstud y vaccine within 28 days before study  intervention administration 
at Visit A101.
4.Anticipated receipt of any nonstud
y vaccine within 28 days after study intervention 
administration at Visit A101.
5.Receipt of short -term (<14 day s) systemic corticosteroids.  Study  intervention 
administration should be delay ed until sy stemic corticosteroid use has been discontinued 
for at least 28 days.  Inhaled/nebulized, intra -articular, intrabursal, or topi[INVESTIGATOR_2855] (skin or 
eyes) corticosteroids are permitted.
10.11.8.
Substudy A Intervention and Concomitant Therapy
Study  interventions are all prespecifi ed investigational and medical devices, and other 
interventions (eg, surgical and behavioral), intended to be administered to the study  
participants during the study conduct.
Combined RSVpreF and bivalent BNT162b2 (original */Omi BA.4/BA.5) vaccine 
[RSVpreF+BNT162b2
] 0.8 mL, which is a combination of the following:
o120 µg RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal 
amounts (60µgper strain) from virus subgroups A and B
o30 µg Bivalent BNT162b2 ( 15 µg original/Omi BA.4/BA.5), which contains 
original BNT162b2 and BNT162b2 Omicron ( 15µg B.1.1.529 sublineage 
BA.4/BA.5)
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 102120 µg RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts
(60µgper strain) from virus subgroups A and B
Licensed QIV
30 µg Bivalent BNT162b2 (15 µg original/Omi BA.4/BA.5), which contains original 
BNT162b2 and BNT162b2 Omicron (15 µg B.1.1.529 sublineage BA.4/BA.5)
Normal saline (0.9% sodium chloride solution for injection) 0.8 mL
*Original refers to the ancestral s
train (Wuhan -Hu-1; [LOCATION_003] -WA1/2020), also referred to in 
this protocol as the reference strain.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].11.8.1. Study Intervention(s) Administered
Study  interventions for Substudy  A will include the following :
Substudy A Study Interventions
Intervention Name [CONTACT_228018] 
[RSVpreF+BNTb162b2]Bivalent BNT162b2 
(Originala/Omi
BA.4/BA.5)RSVpreF QIV Normal Saline Placebo
Arm Name
(group of participants receiving a 
specific study intervention or no 
study intervention)Group s 1, 2: 
Combination 
[RSV preF+ BNT162b2]Group s3, 6, 7:
Bivalent BNT162b2 
(origina la/Omi BA.4/BA.5)
(30µg)Group s 4, 6, 7:
RSV preF (120 µg)Group s1, 5, 7:
QIVGroup s2, 3, 4, 5, 6:
Placebo
Targeted Influenza Strains NA NA NA For each season, 
strains as 
recommended by 
[CONTACT_228003]
(0.9% sodium chloride 
solution for injection)
Unit Dose Strength(s) As detailed in the IPM As detailed in the IPM As detailed in the 
IPMAs detailed in the IPM NA
Dosage Level(s) or Volume RSVpreF 120 µg
Bivalent BNT162b2 30µg30µg 120µg 0.7 mL 0.8 mL
Route of Administration Intramuscular injection Intramuscular injection Intramuscular 
injectionIntramuscular 
injectionIntramuscular injection
Use Experimental Comparator (Group 3) 
Experimental (Group s 6and 
7)Comparator (Group 4) 
Experimental 
(Group s 6and 7)Comparator (Group 5)
Experimental 
(Groups 1 and 7)Placebo for blinding
IMP or NIMP/AxMP IMP IMP IMP IMP IMP
Sourcing Provided centrally by [CONTACT_228004]
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 104Substudy A Study Interventions
Intervention Name [CONTACT_228018] 
[RSVpreF+BNTb162b2]Bivalent BNT162b2 
(Originala/Omi
BA.4/BA.5)RSVpreF QIV Normal Saline Placebo
Packaging and Labeling Study intervention will be 
generated by [CONTACT_228005]-level combinations 
detailed below:
 RSVpreF 
 Bivalent BNT162b2 
(originala/Omi 
BA.4/BA.5) 
Each vial will be labeled per 
country requirement.Study intervention will be 
provided in a glass vial as 
open -label supply. Each 
vial will be
labeled per country 
requirement.Study intervention 
will be provided in a 
glass vial as 
open -label supply. It 
is reconstituted with a 
PFS of sterile water 
diluent for injection 
(supplied).  Each vial 
and PFS will be 
labeled per country 
requirement.Study intervention 
will be provided as a 
PFS as open -label 
supply. Each carton 
will be labeled per 
country requirement.Study intervention will be 
provided as either a PFS 
or a glass/plastic vial as 
open -label supply. Each 
PFS or vial will be labeled 
per country requirement.
SRSD IB IB IB USPI [CONTACT_208130]
a. Original refers to the ancestral strain (Wuhan -Hu-1; [LOCATION_003] -WA1/2020).
Substudy A Study Arms
Group Number 1 2 3 4 5 6 7
Arm Title Combination 
[RSVpreF+BNT162b2 
(0.8mL)]+ QIVCombination 
[RSVpreF+BNT162b2
(0.8mL)]+ placeboBivalent 
BNT162b2 (30 µg) 
+ placeboRSVpreF (120 µg) 
+
placeboQIV +placebo Coadministration   
RSVpreF + 
bivalent 
BNT162b2 + 
placeboCoadministration
RSVpreF + bivalent 
BNT162b2 + QIV
Arm Type Experimental Experimental Comparator Comparator Comparator Experimental Experimental
Arm Description Participants will receive 
combination [RSVpreF 
(120 µ g) + BNT162b2 
(30µg)]+ QIVParticipants will receive 
combination [RSVpreF 
(120 µ g) + BNT162b2 
(30µg)]+ placeboParticipants will 
receive BNT162b2 
(30µg) + placeboParticipants will 
receive RSVpreF 
(120 µ g) + 
placeboParticipants 
will receive 
QIV + placeboParticipants will 
receive 
coadministered 
RSVpreF (120 µg) 
+ BNT162b2 
(30µg) + placeboParticipa nts will 
receive 
coadministered 
RSVpreF (120 µg) 
+ BNT162b2 
(30µg) + QIV
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 ( 14April 2023)
TMF Doc ID: 164.01
Page 105Substudy A Study Arms
Group Number 1 2 3 4 5 6 7
Associated 
Intervention 
Labels[RSVpreF (120 µg) + 
BNT162b2 (30 µg)]+ QIV[RSVpreF (120 µg) + 
BNT162b2 (30 µg)]+ 
placeboBNT162b2 (30 µg) 
+ placeboRSVpreF (120 µg) 
+ placeboQIV + placebo RSVpreF (120 µg) 
+ BNT162b2 
(30µg) + placeboRSVpreF (120 µg) 
+ BNT162b2 
(30µg) + QIV
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].[IP_ADDRESS]. Administration
See Section [IP_ADDRESS] .
During Substud y A, allstudy  intervention sare to be administered as an intramuscular
injection into the deltoid muscle of the arm, in accordance with the schema ( Section 10.11.2)
and the SoA ( Section 10.11.3 ).
[IP_ADDRESS].2. Medical Devices 
SeeSection 6.1.2.
[IP_ADDRESS].3. Preparation, Handling, Storage, and Accountability
See Section 6.2.
[IP_ADDRESS].3.1. Preparation and Dispensing
See Section 6.2.1.
During Substud
y A, study intervention will be prepared and dispensed by  [CONTACT_228006] (eg, phy sician, nurse, 
physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as 
allowed b y local, state, and institutional guidance. A second unblinded staff member will 
verify  the dispensing .
[IP_ADDRESS].4.
Allocation to Study Intervention
See Section 6.3.
Allocation of study  intervention at Visit A
101in Substudy  A will be conducted via the IRT.
E
-diary  data from Day  [ADDRESS_274565] 20 participants in Groups 6 and 7, will be evaluated prior to enrollment of the remaining 
participants in each group. Initial enrol lment 
will be controlled through the I RT s ystem to 
manage this approach.
[IP_ADDRESS]. Blinding
This is an observer -blinded study .
[IP_ADDRESS].1. Blinding of Participants
Participants will be blinded to their assigned stud y intervention. When the 1- month analy sis 
has been performed, and when directed b y the sponsor (anticipated to be between Visit A102 
and Visit A103), participant smay be unblinded to confirm the vaccine received.  The study  
team will also become unblinded to the participant’s study intervention allocation at this 
time.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].[IP_ADDRESS]. Blinding of Site Personnel
Thestudy  staff receiving, storing, dispensing, preparing, and adminis tering the study  
interventions will be unblinded. All other study  and site personnel, including the investigator 
and investigator staff, will be blinded to assignment of study  intervention. In particular, the 
individuals who evaluate participant safety  will be blinded. Because there are differences in 
physical appearance between study  interventions, study  interventions will be administered in 
a manner that prevents the participants from identify ing the study  intervention based on its 
appearance.
The PI  [INVESTIGATOR_227937]/ administrators topersons 
who will not participate in the evaluation of an y study  participant. To ensure adequate 
coverage, at least 2 unblinded dispensers/ administrators will be assigned per site. Members 
of the study  site nursing/medical staff or clinic pharmacy  willfulfill these roles. Contact 
[CONTACT_228007] y participants should be kept to a minimum. The 
investigator, stud y coordinator, and an y site staff other than the unblinded 
dispensers/ administrators must not be allowed to know the study  intervention assigned to any  
study  participant and must not be allowed to see the study  intervention container contents.
In the event of a Qualit y Assurance audit, the auditor(
s) will be allowed access to unblinded 
study  intervention records at the site(s) to verify  that randomization/dispensing has been done 
accuratel y.
[IP_ADDRESS].3. Blinding of the Sponsor
All laboratory  testing personnel performing serology  assay s will remain blinded to st udy 
intervention assigned/received throughout the study .  The following sponsor/[COMPANY_007] staff, who 
will have no part in the blinded conduct of the study, will be unblinded (further details will 
be provided in a data blinding plan):
Those study  team members who are involved in ensuring that protocol requirements for 
study  intervention preparation, handling, allocation, and administration are fulfilled at the 
site will be unblinded for the duration of the stud y (eg, unblinded study manager, 
unblinded clinical research associate).
Unblinded clinician(s), who are not direct members of the study  team and will not 
participate in an y other study -
related activities, will review unblinded protocol 
deviations.
An unblinded team will support interactions with and anal yses for the IRC (see
Section 10.1.5).  This team comprises a statistician, programmer(s), a clinical scientist, 
and a medical monitor. 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 108When the 1-month analysis has been performed, and when directed b y the sponsor 
(anticipa ted to be between Visit A102 and Visit A103), participant smay be unblinded to 
confirm the vaccine received.  The study team will also become unblinded to the 
participant’s stud y intervention allocation at this time .
[IP_ADDRESS].4. Breaking the Blind
See Section 6.4.4.
[IP_ADDRESS].
Study Intervention Compliance
See Section 6.5.
[IP_ADDRESS]. Dose Modification 
N
A.
[IP_ADDRESS]. Continued Access to Study Intervention After the End of the Study
See Section 6.7.
[IP_ADDRESS]. Treatment of Overdose
SeeSection 6.8.
[IP_ADDRESS].
Prior and Concomitant Therapy
For Substudy  A, the following concomitant medications and vaccinations will be recorded in 
the CRF:
Prior receipt of an y COVID -19 vaccine.
Influenza vaccine *, if received during the 12 months prior to enrollment .
*Include product name [CONTACT_228019].
Any vaccinations received from [ADDRESS_274566] visit 
(A103).
Prohibited medications listed in Section [IP_ADDRESS].1 , if taken, will be recorded and 
include start and stop dates, name [CONTACT_11889], dose, unit, route, and frequency .
[IP_ADDRESS].1. Prohibited During the Study
Receipt of the following vaccines and medications during the time periods listed below may  
exclude a participant from the per -protocol anal ysis from that point onward; however, it is 
anticipated that the participant would not be withdrawn from the study  (see Section 7).
Medications should not be withheld if required for a participant’s medical care.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 109Unless considered medically  necessary , no vaccines other than study  intervention should 
be administered within 28 day s before and 28 days after study  vaccination at Visit 1.
Licensed or nonstudy  investigational coronavirus vaccine from enrollment through 
31August 2023 .
Licensed or nonstudy  investigational influenza vaccine from enrollment through 
31August 2023.
Licensed or nonstud
y investigational RSV vaccine from enrollment through
31August 2023.
Receipt of chronic s ystemic treatment with known immunosuppressant medications, or 
radiotherap y, within 60 days before enrollment through conclusion of the study is 
prohibited.
Receipt of s ystemic corticosteroids ( ≥20 mg/day  of prednisone or equivalent) for 
≥14days is prohibited from 28 day s prior to enrollment through 28 day s after 
administration of the study  intervention.
Receipt of blood/plasma products, immunoglobulins, or monoclonal antibodies, from 
60days before study  intervention administration through conclusion of the study .
Prophy lactic antipy retics and other pain medication to prevent s ymptoms associated with 
study  intervention administration are not permitted.  Howe ver, if a participant is taking a 
medication for another condition, even if it may  have antipy retic or pain -relieving 
properties, it should not be withheld prior to study vaccination.
[IP_ADDRESS].2. Permitted During the Study
Medication other than that described as prohi bited in Section [IP_ADDRESS].1 required for 
treatment of preexisting conditions or acute illness is permitted.
Inhaled, topi[INVESTIGATOR_2855], or l ocalized injections of corticosteroids (eg, intra -articular or intrabursal 
administration) are permitted.
10.11.9.
Discontinuation of Substudy A Intervention and Participant 
Discontinuation/Withdrawal
SeeSection 7.
10.11.10. Substudy A Assessments and Procedures
For Substudy  A, the minimal blood sampling volume for all individual participants in this 
study  is approximat ely 100mL.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 110For all participants in Substudy  A, other additional blood samples may  be taken for safet y 
assessments, provided the total volume taken during the study  does not exceed 550 mL 
during an y period of 60 consecutive day s.
[IP_ADDRESS]. Immunogenicity Assessments
Samples will be collected at time points as specifi ed in Section 10.11.3 from all applicable 
participants, and the following assay s will be performed :
HAI titers for the matched seasonal strains (2×A, 2×B) recommended b y WHO for 
Groups 1, 5, and7.
SARS -CoV -2 neutralization assay  (reference strain) for Groups 1, 2, 3, 6,and7.
SARS -CoV -2 neutralization assay s (Omicron BA.4, Omicron BA.5; other variant s, 
including other Omicron sublineages, may  also be evaluated) for Groups 1, 2, 3, 6, and7.
RSV A and RSV B se rum NTs for Groups 1, 2, 4, 6,and7.
[IP_ADDRESS].
N-Binding Antibody Test
The N -binding antibody  test willbe performed b y the central laboratory  on each blood 
sample to establish prior exposure to SARS- CoV -2 up to each time point.  
[IP_ADDRESS]. Biological Samples
See Section 8.2.1.
[IP_ADDRESS]. Safety Assessments
See Section 8.3.
[IP_ADDRESS]. Stoppi[INVESTIGATOR_227938]  A participants, based on review of 
AEs, ECG, and laboratory  data , and appl y to study vaccination (Day 1)through Day  28.  
These data will be monitored on an ongoing basis by  [CONTACT_093] (or medicall y qualified 
designee) and sponsor in order to promptly  identify  and flag any  event that potentially  
contributes to a stoppi[INVESTIGATOR_1877]. In the event that sponsor personnel confirm that a stoppi[INVESTIGATOR_163783], the following actions will commence:
The I RC will review all appropriate data.
The stoppi[INVESTIGATOR_227939].
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 111For all participants already  vaccinated, all other routine study  conduct activities, 
including ongoing data entry , reporting of AEs, participant e -diary  completion, blood 
sample collection, and participant follow -
up, will continue during the pause.
A stoppi[INVESTIGATOR_227940] 28 day safter study  
intervention administration. 
Stoppi[INVESTIGATOR_227941]:
If any participant vaccinated with the combined RSVpreF and bivalent BNT162b2
(original/Omi BA.4/BA.5) vaccine [RSVpreF+BNT162b2 ]develops:
1.A new ECG abnormality  that a cardiologist ju dges consistent with probable or possible 
myocarditis or pericarditis, including:
Sustained atrial or ventricular arrh ythmias
Second- degree Mobitz Ty pe II or worse AV block, new bundle branch block
Diffuse ST- segment elevation or PR -segment inversion, comp atible with pericarditis
2. An abnormal troponin value that is confirmed abnormal on repeat testing, assessed as 
related to stud y intervention by [CONTACT_093].
3.If ≥1 participant vaccinated with an y [RSVpreF+BNT162b2] combination develops 
confirmed m yocard itis or pericarditis.
4.If any participant vaccinated with any  [RSVpreF+BNT162b2 ]combination dies.
A charter for the IRC will be prepared and finalized before the first participant provides
consent.
[IP_ADDRESS].
Adverse Events, Serious Adverse Events, and Other Safety R eporting
See Section 8.4.
[IP_ADDRESS]. Study Procedures
[IP_ADDRESS].1.
Visit A101 – Vaccination (Day 1)
Before enrollment and before an y stud y
-related procedures are performed, voluntary , written, 
study -specific informed consent will be obtained from the participant.  Each signature [CONTACT_228020] y dated b y the signatory.  The investigator or theirdesignee will also 
sign the ICD.  A cop y of the signed and dated ICD must be given to the participant.  The 
source data must reflect that the informed consent was obtained before participation in the 
study .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 112It is anticipated that the procedures below will be conducted in a stepwise manner.
Assign a participant number using the IRT s ystem.  
Obtain the participant’s demograph y (including date of birth, sex, race, and ethnicity).  
The full date of birth will be collected (as permitted by  [CONTACT_427]) to critically  
evaluate the immune response and safet y profile by [CONTACT_654].
Obtain medical history data* , including confirmed COVID- 19 diagnosis ( see 
Section 8.4.8) or as ymptomatic positive SARS -CoV - [ADDRESS_274567] result (NAAT or antigen test), 
and an y other medical history of clinical significance.
*Include date of onset and resolution (if applicable).
Perform a clinical assessment.  If the clinical assessment indicates that a phy sical 
examination is necessary to comprehensivel y evaluate the participant, perform a ph ysical 
examination and record any  findings in the source documents and, if clinically  
significant, record on the medical history CRF or on the AE CRF as per Section 10.3.
Measure the participant’s height and weight .
Measure the participant’s vital signs ,including oral temperature, pulse rate, and seated 
blood pressure .
Discuss contraceptive use as describ ed in 
Section 5.3.1.
Review documentation of all prior COVID -[ADDRESS_274568] prior receipt of an y 
COVID -19 vaccine as described in Section [IP_ADDRESS] .
Record details of an y influenza vaccine received in the prior 12 months, as described in 
Section [IP_ADDRESS].
Record nonstud y
vaccinations as described in Section [IP_ADDRESS].
Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met.
Ensure that the participant meets none of the temporary  delay  criteria as described in 
Section 5.5.
Obtain the participant’s randomization number and study  intervention allocation using 
the IRT s ystem.
Collect a blood sample (approximately  50 mL), before administration of study  
intervention, for immunogenicity  assessment.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 113Unblinded s ite staff member(s) w ill dispense/administer study  intervention into the 
deltoid muscle of the arm as described in Section 10.11.8.  Please refer to th e IPM for 
further instruction on this process.
Site staff must observe the participant for at least [ADDRESS_274569] any acute reactions (including time of 
onset) in the participant’s sourc
e documents and on the AE page of the CRF, and on an 
SAE form as applicable.
Issue a measuring device to measure local reactions at the injection site and a 
thermometer for recording daily temperatures and provide instructions on their use.
Explain the e -diary  completion requirement to the participant and assist the participant 
with downloading the study  application onto the participant’s own device or issue a 
provisioned device if required.  Provide instructions on e
-diary  completion and ask the 
participan t to complete the reactogenicit y e-diary  from Day 1 through Day  7, with Day 1 
being the day  of vaccination.
Ask the participant to contact [CONTACT_214350] y if they experience 
any of the following from Day  1 through Day  7 after vac cination (where Day  1 is the day  
of vaccination) to determine if an unscheduled reactogenicity  visit is required:
Fever ≥39.0°C ( ≥ 102.1°F).
Redness or swelling at the injection site measuring greater than 10 cm 
(>20 measuring device units).
Severe pain at the injection site.
Any severe s ystemic event.
Record AEs as described in Section 8.4.1.
Ask the participant to contact [CONTACT_214351] a medicall y attended event 
(eg,doctor’s visit, emergency  room visit) or hospi[INVESTIGATOR_149323].
Ask the participant to co ntact the site staff or investigator immediatel y if the participant 
experiences acute chest pain, shortness of breath, or palpi[INVESTIGATOR_814] (see
Section [IP_ADDRESS].5).
Schedule an appointment for the participant to return for the next study  visit.
Remind the participant to bring the e -diary  to the next visit.
Complete the source documents.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 114The investigator or an authorized designee completes the CRFs and updates the study  
intervention accountability  records.
The investigator or appropriately  qualified designee reviews the reactogenicity  
e-diary  data online following vaccination to evaluate participant compliance and as part 
of the ongoing saf ety review.  Dail y review is optimal during the active diary period.
[IP_ADDRESS].2. Visit A102 – 1 -Month Follow -Up Visit (After Vaccination) – 28to 35Days 
After Visit A101
Record AEs as described i nSection 8.4.
Record nonstud y vaccinations as described in Section [IP_ADDRESS].
Record prohibited medication use as described in Section [IP_ADDRESS].1.
Verify  understanding of and 
compliance with protocol requirements for contraception as 
described in Section 5.3.1 .
Collect a blood sample of approximately  50mL for immunogenicit y testing.
Review the participant’s reactogenicity  e-diary  data.  Collect stop dates of any  
reactogenicity  e-diary  events ongoing on the last day  that the reactogenicity  e-diary  was 
completed and record stop dates in the CRF if required .
If not alread y completed, collect the participant’s e -diary  or assist the participant with 
removing the stud y application from their own personal device.
oEnsure all e -diary  data have been transferred prior to e -diary  deactivation or removal 
of the app.
Record an y AEs that occur within the 48 hours after the blood draw as described in
Section 8.4.1.
[IP_ADDRESS].3. Visit A103 –
6-Month Telephone Contact – 175 to 189 Days After 
Visit A101
Contact [CONTACT_228008].
Record SAEs as described in Section 8.4.
Record nonst udy vaccinations as described in Section [IP_ADDRESS] .
Record prohibited medication use as described in Section [IP_ADDRESS].1.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 115Complete the source documents.
The investigator or an authorized designee completes the CRFs.
[IP_ADDRESS].4. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction
If a Grade 3 local reaction ( Section [IP_ADDRESS]), s ystemic event ( Section [IP_ADDRESS] ), or fever of 
≥39.0°C ( ≥102.1°F) (Section [IP_ADDRESS]) is reported in the reactogenicit y e-diary , a telephone 
contact [CONTACT_214345] a site visit is 
clinically  indicated.  If a suspected Grade 4 local reaction ( Section [IP_ADDRESS]), sy stemic event 
(Section [IP_ADDRESS]), or fever ( Section [IP_ADDRESS]) is reported in the reactogenicit y e -diary , a 
telephone contact [CONTACT_228009] [ADDRESS_274570] be scheduled as soon as possible to assess the participant unless any  of the 
following is true:
The participant is unable to attend the unscheduled visit.
The local reaction/s ystemic event is no longer present at the time of the telephone 
contact.
The participant recorded an incorrect value in the reactogenicity  e-diary  (confirmation of 
a reactogenicit y e-diary  data entry  error).
The PI  [INVESTIGATOR_214313].
This telephone contact [CONTACT_228010]’s source documentation and the 
CRF.
If the participant is unable to attend the unscheduled visit, or the PI  [INVESTIGATOR_227942], an y ongoing local reactions/sy stemic events must be assessed 
at the n ext study  visit.
During the unscheduled visit, the reactions should be assessed b y the investigator or a 
medically  qualified member of the study  staff, such as a study  physician or a study  nurse, as 
applicable to the investigator’s local practice, who will:
Measure bod y temperature ( °F/°C).
Measure minimum and maximum diameters of redness (if present).
Measure minimum and maximum diameters of swelling (if present).
Assess injection site pain (if present) in accordance with the grades provided in 
Section
[IP_ADDRESS].
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 116Assess sy stemic events (if present) in accordance with the grades provided in 
Section [IP_ADDRESS].
Assess other findings associated with the reaction and record this on the AE page of the 
CRF if appropriate.
The investigator or an authorized designe e will complete the unscheduled visit 
assessment page of the CRF.
[IP_ADDRESS].5. Additional Procedures for Monitoring of Potential Myocarditis or 
Pericarditis
Any study  participant who reports acute chest pain, shortness of breath, palpi[INVESTIGATOR_814], or any  
other sy mptom(s) t hat might be indicative of m yocarditis or pericarditis within 28daysafter 
study  vaccination must be specifically  evaluated for possible my ocarditis or pericarditis.
In addition to a clinical evaluation, the following should be performed:
ECG and
Measurement of the troponin level
If my ocarditis or pericarditis is suspected based upon the initial evaluation, the following 
should also be performed:
Evaluation by  a cardiologist,
Cardiac echocardiogram and/or
Cardiac magnetic resonance study
Details of the s ymptoms reported, and results of the investigations performed, will be 
recorded in the CRF.
10.11.11. Statistical Considerations –Substudy A
Methodology
 for summary  and statistical anal yses of the data collected in this substudy  is 
described here and further detailed in the SAP, which will be maintained by [CONTACT_456].  The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be reflected in a 
protocol amendment.
[IP_ADDRESS]. Statistical Hypotheses
The estimands corresponding to the primary  and secondary  objectives are described in the 
table in Section 10.11.5 .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 117Both primary  and secondary  immunogenicity  objectives arehypothesis -testing objectives. 
Thesubsections below describe details of hy potheses to be tested for each objective.
[IP_ADDRESS].1. Statistical H ypotheses for Combined Vaccine Coadministered With QIV
A total of [ADDRESS_274571] primary  immunogenicity objective as 
described below for each vaccine component .
1.The null hy pothesis (H 0) to assess noninferiorit yof the response with resp
ectto RSVpreF 
will be evaluated by [CONTACT_228011] A and RSV B as measured 
by [CONTACT_110586]:
H0:ln(µ 1) -ln(µ 4) ≤ln(0.5)
where ln(0. 5) corresponds to a 2-fold margin for noninferiority ,and ln(µ 1) and ln(µ 4) are 
the natural log of t
he geometric mean of NT at 1 month after vaccination for Group 1 and 
Group 4,respectivel y. 
2.The null hy pothesis (H 0) to assess noninferiorit y of the response with resp
ectto 
BNT162b2 will be evaluated by  [CONTACT_228012] -CoV -2 
Omicron BA.4/BA.5 strain and the reference strain as measured b y NT :
H0:ln(µ 1) -ln(µ 3) ≤ln(0.5) 
where ln(0. 5) corresponds to a 2-fold margin for noninferiority ,and ln(µ 1) and ln(µ 3) are 
the natural log of the geometric mean of NT at 1 month after vaccination for Group 1 
and 
Group 3,respectivel y. 
3.The null hy pothesis (H 0) to assess noninferiorit y of the response with resp
ectto QIV will 
be evaluated b y the following h ypothesis for each of the 4 strains included in QIV as 
measured b y HAI titer:
H0:ln(µ 1)
-ln(µ 5) ≤ln(0.5) 
where ln(0. 5) corresponds to a 2-fold margin for noninferiority ,and ln(µ 1) and ln(µ 5) are 
the natural log of the geometric mean of HAI titers at 1 month after vaccination for 
Group 1 
and Group 5,respectivel y. 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].[IP_ADDRESS]. Statistical Hypotheses for Combined Vaccine Alone
A total of 4 hy potheses will be tested for the second primary  immunogenicity  objective as 
described below for each vaccine component.
1.The null hy pothesis (H 0) to assess noninferiorit y of the response with respectto RSVpreF 
will be evaluated by [CONTACT_228013] A and RSV B as measured 
by [CONTACT_110586]:
H0:ln(µ 2) -ln(µ 4) ≤ln(0.5) 
where ln(0. 5) corresponds to a 2-fold margin for noninferiority  and ln(µ 2) and ln(µ 4) are 
the natural log of the geo metric mean of NT at 1 month after vaccination for Group 2and 
Group 4,respectivel y. 
2.The null hy pothesis (H 0) to assess noninferiorit y of the response with resp
ectto 
BNT162b2 will be evaluated by  [CONTACT_228012] -CoV -2 
Omicron BA.4/BA.5 strain and the reference strain as measured b y NT:
H0:ln(µ 2) -ln(µ 3) ≤ln(0.5) 
where ln(0. 5) corresponds to a 2-fold margin for noninferiority  and ln(µ 2) and ln(µ 3) are 
the natural log of the geometric mean of NT at 1 month after vaccination for Group 2and 
Group 3,respectivel y. 
[IP_ADDRESS].3.
Statistical Hypotheses for Coadministration of [ADDRESS_274572] of the secondar y objective ssimilar to
Section [IP_ADDRESS].1, except th atGroup 1 will be replaced with Group 7 .
[IP_ADDRESS].4. Statistical Hypotheses for Coadministration of 2 Individual Vaccines
A total of 4 hy potheses will be tested for the second of the second ary objective ssimilar to
Section [IP_ADDRESS].2 ,except thatGroup 2 will be replaced with Group 6.
[IP_ADDRESS].5. Multi plicity Adjustment
TypeI error of 5% is equally  split between the 2 primary immunogenicity  objectives (2- sided 
2.5% for each). Thefirst primary  immunogenicity objective will be achieved if all 8 null
hypotheses are rejected . The second primary  immunogenicity  objective will be achieved if 
all 4 null hy potheses are rejected. The stud y is considered successful if either primary 
immunogenicit y objective is achieved.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID- 19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 119The se condary  immunogenicity  objectives will be tested sequentiall y after the primary 
objective(s) is achieved as described in the schema below.
[IP_ADDRESS]. Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined in Substudy  A:
Population Description
Enrolled All participants who sign the ICD.
Random ized population All participants who are assigned a randomization number in the IWR 
system regardless of whether the study intervention was administered.
Safety population All participants who receive the study intervention.
mITT immunogenicity
populationAll randomized participants who receive the study intervention and have at 
least [ADDRESS_274573] 1 valid and determinate assay result at the 1- month postvaccination 
visit.
[IP_ADDRESS]. Statistical Analyses
[IP_ADDRESS].1. General Considerations
Refer to Section 9 for general considerations of statistical anal yses.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].[IP_ADDRESS]. Primary Endpoint(s)/Estimand(s) Analysis
Endpoint Statistical Analysis Methods
Safety Descriptive statistics will be provided for each reactogenicity  
endpoint in each vaccine group (Group 1 to Group 7 individually ) . 
Local reactions (pain at the injection site , redness, and swelling ) 
and sy stemic events (fever, fatigue, headache, chills, vomiting, 
diarrhea, new or worsened muscle pain, and new or worsen edjoint 
pain) from Day  1 through Day  7 after vaccination will be presented 
by [CONTACT_228014] y.  Descriptive summary  
statistics will include counts and percentages of participants with 
the indicated endpoint and the associated Clopper -Pearson 95% CIs 
(Section 9.3.1).
AEs andSAEs will be categorized according to MedDRA terms. 
All of the AEs 
reported through the 1 -month follow -up visit and 
SAEs reported throughout the study  will be descriptively  
summarized with counts, percentages, and associated 
Clopper -Pearson 95% CI for each vaccine group (Section 9.3.1).
Immunogenicity GMRs of RSV A and RSV B NTs (Group 1 to Group 4) , GMRs of 
SARS -CoV -2 Omicron BA.4/BA.5
–strain NTs and 
reference -strain NTs (Group 1 to Group 3), i nfluenza 
strain
-specific GMRs of HAI titers (Group 1 to Group 5) at 
1month after vaccination will be provided with 97.5% CI s 
(Section [IP_ADDRESS].3). Using a 2-fold noninferiority margin, success 
for the first primary  immunogenicity  objectiv e will be declared if 
the lower bound of the 2 -sided 97.5% CI  for the GMR is greater 
than 0.5 f or both RSV A and RSV B antigens , for both the 
Omicron BA.4/BA.5 and reference strains, and for all 4 QIV
strains .
GMRs of RSV A and RSV B NTs (Group 2 to Group 4) and
GMRs of SARS -CoV -2 Omicron BA.4/BA.5 –strain NT sand 
reference -strain NTs (Group 2 to Group 3) at 1 month after 
vaccination will be provided with 97.5% CI s (Section [IP_ADDRESS].3).
Using a 2
-fold noninferi ority margin, success for the second
primary  immunogenicity  objectiv e will be declared if the lower 
bound of the 2- sided 97. 5% CI  for the GMR is greater than 0.5 for 
both RSV A and RSV B antigens andfor both the Omicron 
BA.4/BA.5 and reference strains .
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].[IP_ADDRESS]. Secondary Endpoint(s)/Estimand(s) Analysis
Endpoint Statistical Analysis Methods
Secondary
immunogenicityGMRs of RSV A and RSV B NTs (Group 7 to Group 4), GMRs of 
SARS -CoV -2 Omicron BA.4/BA.5–strain NT sand reference -strain
NTs (Group 7to Group 3), influenza strain -specific GMRs of HAI 
titers (Group 7 to Group 5) at 1 month after vaccination will be 
provided with 97.5% CIs (Section [IP_ADDRESS].3). Using a 2-fold 
noninferiority margin, success for the first of the secondary
immunogenicit y objectiv eswill be declared if the lower bound of 
the 2- sided 97.5% CI for the GMR is greater than 0.5 for both RSV 
A and RSV B antigens , for both the Omicron BA.4/BA.[ADDRESS_274574] primary  
immunogenicit y objective is achieved .
GMRs of RSV A and RSV B NTs (Group 6 to Group 4) and GMRs 
of SARS -CoV -2 Omicron BA.4/BA.5–strain NT sand 
reference -strain NTs (Group 6 to Group 3) at 1 month after 
vaccination will be provided with 97.5% CI s (Section [IP_ADDRESS].3).
Using a 2
-fold noninferiority margin, success for the second of the 
secondary  immunogenicity  objectiv eswill be declared if the lower 
bound of the 2- sided 97. 5% CI  for the GMR is greater than 0.5 for 
both RSV A and RSV B antigens and for both the Omicron 
BA.4/BA.5 and re ference strains , after the second primary  
immunogenicit y objective is achieved.
[IP_ADDRESS].4. Exploratory Endpoint(s) Analysis
Endpoint Statistical Analysis Methods
Exploratory GMTs of NTs for each RSV subgroup (A or B), GMTs of QI V 
strain- specific HAI titers , and GMTs of SARS -CoV -2strain–
specific NTs will be descriptively  summarized with 2 -sided 
95% CIs for each applicable vaccine group both before vaccination 
and at the 1-month postvaccination visit (Section 9.3.1).
GMFRs of NTs for each RSV subgroup (A or B) ,GMFRs of 
influenza strain -specific HAI titers , and GMFR sof SARS -CoV -
2
strain–specific NTs from before vaccination to the 1- month
postvaccination visit will be descriptivel y summarized with 2 -sided 
95% CI s for each applicable vaccine group (Section 9.3.1).
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 122Endpoint Statistical Analysis Methods
The number and percentage of participants achieving strain -specific 
HAI seroconversion, SARS- CoV -2strain–specific seroresponse at 
1month after vaccination, and the number and percentage of 
participants with strain -specific HAI titers ≥1:40 before vaccination
and 1 month after vaccination will be summarized with 2- sided 
Clopper -Pearson 95% CIs for each applicable vaccine group 
(Section 9.3.1).
Note: HAI s eroconversion is defined as an HAI titer <1:10 prior to 
vaccination and ≥
1:40 at the postvaccination visit, or an HAI titer of 
≥1:10 prior to vaccination with a 4- fold rise at the postvaccination 
visit. SARS -CoV -2 seroresponse is defined as achieving a ≥4 -fold 
rise from baseline (before the study  vaccination).  If the baseline 
measurement is below the LLOQ, the postvaccination measure of 
≥4×LLOQ is considered seroresponse .
GMTs may  be compared between other vaccine groups (eg,Group 1 
vs Group 2; Group 1 vs Group 7 ; Group 2 vs Group 6; etc) with 
GMRs and associated 2- sided 95% CI s (Section [IP_ADDRESS].3 ) .
[IP_ADDRESS]. Interim Analyses
No formal interim anal ysis will be conducted for this study  phase.  
The primary  anal ysis will be performed on safety  and immunogenicit y data through 1 month 
after vaccination (ie ,Visit A102); all ty peI error will be spent at this analysis. Once this 
analysis has been completed , study  participants and the study  team may be unblinded to
study  intervention allocation.
6-Month safet y data will be summarized when they become available.
[IP_ADDRESS]. Sample Size Determination
Table 5presents the power to demonstrate the noninferiority for each antigen included in 
Group 1 ([RSVpreF+BNT162b2] +QIV )as well as the power to demonstrate the 
noninferiority  for each antigen included in Group 2 ([RSVpreF+BNT162b2] +placebo). The 
power for the secondary  objectives is similar to that for the primary  objective sas the 
comparisons and assumptions are similar.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 123For allassay  results, no interference is assumed (ie ,GMR=1) . The SDs of the log titers are 
based on different reference stud ies.With 135evaluable participants per vaccine group, 
there is ~90% power to declare noninferior ity forall 8 antigens included in Group 1 , and 
~92% power to declare noninferiority  for all [ADDRESS_274575] EMEANS statement.
Assuming 10% of the participants are nonevaluable, approximate ly150 participants per 
group need to be enrolled for Group s
1 through 7.
Table 5. Power to Demonstrate Noninferiority (N=135 per Group)
Vaccine 
Component
(SD Reference 
Study)Antigen /Endpoint Comm on SD 
(Loge Scale) Difference
(Log e Scale)Noninferiority 
MarginPower to 
Declare 
Noninferiority
(1-
Sided Alpha 
= 0.0 125)
RSVpreF
(C3671013)RSV A NT 1.1 0 2-Fold 99.8%
RSV B NT 1.1 0 2-Fold 99.8%
BNT162b2
(C4591044)SARS -CoV- 2 
Omicron 
BA.4/BA.5 –strain 
NTs1.5 0 2-Fold 93.8%
SARS -CoV- 2 
reference -strain 
NTs1.3 0 2-Fold 98.3%
QIV
(C3671006)H1N1 HAI 1.1 0 2-Fold 99.8%
H3N2 HAI 1.1 0 2-Fold 99.8%
B strain 1 HAI 1.2 0 2-Fold 99.3%
B strain 2 HAI 1.2 0 2-Fold 99.3%
Overall pow er to reject all 8tests (Group 1 or 7vs Group 4, Group 1 or 7vs Group 3, 
Group 1 or 7vs Group 5)90.2%
Overall pow er to reject all first 4 tests (Group 2 or 6 vs Group 4, Group 2 or 6 vs Group 3) 91.8%
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].12. Appendix 1 2: Protocol Amendment History
The protocol amendment summary  of changes table for the current amendment is located 
directly  before the TOC. The protocol amendment summary  of changes tables for past 
amendment(s) can be found below:
Description of Change Brief Rationale Section # and Na me
Substantial Modification(s)
Added Substudy  B New substudy  on 
alternative formulation 
of RSVpreF and 
BNT162b2 
(Omi XBB.1.5) 
combination vaccine 
[RSVpreF+BNT162b2] Section 10.12 Appendix 12: 
Substudy  B (Phase 1/2)
Non-substantial Modification(s)
Updated/removed text in 
the body  of protocol that 
was specific to 
Substudy A Substudy -specific text is 
included in substudy  
appendicesSection 1.1 Synopsis
Section 2.3.1 Risk Assessment
Section 7.2 Participant 
Discontinuation/Withdrawal From 
the Study
Section 5.[ADDRESS_274576] for Substudy  A
Section 10.11.4 Introduction –
Substudy  A
Updated references and 
text to include 
Substudy BChanges to align with 
master protocol formatSections 1 through 9
Section [IP_ADDRESS] Data Monitoring 
Committee
Section 10.2 Appendix 2: Clinical 
Laboratory  Tests
Section 10.5 Appendix 5: Genetics
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 125Description of Change Brief Rationale Section # and Na me
Added stoppi[INVESTIGATOR_227943] 1.1Synopsis
Added IND number and 
clintrials.gov IDNot available at the time 
of original protocolTitle page
Section 1.1 Synopsis
Updated text on 
anaph ylaxis and 
myocarditis assessment 
for RSVpreFConsolidated the risk 
text from RSV and 
COVID; updated based 
on the recent updates for 
both programsSection 2.3.1 Risk Assessment
Removed text on 
bivalent BNT162b2 
vaccine approvalUpdated formulation Section [IP_ADDRESS] SARS -CoV -2
Removed collection of 
date of birthNew requirement Section 8.1 Administrative 
Procedures
Added instructions for 
noting COVID -19 
symptoms for 
Substudy AEditorial change Section 10.11.3 SoA –Substudy  A
“RSV” was updated to 
“RSVpreF” as per 
PACL  (26 April 2023)Correction of 
typographical error Section 2.3 Benefit/Risk Assessment
Updated information on 
RSVpreF Introductory  paragraph 
on clinical studiesSection [IP_ADDRESS] RSVpreF 
Vaccination
Added/updated text 
Substudy  B formulation 
to read “ alternative 
formulation of RSVpreF 
and BNT162b2 (Omi 
XBB.1.5) combination 
vaccine
[RSVpreF+BNT162b2] ”Consistency  throughout 
the document Section 1: Protocol Summary
Section 4.3: Justification for Dose
Section 10.12 Appendix 12: 
Substudy  B
Section 10.13 Appendix 13: 
Abbreviations
Added a review of 
e-diary  data from Day s [ADDRESS_274577] Regulatory  
recommendation since 
there is no prior human 
experience with the 
combined RSVpreF and Section [IP_ADDRESS] Overall De sign
Section [IP_ADDRESS].4 Allocation to 
Study  Intervention
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 126Description of Change Brief Rationale Section # and Na me
20 participants in 
Stratum 2 prior to
enrollment of the 
remaining participants in 
each group per PACL 
(01June 2023)bivalent BNT162b2 
(original/Omi 
BA.4/BA.5) vaccine
Stoppi[INVESTIGATOR_1877] #2 
updated from “troponin 
I” to “troponin” per 
PACL  (12July 2023)To accommodate sites 
not able to measure 
troponin ISection [IP_ADDRESS] Stoppi[INVESTIGATOR_1869]
“Licensed influenza 
vaccine” updated to 
“influenza vaccine” per 
PACL  (12 July  2023)To accommodate 
participants that may  
have received 
investigational influenza 
vaccinesSection 10.11.3 SoA – Substudy  A 
(Phase 1/2)
Section [IP_ADDRESS] Prior and 
Concomitant Therap y
Section [IP_ADDRESS] Study Procedures 
Added volume for 
normal saline placebo 
per PACL  
(26April 2023)Addition of text that 
was inadvertently  
omitted in original 
protocolSection 10.11.8 Substudy  A 
Intervention and Concomitant 
Therap y
Section [IP_ADDRESS] Study  
Intervention(s) Adm inistered
Added volume for QIV Addition of text that 
was inadvertently  
omitted in original 
protocolSection [IP_ADDRESS] Study  
Intervention(s) Administered
Updated barrier 
requirementsNew information for 
Comirnaty  and Abry svoSection 4.2.3 Choice of 
Contraception/Barrier Requirements
Removed text 
inadvertentl y included 
previouslyTypographical errors 
correctedSection [IP_ADDRESS] Study  Procedures
Section [IP_ADDRESS] Analysis Sets
Section [IP_ADDRESS] Statistical 
Analy ses
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].13. Appendix 1 3: Abbrevia tions
Abbreviation Term
ADE adverse device effect
AE adverse event
AESI adverse event of special interest
AKI acute kidney  injury
Al(OH) [ADDRESS_274578]
BNT162b2 [COMPANY_007]’s COVID -19 vaccine
CBER Center for Biologics Evaluation and Research ([LOCATION_002])
CDC Centers for Disease Control and Prevention ([LOCATION_002])
CFR Code of Federal Regulations ([LOCATION_002])
ChAdOx1 -S ChAdOx1 -S (recombinant) SARS -CoV -2 vaccine ([COMPANY_008])
CHF congestive heart failure
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI [INVESTIGATOR_159840] K idney  Disease Epi[INVESTIGATOR_227944] -[ADDRESS_274579]
ECG electrocardiogram
eCrCl estimated creatinine clearance
eCRF electronic case report form
EDB exposure during breastfeeding
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.[ADDRESS_274580] European Union Drug Regulating Authorities Clinical Trials 
(European Clinical Trials Database)
FDA Food and Drug Administration ([LOCATION_002])
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GMFR geometric mean fold rise
GMR geometric mean ratio
GMT geometric mean titer
HAI hemagglutination inhibition assay
HBe hepatitis B e
HBeAg hepatitis B e antigen
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HD high dose
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therap y
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ID identification
IgG immunoglobulin G
IMP investigational medicinal product
IND investigational new drug
INR international normalized ratio
IPAL investigational product accountability  log
IPM investigational product manual
IRB institutional review board
IRC internal review committee
IRT interactive response technology
ISO International Organization for Standardization
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 129Abbreviation Term
IV intravenous(l y)
IWR interactive Web -based response
KDIGO Kidney  Disease Improving Global Outcomes
LBBB left bundle branch block
LFT liver function test
LLOQ lower limit of quantitation
LNP lipid nanoparticle
LRTI lower respi[INVESTIGATOR_227945] -RSV RSV -associated lower respi[INVESTIGATOR_227946]- to-treat
modRNA nucleoside -modified messenger ribonucleic acid
MQI medically  qualified individual
mRNA messenger ribonucleic acid
mRNA -1273 mRNA -1273 SARS -CoV -2 vaccine (Moderna)
NA not applicable
NAAT nucleic acid amplification test
N-binding SARS -CoV -2 nucleoprotein –binding
NIMP noninvestigational medicinal product
NT neutralizing titer
Omi Omicron
PACL protocol administrative change letter
PFS prefilled s yringe(s)
PI [INVESTIGATOR_227947]’ sSerious Adverse EventSubmission Assistant
PT prothrombin time
PVC premature ventricular contraction
QIV quadrivalent influenza vaccine
QTcF QT interval corrected by [CONTACT_228015][INVESTIGATOR_227948] A respi[INVESTIGATOR_227949] A
RSV B respi[INVESTIGATOR_227949] B
RSVpreF respi[INVESTIGATOR_227950] F subunit vaccine
[RSVpreF+BNT162b2] Substudy  A: combination RSVpreF and bivalent BNT162b2 
(original/ Omi BA.4/BA.5) vaccine 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 130Abbreviation Term
RT-PCR reverse transcription– polymerase chain reaction
S1 spi[INVESTIGATOR_144870] S1subunit
SADE serious adverse device effect
SAE serious adverse event
SAP statistical analy sis plan
SARS severe acute respi[INVESTIGATOR_214322] -CoV severe acute respi[INVESTIGATOR_227951] -CoV -[ADDRESS_274581] characteristics (European Union)
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safet y document
ST-T ST-segment and T -wave
S[LOCATION_003]R suspected unexpected serious adverse reaction
TBA to be advised
T bili total bilirubin
Th1 T-helper t ype [ADDRESS_274582]
USPI [INVESTIGATOR_227952] ([LOCATION_002])
WHO World Health Organization
WOCBP woman/women of childbearing potential
WT wild ty pe
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page [ZIP_CODE].REFERENCES
1Viper Group COVID19 Vaccine Tracker Team. COVID19 vaccine tracker: 
[COMPANY_007]/BioNTech: Comirnaty .  Available from: 
https://covid19.trackvaccines.org/vaccines/6/.  Accessed: 02 Jun 2022.
2[COMPANY_007] and BioNTech. BNT162b2 [COMI RNATY (COVID -19 vaccine, mRNA)] 
evaluation of a booster dose (third dose). Vaccines and Related Biological Products 
Advisory  Committee meeting briefing document, 17 Sep 2021. Available from: 
https://www.fda.gov/media/152161/download. Accessed: [ADDRESS_274583] of vaccination one year after pandemic 
declared [press release]. Available from: https://www.pfizer.com/news/press -
release/press -release -detail/real- world -evidence -confirms- high-effectiveness- pfizer.  
Publishe d: 11 Mar 2021. Accessed: 02 Jun 2022.
4WHO. Tracking SARS -CoV -2 variants. 21 Sep 2023. Available from : 
https://www.who.int/activities/tracking -SARS -CoV -2-variants . 
Accessed :10 October 2023. 
5Bivalent RSV prefusion F vaccine in adults ≥60 years of age.Vaccines and Related 
Biological Products Advisory  Committee. 28 Feb 2023. Available from: 
https://www.fda.gov/media/165737/download
. Accessed :11 Apr 2023. 
6[COMPANY_007]. U.S. FDA Approves ABRYSVO™, [COMPANY_007]’s Vaccine for the Prevention of 
Respi[INVESTIGATOR_227953] (RSV) in Older Adults [press release] . Available from: 
https://www.pfizer.com/news/press -release/press- release -detail/us- fda-approves-
abrysvotm -pfizers -vaccine -prevention
. Accessed: 31 May  2023.
7CDC. Increased respi[INVESTIGATOR_227954] a ctivit y, especially  among children, early in the 2022 -
2023 f all and winter. Available from: 
https://emergency .cdc.gov/han/2022/han00479.asp. Published: 04 Nov 2022. 
Accessed :11 Apr 2023. 
8Weber MW, Mulholland EK, Greenwood BM. Respi[INVESTIGATOR_227955]. Trop Med Int Health .1998;3(4):[ADDRESS_274584] all the viruses gone? 
Disappearance of seasonal respi[INVESTIGATOR_227956]
-19 pandemic. 
J Med Virol . 2021;93(7):4099 - 4101.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 13210Janssen C, Mosnier A, Gavazzi G, et al. Coadministration of seasonal influenza and 
COVID -19 vaccines: a systematic review of clinical studies. Hum Vaccin Immunother .
2022;18(6):2131166.
11Cohen KW, L inderman SL, Moodie Z, et al. Longitudinal analy sis shows durable and 
broad immune memory  after SARS -CoV -2 infection with persisting antibody  responses 
and memory  B and T cells. Cell Rep Med. 2021;2(7):100354.
12Du L , He Y, Zhou Y, et al. Thespi[INVESTIGATOR_119901] -CoV --a target for vaccine and 
therapeutic development. Nat Rev Microbiol. 2009;7(3):[ADDRESS_274585] 2021
-January 2022. 
MMWR Morb Mortal Wkly  Rep. 2022;71(7):[ADDRESS_274586] the 
Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):[ADDRESS_274587] BNT162b2 vaccination neutralization of 
SARS -CoV -2 Omicron infection. N Engl J Med. 2022;386(5):492 -4.
16Zou J, Kurhade C, Patel S, et al. Neutralization of BA.4 –BA.5, BA.4.6, BA.2.75.2, 
BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med. 2023. DOI: 
10.1056/NEJMc2214916 .
17Link -Gelles R, Ciesla AA, Roper LE, et al. Early  estimates of bivalent mRNA booster 
dose vaccine effectiveness in preventing s ymptomatic SARS -CoV - 2 infection 
attributable to Omicron BA.5– and XBB/XBB.1.5–r elated s ublineages among 
immunocompetent a dults — increasing c ommunity  access to t esting program, United 
States, December 2022 –January  2023. MMWR Morb Mortal Wkly  Rep .
2023;72:119 -24. DOI:http://dx.doi.org/10.[ZIP_CODE]/mmwr.mm7205e1 .
18Surie D, DeCuir J, Zhu Y, et al. Early estimates of bivalent mRNA vaccine 
effectiveness in preventing COVID - 19–a ssociated hospi[INVESTIGATOR_227957] a dults aged ≥65years — IVY Network, 18 states, 
September 8 –November 30, 2022. MMWR Morb Mortal Wkly  Rep. 2022;71:1625 -30. 
DOI: http://dx.doi.org/10.[ZIP_CODE]/mmwr.mm715152e2.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 13319Tenforde MW, Weber ZA, Natarajan K, et al. Early  estimates of bivalent mRNA 
vaccine effectiveness in preventing COVID -19–a ssociated emergency  department or 
urgent c are encounters and hospi[INVESTIGATOR_227958] a dults —VISION 
Network, nine s tates, September –November 2022. MMWR Morb Mortal Wkly  Rep.
2022;71:1616-24. DOI: http://dx.doi.org/10.[ZIP_CODE]/mmwr.mm715152e1.
20Link -Gelles R, Ciesla AA, Fleming -Dutra KE, et al. Effectiveness of bivalent mRNA 
vaccines in preventing s ymptomatic SARS -CoV -2 infection — increasing community  
access to t esting program, [LOCATION_002], September –November 2022. MMWR Morb 
Mortal Wkly  Rep. 2022;71:1526 -30. 
DOI: http://dx.doi.org/10.[ZIP_CODE]/mmwr.mm7148e1.
21Lin DY, Xu Y, Gu Y, et al. Effectiveness of bivalent boosters against severe Omicron 
infection. N Engl J Med. 2023;388(8):[ADDRESS_274588] 
Omicron 
infection and s evere outcomes in c hildren under 12 years of age. medRxiv 
Preprint. Available from :
https://www.medrxiv.or g/content/10.1101/2023.01.18.23284739v1 .
Published: 19 Jan 2023. Accessed: 01 Feb 2023.
23Arbel R, Peretz A, Sergienko R, et al . Effectiveness of a bivalent mRNA vaccine 
booster dose to prevent severe COVID -19 outcomes: a retrospective cohort study . 
Lancet Infect Dis. 2023; 23(8):914 -21. 
24Wang Q, Iketani S, L i Z, Liu L, et al . Alarming antibody  evasion properties of rising 
SARS -CoV -2 BQ and XBB subvariants. Cell. 2023;186(2):279 -286.
25WHO. XBB.1.5 updated risk assessment, 24 February  2023. Available from: 
https://www.who.int/docs/default
-
source/coronaviruse/22022024xbb.1.5ra.pdf?sfvrsn=7a92619e_3 .Accessed:
[ADDRESS_274589] 2023.
26WHO. XBB.1.5 updated risk assessment, 20 June 2023. Available at: 
https://www.who.int/docs/default
-
source/coronaviruse/20230620xbb.1.5.pdf?sfvrsn=fff6f686_3. Accessed: [ADDRESS_274590] 2023.
27FDA ,CBER. 182nd Meeting of the Vaccines and Related Biological Products Advisory  
Committee (VRBPAC). Zoom video c onference [transcript] . 15 Jun 2023. Available 
from: https://www.fda.gov/media/169804/download . Accessed: [ADDRESS_274591] 2023. 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 13428[COMPANY_007]. [COMPANY_007] and BioNTech receive U.S. FDA approval for 2023- 2024 COVID -19 
vaccine [press release]. Available from: https://www.pfizer.com/news/press -
release/press -release -detail/pfizer -and-biontech -receive -us-fda-approval -2023 -2024-
covid. Published: 11 Sep 2023. Accessed: [ADDRESS_274592] 2023.
29Hall CB, Simőes EAF, Anderson L J. Clinical and epi[INVESTIGATOR_227959]. Curr Top Microbiol I mmunol. 2013;372:39 -
57.
30Chadha M, Hirve S, Bancej C, et al. Human respi[INVESTIGATOR_227960]—early  findings from the WHO global respi[INVESTIGATOR_227961]. Influenza Other Resp Viruses. 2020;14(16):638 -46.
31Murata Y, Falsey  AR. Respi[INVESTIGATOR_227962]. Antivir Ther. 
2007;12(4 Pt B):659 -70.
32Falsey  A, Hennessey  PA, Formica MA, et al. Respi[INVESTIGATOR_227963] y and high -risk adults. N Engl J Med. 2005;352(17):[ADDRESS_274593] Dis. 2019;69(2):197 -203.
34Sundaram ME, Meece JK, Sifakis F, et al. Medically  attended respi[INVESTIGATOR_227964] ≥50 y ears: clinical characteristics and outcomes. 
Clin I nfect Dis. 2014;58(3):342 -
9.
35Belongia EA, King JP, Kieke BA, et al. Clinical features, severit y, and incidence of 
RSV illness during 12 consecutive seasons in a community  cohort of adults ≥[ADDRESS_274594] Dis. 2018;5(12):ofy 316.
36Wyffels V, Karibury o F, Gavart SF, et al. A real -world anal ysis of patient 
characteristics and predictors of hospi[INVESTIGATOR_227965]. Adv Ther. 2020;37(3):1203 -17.
37Nuwer R. Better awareness of RSV in older adults is needed to fight a growing burden . 
Available from: https://www.nature.com/articles/d41586-023-[ZIP_CODE]-y. Published: 
27 Sep 2023. Accessed: [ADDRESS_274595] Dis Ther. 2021;10(Suppl 1):S47- S60.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 13539[COMPANY_007]. A BRYSVO (respi[INVESTIGATOR_227966]) .US Prescribing Information
(USPI ),[LOCATION_001], NY: [COMPANY_007] I nc.Available from:
https://www.fda.gov/media/168889/download. Updated: Aug 2023.  Accessed:
[ADDRESS_274596] 2023. 
40Polack 
FP, Thomas SJ, Kitchin N, et al. Safet y and efficacy of the BNT162b2 mRNA 
Covid -19 vaccine. N Engl J Med. 2020;383(27):2603 -15.
41[COMPANY_007] and BioNTech. [COMPANY_007] -BioNTech COVID -19 vaccine. Vaccines and Related 
Biological Products Advisory  Committee meeting briefing document, 10 Dec 2020. 
Available from: https://www.fda.gov/media/144245/download. Accessed: 
13 May  2022.
42[COMPANY_007]. [COMPANY_007] and BioNTech confirm high efficacy  and no serious safet y concerns 
through up to six months following second dose in updated topline anal ysis of landmark 
COVID -19 vaccine study [press release]. Available from: 
https://www.pfizer.com/news/press -release/press- release -detail/pfizer -and-biontech -
confirm -high-efficacy -and-no-serious. Published: 01 Apr 2021. Accessed: 25 Feb 2022.
43FDA
. Emergency  use authoriz ation (EUA) for an unapproved product: review 
memorandum. [COMPANY_007] -BioNTech COVID-19 vaccine BNT162b2 as a single booster 
dose. Available from: https://www.fda.gov/media/152432/download. 
Accessed: 02 Jun 2022.
44[COMPANY_007]. [COMPANY_007] and BioNTech receive expand ed U.S. FDA emergency  use authorization 
of COVID -19 vaccine booster to include individuals 18 and older [press release]. 
Available from: https://www.pfizer.com/news/press -release/press -release -detail/pfizer -
and-biontech -receive -expanded -us-fda-emergency -use. Published: 19 Nov 2021. 
Accessed: 02 Jun 2022.
45[COMPANY_007] and BioNTech. Safet y and efficacy data in support of a planned emergency use 
authorization amendment for a booster dose of the [COMPANY_007]-BioNTech COVID- 19 vaccine 
in individuals 18 y ears of age and older. EUA [ZIP_CODE]. 2021;7:10 -2.
46FDA. Coronavirus (COVID -19) update: FDA authorizes Moderna, [COMPANY_007] -BioNTech 
bivalent COVID -19 vaccines for use as a booster dose. Available from: 
https://www.fda.gov/news -events/press -announcements/coronavirus- covid - 19- update -
fda-
authorizes- moderna -pfizer -biontech -bivalent -covid -19-vaccines- use. 
Accessed: 10 Feb 2023.
47Our World in Data. SARS -CoV -2 variants in analy zed sequences, [LOCATION_002]. 
Available from: https://ourworldindata.org/grapher/covid- variants -area?time=2021-12-
20..2022-08- 01&country=~[LOCATION_003]. Accessed: 13 Feb 2023.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 13648Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by  [CONTACT_7544] -CoV -2 
Omicron subvariants BA .2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387(1):86 -8.
49Tegally  H, Moir M, Everatt J, et al. Emergence of SARS -CoV -2 Omicron lineages 
BA.4 and BA.5 in South Africa. Nat Med. 2022. Available from: 
https://doi.org/10.1038/s41591 -022-[ZIP_CODE]-2. Accessed : [ADDRESS_274597] SARS -CoV -2 infection and COVID -19 disease: results of a s ystematic review 
and meta -regression. Lancet. 2022;399([ZIP_CODE]):924 -44.
51[COMPANY_007]. [COMPANY_007] a nd BioNTech announce updated clinical data for Omicron BA.4/BA.5 -
adapted bivalent booster demonstrating substantially  higher immune response in adults 
compared to the original COVID -19 vaccine [press release]. Available from: 
https://www.pfizer.com/news/press - release/press- release -detail/pfizer -and-biontech -
announce -updated -clinical -data-omicron. Published: 04 Nov 2022. 
Accessed: 10 Nov 2022.
52WHO. TAG -VE statement on Omicron sublineages BQ.1 and XBB. Available from: 
https://www.who.int/news/item/27 -10-2022- tag-ve-statement -on-omicron -sublineages-
bq.1- and-xbb. Accessed: 10 Feb 2023.
53Zou J, Kurhade C, Patel S, et al.  I
mproved neutralization of Omicron BA.4/5, BA.4.6, 
BA.2.75.2, BQ.1.1, and XBB.1 with bivalent BA.4/5 vaccine. bioRxiv. 
Preprint posted: 17 Nov 2022. DOI: https://doi.org/10.1101/2022.11.17.516898.
54FDA. Recommendation for the 2023-2024 formula of COVID- 19 vaccines in the U.S.
Available from: https://www.fda.gov/media/169591/download . Accessed :[ADDRESS_274598] 2023.
55ClinicalTr ials.gov. Identifier [STUDY_ID_REMOVED]: A Study  to Learn About the Safet y and 
Immune Activity  of RSVpreF in Children Who Are at High Risk of Getting RSV 
Disease (PI[INVESTIGATOR_227967]) .
Available from: https://clinicaltrials.gov/study /[STUDY_ID_REMOVED] . 
Accessed: 
[ADDRESS_274599] 2023.
56CDC. Advisory  Committee on Immunization Practices (ACI P). Grading of 
Recommendations, Assessment, Development, and Evaluation (GRADE): [COMPANY_007] 
RSVpreF vaccine (ABRYSVO) . Available from: 
https://www.cdc.gov/vaccines/acip/recs/grade/[COMPANY_007] -Bivalent -RSVpreF -adults.html
. 
Accessed :[ADDRESS_274600] 2023. 
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
PF-07960613 (Combination COVID -19 and RSV Vaccine)
Protocol C5 481001
Final Protocol Amendment 2, 18January 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (14 April 2023)
TMF Doc ID: 164.01
Page 13757FDA . Guidance for industry : toxicity  grading scale for healthy  adult and adolescent 
volunteers enrolled in preventive vaccine clinical trials. Rockville, MD: Center for 
Biologics Evaluation and Research; Sep tember 2007. Available from: 
https://www.fda.gov/regulatory -information/search -fda-guidance -documents/toxicity -
grading- scale -healthy -adult- and-adolescent -volunteers -enrolled -preventive -vaccine -
clinical . Accessed: 10 October 2023.
58[COMPANY_007]. Vaccines and Related Biological Products Advisory  Committee Meeting
VRBPAC briefing document : respi[INVESTIGATOR_227968] F 
subunit vaccine (RSVpreF/Abry
svo). 18 May  2023. Available from: 
https://www.fda.gov/media/168186/download. Accessed: 11 Aug 2023 .
59FDA. Abry svo. Summary  basis for regulatory  action .  31 May  2023. Available from: 
https://www.fda.gov/media/169721/download?attachment.  Accessed: 16 Aug 2023.
60FLUZONE HI
GH-DOSE QUADRIVALENT (influenza vaccine). US Prescription 
Information (USPI) ,Swiftwater, PA: [COMPANY_011] Pasteur Inc. Available from: 
https://www.fda.gov/media/139731/download. Updated: Mar 2023. Accessed: 
05Apr2023.
61FDA
. Coronavirus (COVID -19) update: FDA authorizes Moderna, [COMPANY_007] -BioNTech 
bivalent COVID -19 vaccines for use as a booster dose. Available from: 
https://www.fda.gov/news -events/press -announcements/coronavirus- covid - 19- update -
fda-
authorizes- moderna -pfizer -biontech-bivalent -covid -19-vaccines- use. 
Accessed: 10Feb2023.
62CDC. Symptoms of COVID -19. Available from: 
https://www.cdc.gov/coronavirus/2019- ncov/s ymptoms -testing/sy mptoms.html. 
Accessed: 09 Feb 2023.
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
Document Approval Record
Document Name:	

	



	


Document Title: !"#$%#&#'#!"%#()*%*!+ *,,
+"-#+**!"'",)*+# $*+#+ * #./-*+*
+'#*"(#*("(!*%%+##*+% *+-"$* 0	1
+ ($*+&#%&!*+ *$* %
Signed By: [CONTACT_1782](GMT) Signing Capacity
	10
0

56
765 '
8
	10
0

16	6: '
8
090177e19fb526e9\Approved\Approved On: 19-Jan-2024 09:51 (GMT)
[COMPANY_003]